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During the two last decades, mesenchymal stromal cells (MSCs) have been 
topics of intensive investigation due to their intriguing characteristics, which 
make them exciting prospects for cell-based therapies. MSCs possess 
immunomodulatory functions and a broad differentiation capability, meaning 
that they have several potential therapeutic applications, such as a systemic 
treatment for immunological disorders or locally administered to correct tissue 
defects.  
  
The most widely studied and utilized characteristic of MSCs has been their 
immunomodulatory property. Graft-versus-Host disease (GvHD), a severe and 
highly lethal complication following allogeneic stem cell transplantation, has 
been one of the first indications where the use of MSCs has been widely 
explored. MSCs have also been evaluated for the treatment of Crohn’s disease, 
multiple sclerosis, and chronic inflammation. The repair of bone and cartilage 
defects is also another application of significant interest. 
 
The cell therapy field has taken tremendous steps from research laboratories 
towards the clinic, hand in hand with the development of a whole new branch of 
the biotechnology industry. Regulations for GMP manufacturing of advanced 
therapy medicinal products (ATMPs) have been framed in conjunction with the 
development of MSC therapies and the evaluation of the risks associated with 
the manufacturing process have been complemented with accumulated 
knowledge. According to the regulatory authorities, a risk- and evidence-based 
approach should be used to evaluate safety risks and sources of alterations or 
impairments in product functionality.   
 
Culturing MSCs ex vivo is relatively simple; however, culturing conditions 
and handling of the cells can modify their characteristics and functionality. This 
fact sets limitations on the manufacturing and demands a deep understanding 
of the mechanisms affecting cell products. The selection of suitable cell sources, 
culture medium supplements, and optimization of culturing conditions are the 
key parameters to be considered if one wishes to achieve high yields of 
functional MSCs. During the last fifteen years, the safety of MSC products has 
been improved by replacing fetal bovine serum (FBS) as a medium supplement 
with human origin platelet lysates (PLs); in this way one can obtain MSCs which 
do not express bovine xenoantigens and do not pose a risk of transferring animal 
pathogens. 
 
As is the case with all somatic cells, also MSCs age during the expansion 
process. Natural aging, called replicative senescence, is known to limit the 




senescence may also be triggered by external sources such as DNA damaging 
agents, oxidative stress, or sub-optimal culturing conditions. Because the 
progression of aging impairs the cellular functions and alters the secretory 
profile of the cells, the presence of senescent cells in MSC cultures is 
undesirable. Therefore, careful monitoring of cellular aging during MSC 
expansion is essential for product quality.  
 
If one wishes to ensure efficient distribution and appropriate-timed dosing of 
MSC products, manufacturing of MSCs as “off-the-shelf” products will be 
necessary but requires cryopreservation of the cells.  Cryopreservation of the 
intermediate or the final product allows a predictable manufacturing scheme 
and improves the availability of the released products. However, the effect of 
cryopreservation on the functionality and aging of the MSCs is a topic of 
intensive debate and requires more investigation.  
 
This study has focused on determining optimal expansion conditions for 
clinical-grade bone marrow (BM) MSCs by using platelet-derived culture 
medium supplements. We also explored the potential of PL to promote 
osteogenic differentiation of MSCs as compared to FBS supplemented culture. 
We also aimed to improve product quality by introducing an imaging-based 
screening method to detect aging-related morphological changes from the MSC 
cultures. Finally, we investigated how any additional freezing steps during the 
manufacturing process of BM-MSCs would affect the basic manufacturing 
parameters and alter the cellular aging process.  
 
We found that PL prepared of pooled fresh platelets and plasma with two 
freeze-thaw cycles effectively supported MSC expansion and maintained their 
functionality in an ambient oxygen concentration. We also observed that PL 
could promote osteogenic differentiation at least equally with FBS in 2D cultures 
and slightly better in a 3D culture system. We were able to detect and quantify 
aging-related morphological changes from MSCs cultures and demonstrated 
that the rapid increase in cell size evident after passage 5 was indicative of the 
expression of primary senescence markers. When the effect of interim freezing 
steps was investigated, we found that interim freezing at passages 0 and 1 did 
not alter the basic manufacturing parameters and did not accelerate the 
initiation of senescence. Our results suggest that the manufacturing process for 
clinical-grade MSCs may be scaled up by using additional freezing steps in the 
early passages.  
 
This study was a part of the manufacturing development process during the 
establishment of The Advanced Cell Therapy Centre in the Finnish Red Cross 
Blood Service and has yielded insights into the establishment and scaling up of 
PL supplemented culture system for clinical-grade MSCs. In addition, our 




manufacturing of MSCs and be a useful tool as an in-process monitoring method 






1 REVIEW OF THE LITERATURE 
1.1 MESENCHYMAL STROMAL CELLS 
Mesenchymal stromal cells (MSCs) are multipotent cells, which reside in the 
bone marrow and the stroma of multiple organs and tissues. They are a 
heterogeneous population of cells, which comprise a small proportion of self-
renewing stem cells and stromal cells in various differentiation stages. Upon 
plating on standard tissue culture plastic, the MSCs adhere to the plastic surface 
and form colonies of cells with a fibroblast-like morphology. MSCs possess a 
differentiation potential to at least mesodermal lineage cells as well as a 
capability to modulate immune functions by producing a large variety of 
secreted and membrane-bound factors (Dominici et al. 2006; Uccelli et al. 
2008; Viswanathan et al. 2019).  
 
The first indication of MSCs was presented in the 18th century by the German 
pathologist Julius Fredrich Cohneim, who characterized a non-hematopoietic, 
adherent, and spindle-shaped cell population within hematopoietic cells 
(Cohneim 1867). Soon after Cohneim’s observations, in 1869, Emile Goujon 
showed that these BM-derived cells had an intrinsic osteogenic potential 
(Goujon 1869). The first clear evidence of MSCs was provided by Alexander 
Friedenstein in 1976 when he analyzed precursor cells from BM and showed that 
these fibroblast-like cells formed clonal colonies and could be cultured for 
several passages. Friedenstein called these cells osteogenic precursor cells since 
they could differentiate into osteoblasts. Furthermore, these cells could also 
differentiate into adipocytes and chondrocytes. (Friedenstein 1976).  
 
Despite the relatively long history of MSCs, many of their in vivo functions 
are still unclear, and also the definition of MSCs has been questioned (Sacchetti 
et al. 2016; da Silva Meirelles et al. 2008; Elahi et al. 2016; Reinisch et al. 2015). 
MSCs reside in all postnatal tissues, but whether all of these cells are MSCs 
remains unclear (da Silva Meirelles et al. 2006; Sacchetti et al. 2007; Bernal and 
Arranz 2018; Kozlowska et al. 2019). The term MSC was initially restricted to 
BM-derived cells, but nowadays the abbreviation has been widened to describe 
cells also from many other sources such as from adipose tissue (AT), umbilical 
cord blood (UCB) and umbilical cord (UC), placenta, skin or dental pulp 
(Viswanathan et al. 2019).    
 
MSCs are not restricted to humans and have been well characterized also in 
mice (Baddoo et al. 2003), rats (Santa María et al. 2004), baboons (Devine et al. 
2001), pigs (Moscoso et al. 2005), cows (Bosnakovski et al. 2005) and horses 
(Ringe et al. 2003). The therapeutic potential of MSCs has been tested, 




1.1.1 ORIGIN OF MSCS 
 
Currently, there are two distinct descriptions of the origin and properties of 
MSCs. The first model describes MSCs as progenitor cells that are found in the 
BM. These progenitors can form in a hematopoietic microenvironment and 
differentiate into skeletal tissues (Friedenstein 1976; Bianco et al. 2013; 
Sacchetti et al. 2007). The second model was suggested by Arnold Caplan and 
described MSCs as progenitors for multiple tissues, also tissues other than 
skeletal types (Caplan 1991). Caplan also introduced the name “mesenchymal 
stem cell” to underline the self-renewal property of MSCs. However, only a 
minor population of MSCs are capable of self-renewal, and therefore, the name 
mesenchymal stromal cell or multipotent mesenchymal stromal cell has been 
chosen as being more appropriate (Dominici et al. 2006; Horwitz et al. 2005). 
 
According to the conventional description of MSCs, they are multipotent 
progenitor cells originating from the mesoderm of the embryonal inner cell 
mass and have a restricted potential to differentiate into lineage-committed cells 
(Figure 1.). Recent reports suggest that instead of one universal MSC, cells from 
different tissue sources have a distinct transcriptome and functionality, 
although they share the essential criteria of MSCs (Sacchetti et al. 2016; Reinisch 
et al. 2015; Grégoire et al. 2019; Jin et al. 2013; De Almeida et al. 2016; Elahi et 
al. 2016). MSCs from different tissue origins have also been reported to vary 
according to their phenotype, proliferation potential, expression of cell surface 
markers, differentiation capacities, and secretome (Ribeiro et al. 2013; 
Kozlowska et al. 2019; Elahi et al. 2016; Moll et al. 2019; Banfi et al. 2000; 
Pittenger et al. 1999b).  
 
Non-BM-MSCs have been suggested to originate from pericytes and to 
express similar surface antigens to MSCs isolated from skeletal muscles, 
placenta, AT, and pancreas (Crisan et al. 2008; Caplan 2008). These pericytes 
could also differentiate into osteoblasts, adipocytes, chondrocytes, and muscle 
cells (Crisan et al. 2008). A subpopulation of MSCs express CD146, which is a 





Figure 1. Hierarchy of stem cells. Multipotent mesenchymal progenitor cells (MMPC) originate from 
the inner cell mass of a blastocyst. Both germ cells and somatic stem cells, such as hematopoietic 
stem cells (HSCs), originate from the mesodermal layer of the inner cell mass. MMPCs and HSCs, 
are multipotent stem cells indicating that they can self-renew, and can differentiate into various 
lineage-specific cell types. The differentiation potential of multipotent stem cells is restricted to one 
or more specialized cell types. The figure is modified from (Hayes et al. 2012; Tyndall and Uccelli 
2009). 
1.1.2 MSC SOURCES 
 
MSCs are usually isolated from BM, but there they comprise only 0.001-0.01% 
of the BM mononuclear cells. Cells with MSC-like characteristics have been later 
isolated from the stroma of multiple tissues and organs, such as from AT (Zuk 
et al. 2002), UC (Sarugaser et al. 2005) or UCB (Erices et al. 2000), placenta (In 
’t Anker et al. 2004), skin (Shih et al. 2005), the dental pulp  (Gronthos et al. 
2000), synovial membrane (De Bari et al. 2001), breast milk (Patki et al. 2010), 
and amniotic fluid (In ’t Anker et al. 2003). 
 
The best-characterized MSCs are the BM-derived MSCs. However, the 




for MSCs used in clinical applications have been considered. The most widely 
studied alternative sources are AT and other birth-related tissues such as UC, 
UCB, and placenta (Kern et al. 2006; Troyer and Weiss 2008; Parolini et al. 
2008). MSCs are rare in UCB, but for example, placenta, either decidua or other 
placental compartments, or UC, provide a rich and ethically sustainable source 
of stromal cells and have therefore been a source of great interest (Bieback and 
Brinkmann 2010; Parolini et al. 2008; Mattar and Bieback 2015). 
 
Several studies comparing the isolation and properties of BM-, AT-, UCB- and 
UC-MSCs have been published (Bieback et al. 2008; Wagner et al. 2005; Jin et 
al. 2013; Elahi et al. 2016; Kern et al. 2006; Heo et al. 2016; Reinisch et al. 2015; 
Sacchetti et al. 2016; Grégoire et al. 2019). These studies reported differences in 
in vivo frequencies, proliferative potentials, and functional properties. UCB-
MSCs display a tremendous expansion capacity over BM- and AT-MSCs, but the 
isolation of these cells and the establishment of the cultures is challenging 
(Bieback et al. 2008; Jin et al. 2013). The MSC frequency in the UCB is the 
lowest; the success rate in the establishment of the cultures has varied between 
20-60%, whereas BM- and AT-MSCs cultures have been mostly established with 
a 100% success rate (Bieback et al. 2008). UCB-MSCs can be cultured for more 
extended periods than BM- or AT-MSCs. AT-MSCs show, however, shorter 
doubling times at each passage, when compared to BM- and UCB-MSCs (Jin et 
al. 2013). MSCs from all the three sources express senescence markers, but 
UCB-MSCs with much lower levels than BM- or AT-MSCs (Jin et al. 2013).  
 
Although MSCs from different sources may express similar morphologies 
and surface antigen composition, they vary according to their differentiation 
capacity, as well as gene expression and epigenetic profiles (Bieback and Netsch 
2016; Reinisch et al. 2015; Sacchetti et al. 2016). The study of Reinisch et al. 
showed the BM-derived MSCs have distinct expression and methylation 
patterns from those of AT-, UC- or skin-derived MSCs. BM-MSCs were also the 
only MSCs, which could form an ectopic HSC microenvironment when 
compared to MSC from AT, UC, or other sources such as from skin or dental 
pulp (Reinisch et al. 2015).   According to that analysis, BM-MSCs are more 
closely related to AT-MSCs than to UC- or skin MSCs (Reinisch et al. 2015). In 
addition, a study by Sacchetti et al. revealed distinct gene expression profiles of 
UCB-, periosteum-, muscle- and BM-derived MSCs (Sacchetti et al. 2016). 
 
A comparison of the immunomodulatory properties of BM, AT, UCB, and WJ 
originating MSCs is difficult because of the different experimental settings used 
in the experiments. Many studies have reported the more robust 
immunomodulatory properties AT-MSC than BM-MSCs. MSCs derived from 
fetal origins (UC, UCB, and placenta) have been shown to modulate 
immunological functions more efficiently than AT-MSCs (Bieback and 
Brinkmann 2010; Jin et al. 2013; Mattar and Bieback 2015). BM-MSCs seem to 




However, they can produce enough immunosuppression for clinical use as 
shown in early-stage clinical trials (Le Blanc et al. 2004; Ringdén et al. 2006; Le 
Blanc et al. 2008).   
 
The most suitable tissue origin of MSCs should be selected when MSCs are 
considered for therapeutic applications because tissue-specific characteristics 
may have a marked impact on the efficacy or safety of MSCs (Moll et al. 2019, 
2020b). For example, the expression of tissue factor TF/CD142 varies 
depending on the cell source. TF/CD142 is the main reason for the 
incompatibility of MSCs with blood and it triggers blood clotting and can also 
induce an Instant blood-mediated inflammatory reaction (IBMIR). The 
expression of TF/CD146 is low in BM-MSCs, and much higher in AT-, UC- and 
in placenta-derived MSCs (Moll et al. 2020b, 2019; Grégoire et al. 2019), and 
therefore BM-MSC may be the most suitable choice for systemic infusions.  
 The hematopoietic stem cell niche 
 
Stem cells usually reside in a “nest” called the niche, which forms a protective 
environment for them. The niche maintains stemness by keeping the cells in a 
non-differentiated state and supports their physiological functions. The niche-
forming cells regulate the survival, self-renewal, migration, and differentiation 
of the stem cells via various mechanisms such as through growth factors, 
chemokines, and extracellular matrix molecules and cell contacts (Uccelli et al. 
2008). The main components of the HSC niche are pericytes, myofibroblasts, 
BM stromal cells, osteocytes, osteoblasts, and endothelial cells (Muguruma et 
al. 2006).  
 
Different subtypes of stromal cells can be found in the BM. Sachetti et al. 
identified CD146+ cells in the sinusoidal wall area with a colony-forming unit 
(CFU-F) activity and an ability to transfer the BM microenvironment when 
transplanted into mice (Sacchetti et al. 2007). Cells expressing CD271 can be 
found in the trabecular regions of the BM. These cells can also form colonies, 
transfer the BM microenvironment, and can differentiate into mature 
mesodermal cell types (Sacchetti et al. 2007; Tormin et al. 2011). 
 
HSC niche has been demonstrated to consist of two types of compartments 
with different functions located at distinct areas in the BM. The endosteal niche 
is lined by osteoblasts in low oxygen areas of BM, near the bone’s surface. The 
endosteal niche contains CD271+ and CD271+/CD147low/- stromal cell subsets, 
and HSCs, which are maintained long-term in a quiescence state (Tormin et al. 
2011). The vascular niche is located around the sinusoidal area and is enriched 
with CD146+ and CD271+/CD146+ stromal cells together with activated and fast 
proliferating hematopoietic stem progenitor cells (HSPCs)(Tormin et al. 2011). 




CD271+/CD146low/- subset is found in adults, subtype CD271+/CD146+ is 
expressed in cells from children and fetuses, and the third subtype, CD271-
/CD146+, can be detected only from fetal BM (Maijenburg et al. 2012). 
 
The HSC niche controls the differentiation and proliferation of stem cells 
(Crippa and Bernardo 2018). MSCs produce high levels of HSC maintaining 
cytokines such as stromal cell-derived factor 1 (CXCL12; C-X-C motif 
chemokine-12), stem cell factor (SCF or Kit ligand), angiopoietin-1, IL-7, and 
vascular cell adhesion molecule-1 (VCAM-1) and osteopontin (Arai et al. 2004;). 
When new blood cells are needed, HSCs will mature into progenitor cells in the 
vascular niche and be released into the circulation through the sinusoids (Uccelli 
et al. 2008) (Figure 2.).   
 
 
Figure 2. A simplified description of the subtypes of stromal cells in the HSC niche. BM comprises 
two distinct areas with different functions. CD271+ and CD271+/CD146low/- MSCs maintain HSCs in 
the non-proliferative G0 state in hypoxic conditions (light blue areas) until hematopoietic progenitor 
cells are needed. CD146+ and CD271+/CD146+ MSCs are enriched in vascularized regions of BM 
and regulate the mobilization of hematopoietic progenitors to the circulation through the sinusoids.  
The figure is modified from (Sacchetti et al. 2007; Tormin et al. 2011). 
1.1.3 CRITERIA FOR MSCS 
 
MSCs have been found in almost all tissues, and due to the lack of specific 
markers for MSCs, isolation, and identification of these cells may be difficult. 
MSCs are known to express a large variety of surface markers, which however 
are not unique for MSCs, but are shared by other cell types (Mo et al. 2016). Due 
to the heterogeneity of MSC populations, the International Society for Cell and 




definition was published in 2006, but upon the improvement of the 
methodology and thus increasing knowledge, the guidelines for defining MSCs 
have been updated (Dominici et al. 2006; Viswanathan et al. 2019). The minimal 
criteria have been set for in vitro cultured MSCs to facilitate uniform 
characterization of MSCs and most likely do not reflect the in vivo properties of 
MSCs (Mo et al. 2016). 
 
According to the current definition, MSCs are plastic adherent fibroblastoid 
cells with a spindle-shaped morphology. In vitro cultured MSCs should express 
surface antigens CD105, CD73, and CD90 and lack the expression markers such 
as CD34, CD45, CD14 or CD11b, CD79α or CD19 to exclude the presence of 
contaminating cell subsets, such as epithelial cells, as well as cells from 
lymphoid, myeloid and endothelial lineages (Dominici et al. 2006; Viswanathan 
et al. 2019) (Figure 3.). According to the ISCT criteria, MSCs should differentiate 
into osteoblasts, adipocytes, and chondrocytes in vitro  (Pittenger et al. 1999a; 
Dominici et al. 2006).  
 
In addition to the in vitro markers, CD271 has also been used as a marker for 
primitive MSCs. However, CD271 can be applied for freshly isolated MSCs 
before in vitro culturing, because its expression is lost upon culturing and when 
MSCs are exposed to atmospheric oxygen (Álvarez-Viejo et al. 2015; Elahi et al. 
2016). BM-MSCs that reside in the vascular niche of the BM express  CD146 
(Sacchetti et al. 2007). CD146 is also shared by pericytes, which share many 
characteristics with MSCs. It has been debated whether MSCs are pericytes or if 
pericytes are the in vivo progenitors of MSCs (Crisan et al. 2008; Caplan 2017, 
2008).  
 
 According to the ISCT criteria, MSCs should not express HLA-DR; however, 
HLA-DR expression can be detected if MSCs are cultured with human platelet-
derived supplements (Grau-Vorster et al. 2019; Laitinen et al. 2016a) (Figure 
3.). Cell surface HLA-DR expression is a plastic condition, and it is also elicited 
if MSCs are exposed to IFN-γ, which is found in the inflammatory environment 
(Polchert et al. 2008; Stagg et al. 2006). Furthermore, the lack of expression of 
CD34 is not imperative, since it can be detected depending on donors and 
culture passages, but can also be detected from an early culture of AT-derived 








Figure 3. Minimal criteria for defining MSCs. MSCs can be isolated from various sources, and in in 
vitro culture, they are plastic adherent fibroblastoid cells lacking expression of lymphoid, myeloid, 
endothelial, and epithelial markers. MSCs possess differentiation potential to adipocytes, 
osteoblasts, and chondrocytes (Dominici et al. 2006). However, depending on the culture system and 
used cell source, MSCs may express HLA-DR antigen (*1) and CD34 (*2) deviating from the ISCT 
criteria published in 2006 (Grau-Vorster et al. 2019; Laitinen et al. 2016b; Viswanathan et al. 2019). 
Whether MSCs have wider differentiation potentials remains unclear (Sacchetti et al. 2016). 
According to recent reports, cells that share surface antigen composition 
characteristic for MSCs may vary according to their epigenetic profiles and 
differentiation properties (Sacchetti et al. 2016; Reinisch et al. 2015). The 
definition and nomenclature of MSCs have been updated and clarified, along 
with accumulated knowledge since the term mesenchymal stem cells was 
introduced in 1991 (Caplan 1991) (Figure 4.). To acknowledge this more accurate 
characterization, ISCT has continuously revised the MSC criteria and 
recommends denoting the tissue origin together with the abbreviation “MSC” 
and to clarify whether the abbreviation is used for stem or stromal cells. Due to 
the variability of MSC populations, it is evident that one specific marker for 
MSCs cannot be found, and therefore the identity of MSCs is confirmed by a set 
of identity tests  (Dominici et al. 2006; Viswanathan et al. 2019).  The identity 
of MSCs should be verified using a comprehensive assay matrix, which includes 
a quantitative RNA analysis of selected genes, flow cytometric surface antigen 
analysis, as well as proteome analysis and epigenetic profiling ((Viswanathan et 







Figure 4. Timeline for defining MSCs. The figure is partly adopted from (Sipp et al. 2018). 
References for timeline steps;  1(Caplan 1991),  2 (Woodbury et al. 2000), 3(Dominici et al. 2006), 
4(Yang 2011), 5(Mendicino et al. 2014), 6(Sacchetti et al. 2016), 7(Viswanathan et al. 2019). 
1.1.4 DIFFERENTIATION POTENTIAL   
 
Arnold Caplan suggested in 1991 that MSCs could theoretically differentiate into 
a large variety of tissues; bone, cartilage, tendon, ligament, adipocytes, dermis, 
muscle, BM stroma, and connective tissue (Caplan 1991). The differentiation of 
adult MSCs into mesodermal lineage cells, such as osteoblasts, chondrocytes, 
and adipocytes, has been repeatedly confirmed by in vitro assays (Jaiswal et al. 
1997; Purpura 2004; Johnstone et al. 1998; Pittenger et al. 1999). However, 
differences in the efficacy of differentiation due to tissue origin have been 
reported. BM-MSCs have been shown to differentiate robustly into all three 
lineages in various studies (Bieback et al. 2008; Wagner et al. 2005; Jin et al. 
2013; Heo et al. 2016), whereas UC- and UCB-MSC have been reported to 
differentiate only to osteogenic and chondrogenic directions, but not into 
adipocytes (Bieback et al. 2008; Kern et al. 2006). AT-MSC differentiate 
preferably to adipocytes and, to a lesser extent, to osteoblasts and chondrocytes 
(Zajdel et al. 2017). 
 
Many studies have reported a broad differentiation potential, especially for 
BM- and AT-MSCs, and demonstrated that under certain conditions, MSCs 
could also differentiate into tissues other than those of mesodermal origin. 
MSCs were reported to differentiate into skeletal muscle (Dezawa et al. 2005), 
tendon (Kuo and Tuan 2008), myocardium (Shim et al. 2004), smooth muscle 




also shown that MSCs can, in certain conditions, differentiate into neurons 
(Krampera et al. 2007) or epithelial cells (Timper et al. 2006). However, many 
of the studies showing differentiation potentials to cells other than mesodermal 
lineages have been performed in in vitro cultures with selected inducing agents, 
which favor specific differentiation directions, and many of these studies have 
not been confirmed by in vivo results (Strioga et al. 2012; Quinn and Flake 
2008). In addition, even though MSCs might have expressed tissue-specific 
markers, the differentiated cells have not been able to express the characteristics 
and functionality of mature cells (Phinney and Prockop 2007; Volz et al. 2016; 
Fitzsimmons et al. 2018; Krampera et al. 2007). Therefore, the differentiation 
shown in in vitro experimental settings does not necessarily reflect the true 
differentiation potential of MSCs.  
 
The conception of MSCs as a uniform source of progenitors of multiple tissues 
has been, however, challenged by recent studies (Reinisch et al. 2015; Sacchetti 
et al. 2016). Newer studies have used in vivo transplantation experiments, and 
transcriptome analyses to show the impact of tissue origin on the MSC 
functionality, despite fulfilling the minimal criteria listed by ISCT. Studies by 
Sacchetti et al. and Reinisch et al. characterized an inherent property of BM-
MSCs to generate bone and BM stroma (Sacchetti et al. 2016; Reinisch et al. 
2015). BM-MSCs were also shown to differentiate into adipocytes, which may 
support the HSC microenvironment in vivo (Reinisch et al. 2015). According to 
Sacchetti et al., BM-MSCs do not form myocytes and are not spontaneously 
chondrogenic (Sacchetti et al. 2016). Reinisch et al., however, reported that 
when BM-MSCs were compared AT-, UC-MSC, only BM-MSCs exhibited a 
chondrogenic differentiation transcriptional program (Reinisch et al. 2015). 
Sacchetti et al. also reported that UC-MSCs could form cartilage and bone 
inherently and that MSCs isolated from muscles were inherently myogenic but 
were not skeletogenic (Sacchetti et al. 2016).  
 
Despite the large variety of studies demonstrating the differentiation 
potentials of MSCs, the true in vivo nature of MSCs is unclear. MSCs’ homing 
efficacy is low, but some of the intravenously injected MSCs have been found 
from the injury site (Karp and Leng Teo 2009; Strioga et al. 2012). Animal 
studies have also shown that MSCs mediate tissue reconstitution without 
differentiation or fusion to the target organ (reviewed in Strioga et al. 2012). 
Therefore, it is likely that when MSCs are transplanted to the injury site, they 










 Markers for osteogenic differentiation of MSCs  
Ex vivo expanded MSCs have been evaluated for treating bone defects. 
Osteogenic differentiation can be induced by exposing culture-expanded MSCs 
to β-glycerophosphate, dexamethasone, and ascorbic acid 2-phosphate (Jaiswal 
et al. 1997). A variety of transcription factors regulate osteogenic differentiation, 
such as Runx2, which is the primary controller of differentiation, but also osterix 
and β-catenin (Almalki and Agrawal 2016). The osteogenic differentiation of 
MSCs can be divided into three phases. The characteristic for the first phase is 
the increase in cell numbers.  In the second phase, an increase in the expression 
of alkaline phosphatase (ALP) is observed. ALP is required for the formation of 
the collagen matrix. The final phase of the differentiation results in a high 
expression of osteocalcin (OCN) and osteopontin and is followed by calcium and 
phosphate deposition into the collagen matrix (Birmingham et al. 2012).  
1.1.5 CELLULAR CROSSTALK BETWEEN MSCS AND THE IMMUNE 
SYSTEM 
 
MSCs secrete a large variety of soluble and membrane-bound factors, some of 
which exert immunomodulatory functions. MSCs can affect and modulate both 
innate immunity and adaptive immunity, and in general, MSCs have an 
immunosuppressive effect (Uccelli et al. 2008; Le Blanc and Mougiakakos 2012; 
Singer and Caplan 2011). However, after certain stimuli, they may also act as 
proinflammatory cells (Stagg et al. 2006). The multifaceted interactions of 
MSCs with immune cells are summarized in Figure 5.  
 
T cells interact with DCs and other antigen presenting cells to activate the T-
cell receptor and co-stimulatory receptor signaling, which leads to a rapid 
proliferation of T cells and the production of effector cell-activating cytokines 
(Chiesa et al. 2011). CD8+ mediated cytotoxicity is activated because of 
costimulation. Effector CD4+ cells produce the Th1 and Th17 cell subsets, which 
enhance the inflammatory signal (Ghannam et al. 2010). 
 
Innate immunity acts as a first-line barrier against pathogens and factors 
jeopardizing tissue integrity. Natural killer cells (NK cells) are innate immunity 
cells, which produce proinflammatory cytokines and are cytotoxic to infected 
and cancer cells (Glenn 2014). The properties of NK cells are intricately 
regulated by a balance between activating and inhibitory receptors, e.g. they are 
activated by exposure to IL-2 and IL-15 originating from the action of 
inflammatory cytokines IFN-γ and TNF-α on T cells (Spaggiari et al. 2006). 
MSCs can directly block IL-2 and IL-15 induced proliferation of NK cells through 
indoleamine 2,3-deoxygenase (IDO) and prostaglandin E2 (PGE2), MSCs can 
also block cytokine production and the expression of activating receptors in NK 
cells, but cannot, however, inhibit the cytotoxicity of freshly isolated NK cells 





BM-derived MSCs promote the movement of monocytes and macrophages 
from BM to the sites of injury (Chen et al. 2008). Monocytes entering an 
inflammatory site will respond to inductive signals by polarizing to either the 
M1 (pro-inflammatory) or the M2 macrophage subsets (anti-inflammatory). M1 
macrophages secrete IFN-γ and TNF-α; these are agents that support and 
enhance the inflammation signals, whereas M2 macrophages promote the 
switch to the anti-inflammatory and regenerative state by secreting IL-10 and 
TGF-β1  (Le Blanc and Davies 2015). MSCs can promote polarization either 
through inducing a shift from the M1 to the M2 subset or directly from 
monocytes (Gao et al. 2014). MSC-induced direct maturation is initiated by cell-
cell contacts but also by secreted factors such as PGE2, IL-6, and IDO, (Karp 
and Leng Teo 2009; Maggini et al. 2010; Németh et al. 2009). MSCs can induce 
the downregulation of the costimulatory molecules CD86 and MHC II and 
increase the secretion of IL-10 and IL-6 in the polarized M2 macrophages 
(François et al. 2012b; Kim and Hematti 2009; Maggini et al. 2010). IL-10 
secretion prevents neutrophil migration to the inflammatory site and thus 
reduces oxidative stress. M2 polarization also induces the production of 
regulatory T cells (Treg) (Melief et al. 2013). Recent studies have indicated that 
MSCs can influence the Treg proliferation through cell-cell contacts with T cells 
and APCs, as well as through the secretion of soluble factors and exosomes (Negi 
and Griffin 2020).  
 
Dendritic cells (DC) connect the innate and adaptive immunity by secreting 
cytokines and serving as APCs, of which DCs are the primary type. After 
phagocytosing pathogens, DCs mature, become activated, and upregulate the 
expression of MHC and costimulatory molecules. Activated DCs present the 
antigens to T cells, but also directly activate NK cells and B cells (Dubois et al. 
1999; Gerosa et al. 2002). MSCs can affect DCs, both directly and indirectly. 
MSCs prevent the maturation of monocytes and CD34+ precursor cells to DCs 
and reduce the receptors needed for DC maturation, such as MHC II and CD80 
and CD86 (Chiesa et al. 2011; Du Rocher et al. 2012). As a result of exposure to 
MSCs, DCs are unable to activate T-cells due to the reduced ability to present 
antigens, to stimulate T-cell proliferation, and to induce maturation of naїve T-
cells (Beyth et al. 2005; Du Rocher et al. 2012). MSCs can also return mature 
DCs to an immature form, where antigen presenting and co-stimulatory 
molecules are downregulated, IL-12 is secreted, and DCs are unable to stimulate 
the proliferation of lymphocytes (Zhang et al. 2009). 
 
MSCs can inhibit the T cell proliferation independently of the MHC molecules 
by arresting them at the G0/G1 cell cycle phase (Benvenuto et al. 2007; Glennie 
et al. 2005). MSCs do not induce apoptosis in T cells but can promote the 
survival of overstimulated T cells, which are led to activation-induced cell death 
(Benvenuto et al. 2007). Inhibition of T cells has been shown to reduce the 




to increase the production of anti-inflammatory IL-4 by TH2 cells (Aggarwal and 
Pittenger 2005; Zappia et al. 2005). Therefore, MSC shift the balance from pro-
inflammatory T cell activities and cytotoxicity towards anti-inflammatory 
functions. Anti-inflammatory T cells functions are also driven by stimulating the 
production of regulatory CD4+CD25+ T cells (Tregs). MSCs can induce the 
generation of Tregs either indirectly, by inducing IL-10 production by 
plasmacytoid DCs, which then stimulate the generation of Tregs (Aggarwal and 
Pittenger 2005; Fadeel et al. 1998), or directly by the secretion of HLA-G5 
antigen (Selmani et al. 2008).  
 
Controversial results have been published from experiments exploring the 
interactions between B cells and MSCs. The reason for the variable results has 
been hypothesized to be due to variable experimental settings in the in vitro 
studies (Augello et al. 2005; Corcione et al. 2006; Glennie et al. 2005; 
Rasmusson et al. 2007). However, most studies indicate that MSCs can inhibit 
B cell proliferation as well as their differentiation to antibody-producing plasma 
cells and expression of cytokine receptors (Augello et al. 2005; Corcione et al. 
2006; Glennie et al. 2005). The inhibitory effects seem to be due to the release 
of soluble factors and cell-cell contacts between MSCs and B cells (Corcione et 
al. 2006). Other investigators have reported that MSCs could support survival, 
proliferation, and differentiation of B cells in healthy individuals and in children 
with systemic lupus erythematosus (Rasmusson et al. 2007; Traggiai et al. 
2008).  
 
In addition to secreted factors and cell-cell contacts, MSCs can exert their 
immunomodulatory function through exosomes and a wide range of 
extracellular vesicles (EVs), which can transport a large variety of mRNA and 
non-coding RNA (Weiss et al. 2019). The functionality of the exosomes is 
dependent on their cargo. Exosomes can activate or suppress the immune 
system by affecting cytokine secretion, differentiation, and polarization of 





Figure 5. Overview of the immunomodulatory effects of MSCs on innate and adaptive immunity. 
The figure summarizes the publications referred to in paragraph 1.1.6. 
1.1.6 MOLECULAR MECHANISMS UNDERLYING MSC-INDUCED 
IMMUNOSUPPRESSION  
 
MSCs secrete various soluble factors, either constitutively or when stimulated 
by target cells. IFN-γ, TNF-α, and IL-1β secreted by the T cells have been 
identified as significant initiators of the immunomodulatory activities of MSCs 
(Krampera et al. 2006; Németh et al. 2009; Singer and Caplan 2011; Redondo-
Castro et al. 2017). MSCs constitutively secrete Transforming growth factor β 
(TGF-β), hepatocyte growth factor (HGF), IL-10, PGE2, IL-6, IL-8, and HLA-
G5, which affect both directly and indirectly to proliferation, differentiation, and 
function of innate and adaptive immunity cells (Figure 5.)  (Di Nicola et al. 2002; 
English et al. 2007; Selmani et al. 2008; Aggarwal and Pittenger 2005; Németh 
et al. 2009).  
 
Resting MSCs express low levels of MHC I molecules and lack the expression 
of MHC II molecules and costimulatory molecules CD40, CD80, and CD86 
entirely (Krampera et al. 2003; Prasanna et al. 2010). Exposure of MSCs to low 
concentrations of IFN-γ upregulates the expression of MHC II and may convert 




expression of MHC II molecules MSCs does not express CD80 or CD86, which 
are essential costimulatory molecules (Stagg et al. 2006; Galipeau 2017).     
 
MSCs exert most of their immunosuppressive effects by producing IDO, but 
some of the activity may be mediated by IL-6 (Meisel et al. 2004; Moll et al. 
2014a). IDO catalyzes the cleavage of tryptophan to kynurenine. Because 
tryptophan is essential for cell survival, proliferation, and protein synthesis, 
especially for lymphocytes, cleavage of tryptophan impairs the proliferation of 
T cell subsets, NK cells, and dendritic cells (Meisel et al. 2004). In vitro, MSCs 
immunosuppressive activities can be activated (primed/licensed) by IFN-γ 
treatment (François et al. 2012a).   
 
Moll et al. described in 2012 that when MSCs are administered intravenously, 
they become recognized by the complement system and destroyed due to IBMIR 
(Moll et al. 2012). In 2014 Moll et al. also hypothesized that dying MSCs may be 
useful in triggering phagocytosis due to their ability to recognize apoptotic and 
complement opsonized cells and turn them into the polarized M2 type 
regulatory cells (Moll et al. 2014a). Galleu et al. showed later that those GvHD 
patients, who had the highest T cell-mediated cytotoxic reactions towards MSCs, 
had the best responses to the MSC therapy and suggested that GvHD patients 
could be treated with apoptotic MSCs (Galleu et al. 2017). However, the effect of 
apoptotic MSCs can only be seen if the cells had been infused intravenously and 
but not by intraperitoneal delivery, as in the study by Galleu et al. (Galipeau and 
Sensebé 2018). The model of the immunosuppression mediated by fit and 












Figure 6. Suggested model for MSC immunosuppression mediated by fit and apoptotic cells. 
According to the conventional immunosuppression model, culture adapted and fit MSCs exert anti-
inflammatory functions through secreted factors, which result in an increase in the numbers of Tregs 
and M2 macrophages as well as a reduction in immune cell proliferation and cytotoxic activities. 
Together with these functions, MSCs participate in tissue regeneration by expressing morphogens 
and exosomes. According to the model suggested by Galleu et al. intraperitoneally administered 
apoptotic MSCs present “eat-me” signals produced by phosphatidylserine (PtS) to the phagocytosing 
macrophages, which in turn secrete anti-inflammatory factors. Figure modified from (Galipeau and 
Sensebé 2018) and harmonized with Figure 5. 
1.1.7 UTILIZATION OF MESENCHYMAL STROMAL CELLS IN 
CLINICAL APPLICATIONS  
 MSCs for GvHD 
 
One of the prime indications on which the clinical translation of MSCs has first 
focused because of their immunomodulatory properties is acute and chronic 
GvHD. Lazarus and coworkers were the first to test MSCs as medicines to treat 
GvHD in 1995 when culture expanded autologous MSCs were administered to a 
patient. However, this study was an early clinical phase I study and therefore, 
did not aim to study clinical efficacy but rather to investigate the safety and 
feasibility of the MSC therapy (Lazarus et al. 2005). Le Blanc et al. took 
significant steps in clinical utilization of MSCs in 2004 when a 9-year old boy 
with severe grade IV aGvHD was treated with allogeneic MSCs obtained from a 
third-party donor. Treatment with MSCs showed striking results with excellent 




2004). Subsequently, Le Blanc et al. reported good outcomes in a phase II trial 
where 55 patients with steroid-resistant acute or chronic GvHD were treated 
with allogeneic BM-MSCs received from a sibling or third-party donor (Le Blanc 
et al. 2008).  
 
Subsequent studies have, however, shown heterogeneous results, and 
evidence for the clinical benefit of MSCs has not been totally convincing (Fisher 
et al. 2019; Chen et al. 2015; Tolar et al. 2010).  Nonetheless, the comparison of 
pre-clinical and early clinical studies with late clinical studies is challenging due 
to different manufacturing scales and handling procedures (Galipeau and 
Sensebé 2018). Meta-analyses evaluating the safety aspects of treatment with 
MSCs have indicated, however, that they are well-tolerated, and severe adverse 
effects have not been reported (Lalu et al. 2012; Chen et al. 2015; Fisher et al. 
2019).   
 
The long journey of MSCs from bench to the bedside through three industry-
sponsored clinical trials has been recently reviewed by Galipeau (Galipeau 
2020). The first major industry-sponsored phase III clinical trial was performed 
between 2006 and 2009. In the study, cryopreserved allogeneic BM-derived 
MSCs (remestemcel-L, Prochymal®) were provided by Orisis Therapeutics Ltd. 
(Columbia, MD, USA) for treating adults and children with steroid-refractory 
GvHD (NCT00366145). The results of the study were initially presented in a 
conference abstract (Martin et al. 2010) and finally reported much later 
(Kebriaei et al. 2019). The study did not, however, meet the primary endpoint of 
a durable complete response lasting at least 28 days, and the difference between 
responders (30%) and placebo group (35%) was statistically non-significant 
(p=0.42) (Kebriaei et al. 2019). However, a subset study from the data by 
Kurtzberg et al. revealed that children were responsive to MSCs (Kurtzberg et 
al. 2010).  
 
The results of the second major study were reported by Kurtzberg et al. The 
study was initiated in 2007 and enrolled until 2015. The study was distinct from 
the first Prochymal® study. Children and adults with any grade B and D GvHD 
were treated if they showed symptoms of steroid resistance for at least three 
days (NCT00759018). The treatment resulted in an overall response of 65.1% 
(complete responders 14.1%, partial responders 51.3%) on day 28, and day 100 
survival could be predicted from the day 28 results (Kurtzberg et al. 2014).  
 
In 2013 Osiris Therapeutics sold the assets of Prochymal® to Mesoblast Ltd. 
(Melbourne, Australia). A new open-label, single-arm phase III study 
(NCT02336230) was initiated with MSCs (remestemcel-L) with a new product 
name Ryoncil®. The study involved pediatric patients with acute steroid 
refractory GvHD and was completed in 2017. The study successfully met the 
primary endpoint of an improved day 28 overall response rate of 69% with 




compared to the control group, and the effect was sustained at day 180. The 
results of the study have been reported recently (Kurtzberg et al. 2020).  
 
In 2012, based on results reported by Kurzberg et al. (Kurtzberg et al. 2010), 
the MSC product received conditional market approval in Canada for children 
with GvHD, and later in New Zealand and Japan (Galipeau and Sensebé 2018). 
After obtaining the results from the latest phase III study (Kurtzberg et al. 2020)  
Mesoblast Ltd. has filed a Biologics License Application for Ryoncil® to the FDA 
for marketing authorization in USA, Europe, and Asia excluding Japan, to treat 
children with steroid-refractory acute GvHD (Galipeau 2020). The latest 
encouraging results show that MSC products may finally meet the FDA 
requirements for marketing authorization.   
 MSCs for other indications 
 
Because MSCs are one of the crucial contributors to the HSC niche, they have 
been utilized in supporting HSC engraftment after transplantation. MSCs can 
enhance engraftment by reconstituting the damaged microenvironment. They 
can also prevent graft rejection by suppressing T cell activity (Ball et al. 2007). 
The first clinical studies for MSCs as a supporter of HSC engraftment and graft 
survival revealed a rapid hematopoietic recovery (Koç et al. 2000; Lazarus et al. 
2005). Similar results have also been reported in other phase I/II clinical studies 
(Ball et al. 2007; MacMillan et al. 2009). The study of Bernardo et al. did not, 
however, detect improved recovery in patients who had received allogeneic BM-
MSCs or UCB-MSCs after HSC transplantation compared to the control group 
(Bernardo et al. 2011). Furthermore, later studies reported heterogeneous and 
controversial results regarding the ability of MSCs to support engraftment, 
although the use of MSCs was found to be both feasible and safe. A meta-analysis 
by Kallekleiv et al. concluded that no statistically significant benefit of MSCs in 
co-transplantation with hematopoietic stem cells was evident (Kallekleiv et al. 
2016).  
 
The secreted anti-inflammatory cytokines, as well as the ability of MSCs to 
home to injured tissue and to stimulate the recovery of the tissues are the 
properties which make MSCs promising for cell-based therapy for IBD. The 
generally accepted cause for IBD is the immune response to environmental 
factors in genetically susceptible individuals. The therapeutic effects of MSCs in 
IBD have been studied first in animal models, where they have shown promising 
results (Algeri et al. 2015). Although controversial results for the efficacy of 
MSCs have been reported in early clinical trials, an industrial-sponsored phase 
III clinical trial, where Crohn’s disease-related fistulas were treated with MSCs, 
showed significant efficacy as compared to placebo (Panés et al. 2016; Algeri et 
al. 2015). The effect was still evident after one year (Panés et al. 2018). A meta-




fistulas have shown improved healing rates compared to patients who did not 
receive MSCs and also indicated the safety of MSC therapy (Cao et al. 2017; 
Panés et al. 2016).  
 
The osteogenic differentiation potential has been utilized in tissue 
regeneration, especially in treating large bone defects as well as oral and 
maxillofacial defects (Gimbel et al. 2007; Kaigler et al. 2013; Mesimäki et al. 
2009). MSCs have the potential to increase osteoinduction and osteogenesis and 
have also been used together with PRP to provide healing promoting factors to 
the injury site in the bone (Yamada et al. 2004). MSCs have been administered 
systemically, and by injecting locally, but the most promising approach has been 
the combinatorial therapy with MSCs and a biodegradable scaffold (Oryan et al. 
2017). Currently, due to the lack of published clinical trials, controversies in the 
results, and variability in the methods, protocols, and treatment strategies, 
MSCs are not yet a viable option in bone regeneration (Oryan et al. 2017).  
 
The use of MSC therapy has also been explored in liver diseases, especially 
for liver fibrosis (Alfaifi et al. 2018), to improve heart function after myocardial 
infarction (Lalu et al. 2018) or after ischemic heart failure (Michler 2018; 
Kastrup et al. 2017). The utilization of immunomodulatory properties has been 
studied in the treatment of multiple sclerosis (Scolding et al. 2017), as well as in 
neurodegenerative diseases, where also the regenerative potential of MSC is 
being evaluated (Volkman and Offen 2017). Most recently, MSCs have shown 
potential for treating symptoms of a severe acute respiratory syndrome caused 
by Coronavirus-2 (SARS-CoV-2), such as acute respiratory distress syndrome, 
pneumonia and sepsis (Moll et al. 2020a). 
 Translational challenges 
 
A variety of factors such as different culturing conditions, medium supplements, 
tissue origin of MSCs, handling and cryopreservation of cells as well as the route 
of administration may have an impact on the clinical outcomes (Moll et al. 
2020b). The source of the tissue is known to have a significant impact on the 
expression of TF/CD146 on the cell surface. Highly procoagulant Tissue factor 
is known to be the primary cause of blood incompatibility of MSCs, causing the 
IBMIR (Moll et al. 2019). Suboptimal culturing conditions and extensive 
expansion of MSCs may accelerate cellular aging and thus reduce MSCs 
functionality.  The reasons for the modest results of the main study have been 
widely hypothesized, and one of the major causes has been suggested to be the 
extensive expansion of MSCs and the use of cryopreserved instead of fresh cells 







MSCs for the first Prochymal® study were expanded extensively to obtain 
10 000 doses from one donor, whereas early-stage studies have been based on 
approximately ten doses per donor (Galipeau and Sensebé 2018). Therefore the 
final product used in the Prochymal® study may have contained a larger 
proportion of senescent cells than in the small scale studies (Galipeau and 
Sensebé 2018). Prochymal® was also a cryobanked product, which was thawed 
and administered at the point of care. Cryopreservation of MSCs is known to 
impair the immunomodulatory properties of MSCs (François et al. 2012a).  It 
could be argued that MSC therapies could be improved not only by careful 
optimization of manufacturing protocols and monitoring of cell products during 
processing, but also by developing accurate measures for potency, clinical 
outcomes. Examples of clinical studies utilizing MSCs have been listed in Table 
1.  
  
The study presented in this thesis has been linked to the development of the 
manufacturing process for clinical-grade MSCs, which are to be used for treating 
children and adults with acute or chronic GvHD in Finnish university hospitals.  
This study has also concentrated on gathering more knowledge about crucial 
quality attributes such as cellular aging and the effects of freezing during the 
production process of MSCs. The treatment provided by the products 
manufactured in FRCBS Advanced Cell Therapy Centre has been approved by 
the competent national authority, Fimea, under the hospital exemption license. 
The results from the follow-up for treating GvHD with allogeneic BM-MSCs 
have been reported in Salmenniemi et al. (Salmenniemi et al. 2017). The 
following chapters describe important parameters and quality attributes in the 
manufacturing of clinical-grade MSC products and finally report the results of 






















Table 1. Examples of clinical studies performed using MSCs. 




Allogeneic BM-MSCs form HLA 
identical or haploidentical sibling 
or third-party HLA mismatched 
donors. 
Le Blanc et al. 2004 
Ringdén et al. 2006 
Le Blanc et al. 2008 
von Bonin et al. 2009 
Martin et al. 2010*1 
Kurtzberg et al. 2010*1 
Lucchini et al. 2010 
Kurtzberg et al. 2014*2 
Dotoli et al. 2017 
Salmenniemi et al. 2017 
Kurtzberg et al. 2020*3 
Crohn’s disease Autologous and allogeneic AT- 
and BM-MSCs 
Garcia-Olmo et al. 2009 
Duijvestein et al. 2010 
Forbes et al. 2014 
Dhere et al. 2016 
Panés et al. 2016*4 
Panés et al. 2018*5 
Multiple sclerosis Autologous BM-MSCs Karussis et al. 2010 
Yamout et al. 2010 






Liang et al. 2010 
Wang et al. 2014 




Carlsson et al. 2015 
Cai et al. 2016 
Osteoarthritis Autologous BM-MSCs Orozco et al. 2013 
Soler et al. 2016 





Autologous and  
allogeneic BM-MSCs 
Hare et al. 2012 
Bartunek et al. 2013 
Chullikana et al. 2015 
Kastrup et al. 2017 
Liver diseases Allogeneic BM-MSCs Kharaziha et al. 2009 
Detry et al. 2017 
Kidney transplantation Allogeneic AT-MSCs 
Autologous and allogeneic  
BM-MSCs 
Perico et al. 2011 
Vanikar et al. 2014 
Reinders et al. 2015  
Engraftment support 
after HSCT  
Allogeneic BM-MSCs Koç et al. 2000 
Ball et al. 2007  
MacMillan et al. 2009 
Bernardo et al. 2011 
Batorov et al. 2015 
Castello et al. 2018 
*1 An industry-sponsored clinical trial with Prochymal® for adult and pediatric patients. 
*2An industry-sponsored clinical trial with Prochymal® for pediatric patients.  
*3Latest industry-sponsored clinical trial with Ryoncil® for pediatric patients. 
*4An industry-sponsored clinical trial with Alofisel® for adult patients 






1.2 CLINICAL-GRADE MANUFACTURING OF MSCS 
1.2.1 MSC CULTURE PARAMETERS 
 
Clinical-grade MSC cultures utilized for immunomodulatory applications are 
most often isolated from BM. The MSC culture originates from only a few cells, 
and therefore the cells must be expanded extensively ex vivo in order to obtain 
satisfactory cell numbers for clinical use (Ringdén et al. 2006; Bartmann et al. 
2007). First, the primary culture is established by isolating the mononuclear cell 
fraction from the BM aspirate or other sources. MNCs are allowed to adhere for 
72 hours, after which nonadherent cells are removed by washing and culturing 
is continued. The optimal culture medium supports the division of MSCs, but 
not the expansion of other residual cells, for example, macrophages.    
 
The original number of MSCs, which gives rise to the culture, can be 
quantified with the CFU-F assay (Castro-Malaspina et al. 1980). The number of 
colony-forming units is predictive for the replicative capacity of the culture 
(Digirolamo et al. 1999). The age of the BM donor is crucial for the success of 
the culture since the number of colony-forming units has been shown to 
decrease with aging (Lohmann et al. 2012).  
 
In continuous MSCs cultures, the plating density has an impact on cell yields 
and cell characteristics (Samuelsson et al. 2009; Sekiya et al. 2002; Bartmann 
et al. 2007). There are conflicting opinions about the suitable plating density for 
MSCs in clinical-grade cultures. However, lower seeding densities have resulted 
in more immature progenitor cell subsets (Sekiya et al. 2002). Prockop et al. 
proposed that 10 cells/cm2 would be the optimal plating density for MSCs to 
maintain high numbers of the rapidly dividing cells (Prockop et al. 2001). 
Bartmann et al. also claimed that a low seeding density helped to maintain a 
high proliferative potential in MSC cultures (Bartmann et al. 2007). In the study 
of Doucet et al. 2005, a seeding density of 1000 cells/cm2 produced the highest 
cell yields and the shortest culturing time (Doucet et al. 2005). In clinical-grade 
cultures, a density of 1000 cells/cm2 was thought to be a good compromise to 
produce high numbers of cells (Doucet et al. 2005; Sensebé 2008; Sekiya et al. 
2002). 
 
The culture medium should be replaced partially at the beginning of culture 
passage to maintain the concentration of Dickkopf-1 (Dkk-1) at an adequate 
level. Dkk-1 is secreted by MSCs during the lag phase to facilitate entry to the 
cell cycle. Dkk-1 also maintains the cells in an undifferentiated state during their 
expansion (Gregory et al. 2003; Horwitz 2004).  
 
Confluency in the MSC cultures should be kept under 100% during the 




considered as optimal (Abo-Aziza and Zaki 2017). Entirely confluent cultures 
should be avoided since cell contact may induce senescence through a p53 and 
telomere-independent mechanism (Ho 2011). Contact inhibition also hinders 
cell proliferation by affecting transmembrane signaling and cytoskeletal 
reorganization, which results in senescence-associated enlarged cell 
morphology (Nelson 2002, Murphy 2009).   
 
Population doubling (PD) numbers are used as a measure of aging of the cells 
in clinical-grade cultures. The maximum number of doublings for MSCs is 40-
50 PDs in culture (Lepperdinger et al. 2008; Bieback et al. 2011). However, the 
methods used for counting PD numbers have not been standardized between 
laboratories and depend on how the start of the culture has been defined 
(Lepperdinger 2008, Sensebe, Prockop 2010).  
1.2.2 CULTURE SUPPLEMENTS 
 Fetal calf serum 
 
Fetal bovine serum (FBS) has been used as a universal cell culture supplement 
in research and the cell cultivating industry since the 1950s (Puck et al. 1958). 
The FBS contains essential components for cell proliferation and growth, such 
as hormones, vitamins, growth factors, transport proteins, and trace elements. 
However, the specific critical components in FBS are not known (van der Valk 
et al. 2010). The use of FBS involves significant lot-to-lot variation originating 
from seasonal and geographical variation, which leads to unexpected outcomes 
in laboratories (Baker 2016).  
 
FBS is a controversial supplement in cell cultures utilized for clinical 
applications; the most severe concerns involve the risks to patient safety. FBS 
possesses a risk of animal-origin transmissible pathogens such as prions, 
viruses, and mycoplasma (Dormont 1999; Wessman and Levings 1999). The risk 
of zoonogenic infection must be considered in MSCs cultures since prions 
inducing transmissible spongiform encephalopathy (TSE) were demonstrated 
to infect murine MSCs (Cervenakova et al. 2011). FBS may also influence the 
patient’s immune system as a xenoantigen (Selvaggi et al. 1997; Spees et al. 
2004). Heiskanen et al. reported that human embryonic stem cells and MSCs 
cultured in an FBS supplemented medium was contaminated by N- 
glycolylneuraminic acid (Neu5Gc) originating from FBS (Heiskanen et al. 
2007). Anaphylactic or arthus-like immune reactions have been reported with 
patients who have received cells cultured in FCS supplemented medium 
(Selvaggi et al. 1997). MSCs cultured with FBS also express a less stable 
transcriptional profile than MSCs cultured with other supplements and 




passage cells, which may lead to an extended lifespan (Shahdadfar et al. 2005). 
Regulatory authorities have strongly recommended replacing FBS with human 
origin culture supplements in the manufacturing of ATMPs (Bieback et al. 
2019).  
 
The developing biotechnology and pharma industry as well as increased 
needs for research have exacerbated the worldwide shortage of FBS, increased 
prices, and made the supply chain of FBS prone to fraud (Gstraunthaler et al. 
2013; Van der Valk et al. 2018). In 1994, when the global amount of New Zealand 
serum sold for GMP manufacturing as compared to the figures of collected 
serum, it was observed that of the sold 30 000 L of New Zealand serum, only 
half had been produced in New Zealand. New Zealand serum is used in clinical-
grade manufacturing since no prion-mediated BSE infection has been found in 
New Zealand. Another instance of fraud was uncovered in 2003 when a global 
supplier of FBS was caught for blending New Zealand serum with lower grade 
bovine serum albumin, water, and growth-promoting supplements 
(Gstraunthaler et al. 2013; Van der Valk et al. 2018). An investigation by the US 
Federal Food and Drug Administration found that during the years 2008-2013, 
143 FBS batches with a total volume of 280 000 L were affected by crime (Van 
der Valk et al. 2018).  
 
The use of FBS is also accompanied by ethical issues and environmental 
concerns since FBS is a side product of the meat and dairy industry. Animal 
welfare issues have also been introduced into the debate since the 800 000 L of 
FBS produced annually corresponds to 2 000 000 bovine fetuses (Brindley 
2012). 
 Platelet lysates 
 
Platelet-derived growth factors were shown to support the proliferation of MSCs 
in the study of Lucarelli et al., where the platelet-rich plasma was shown to 
promote the proliferation of BM stromal stem cells in a dose-dependent manner 
(Lucarelli et al. 2003). The first replacement of FBS was postulated in a study 
where human autologous plasma and allogeneic serum were used to replace FBS 
in MSC cultures (Shahdadfar et al. 2005). In that study, MSCs proliferated 
markedly better with autologous human serum than in FBS but human serum 
was not able to support differentiation. Allogeneic human serum supplement 
was reported to result in growth arrest, and cell death (Shahdadfar et al. 2005) 
since certain essential growth factors for MSCs are not present in human sera 
(Kuznetsov et al. 2000; Müller et al. 2006).  
 
Doucet et al. suggested the use of PL supplements for ex vivo expansion of 
clinical-grade MSCs in 2005 (Doucet et al. 2005). PL prepared from platelets 




supplement for MSCs, also supporting their differentiation potential  (Doucet et 
al. 2005; Becherucci et al. 2018). It was claimed that PL resulted in better 
support for cell proliferation than FBS (Capelli et al. 2007; Doucet et al. 2005). 
However, one study reported that MSCs cultured with PL had a lower 
immunosuppressive capacity than cells cultured with FBS (Bernardo et al. 
2007a).  The study of Doucet and others found that the best cell yield with 
reduced culturing time resulted in culturing cells with 5% PL and with a density 
of 1000 cells/cm2 (Doucet et al. 2005). PL was found to support the 
characteristics and functionality of MSCs and to be a suitable replacement for 
FBS in large-scale cultures (Doucet et al. 2005; Bernardo et al. 2006; Müller et 
al. 2006; Schallmoser et al. 2007). 
 
Platelets are a source of growth factors and can be obtained as side-products 
of blood donations. Platelet products are also an ethical choice since platelet 
products are suitable for patient use for only up to 4-5 days but are still ideal for 
cell cultures (Bieback et al. 2009). Granules containing the growth-supporting 
factors can be released from platelets by activating the platelets with thrombin 
(tPRP) or through freeze-thaw cycles. However, there is no standardized 
practice for an optimal number of freeze-thaw cycles, and the cycles used have 
varied between 1-5 (Doucet et al. 2005; Laitinen et al. 2016a; Strandberg et al. 
2017). However, when Strandberg et al. explored the optimal number of freeze-
thaw cycles to release the maximum concentrations of growth-supporting 
factors, 3-5 cycles were reported as the optimum (Strandberg et al. 2017). 
 
Platelet-derived growth factor (PDGF), transforming growth factor β1 (TGF-
β1), epidermal growth factor (EGF) and basic fibroblast growth factor (bFGF) 
are essential mitogenic growth factors found in PL supporting MSC, 
chondrocyte and osteocyte proliferation (Doucet et al. 2005; Fekete et al. 2014). 
PDGF and bFGF are critical components of MSC survival, and blocking of 
PDGF-BB and bFGF resulted in a loss of proliferation (Fekete et al. 2012). The 
presence of the platelet-derived growth factor isoform PDGF-BB has been 
reported to protect MSCs from senescence initiated through the p53/p21 
pathway (Zhang et al. 2016).  
 
When platelets are lysed, they also release factors, which initiate and 
maintain blood clotting (Burnouf et al. 2013). Therefore, heparin or some other 
anti-clotting additive is used in the medium. Heparin products of non-human 
origin are approved medicinal products for clinical use and thus have not 










Table 2. Examples of animal serum-free culture systems for MSCs. 













N/A N/A N/A 4 






1×109 0.05×109 2 10 





1×109 25×106 N/A N/A 






2.5×109 0.13×109 1 10 
Lange et al. 





1.5×109 0.08×109 1 7-13  
Capelli et al. 
2007 
5% platelet 
lysate (PL) 1.2×109 0.06×109 2 N/A 
Schallmoser et 
al. 2007 
10% HPL;  























2×109-3×109 0.2×109-0.3×109 2 Several 






500×109 0.5×109 1 10 
Castrén et al. 
2015 
0.5% platelet 
lysate with 2.5% 
AB plasma  
300×109 0.8×109 5 4-16 






300×109 0.1×109 2 8-52 
0.5% platelet 
lysate with 2.5% 
AB plasma  





1.2.3 OXYGEN CONCENTRATION 
 
The physiological oxygen concentration in the BM varies between 1-7% 
depending on the vascularization and distance from a sinus (Chow et al. 2001; 
Ito et al. 2015). Most clinical-grade MSCs are, however, cultured under 
atmospheric oxygen (20-21%), which exposes cells to high oxygen 
concentrations as compared to their physiological environment. Various studies 
have shown that excess oxygen, such as that to which cells are exposed during 
in vitro culturing, has been reported to cause oxidative damage and drive the 
cells into senescence (Burova et al. 2013; Estrada et al. 2013; Ito et al. 2015; Tsai 
et al. 2011). 
 
BM-derived MSCs are especially sensitive to oxygen (Bigot et al. 2015), and 
many studies have reported beneficial effects of in vitro hypoxia on MSCs (Nold 
et al. 2015; Tsai et al. 2011; Jin et al. 2010). When oxygen levels during cell 
culturing have been set to 1-3%, a marked improvement was observed in the 
extension of the MSCs’ lifespan and delay of senescence (Fehrer et al. 2007; Jin 
et al. 2010; Tsai et al. 2011), with an increase in the cell numbers being produced 
(Grayson et al. 2007; Nold et al. 2015; Martin-Rendon et al. 2007). In vitro, 
hypoxia has been shown to promote the proliferation of MSCs without impairing 
their characteristics or immunosuppressive capacity (Nold et al. 2015). 
 
Hypoxia seems to maintain MSCs in a primary undifferentiated state and 
result in a higher number of CFU-F colonies throughout the lifespan of the cell 
culture as compared to culturing at an ambient oxygen level  (Fehrer et al. 2007; 
Grayson et al. 2006), where the number of CFUs becomes markedly reduced 
over time (Schellenberg et al. 2013). Long-term exposure to in vitro hypoxia 
may, however, reduce the adipogenic differentiation markedly and inhibit 
entirely osteogenic differentiation (Fehrer et al. 2007). However, it seemed that 
both capacities could be restored by transferring the cells to ambient oxygen 
conditions (Fehrer et al. 2007). Short-term in vitro hypoxia has been shown to 
improve chondrogenic differentiation (Martin-Rendon et al. 2007). AT-derived 
MSCs also display diverse responses to lower oxygen concentrations and have 
different manifestations of DNA Damage-induced H2AX foci than BM-derived 
MSCs (Bigot et al. 2015). 
 
Reactive oxygen species (ROS) originating from exogenous or intracellular 
sources induce DNA damage and thus drive cells into senescence (von Zglinicki 
2002; Saretzki and von Zglinicki 1999; von Zglinicki et al. 2000). Mitochondria 
are essential in reducing reactive oxygen radicals, which may damage both 
mitochondrial (mtDNA) and cellular DNA and initiate DNA damage response 




maintenance of mtDNA after genotoxic stress, especially in BM-MSCs, and to 
reduce the occurrence of exogenous double strand breaks and chromosomal 
abnormalities (Bigot et al. 2015). According to one study, exogenous ROS were 
reported to promote aneuploidy in MSCs, and aneuploidy was shown to be 
closely associated with replicative senescence (Estrada et al. 2013). 
1.2.4 REGULATORY ASPECTS  
 
MSCs intended for clinical use are manufactured in highly regulated and 
controlled conditions, according to current good manufacturing practices 
(cGMP). MSCs are classified as ATMPs in the European Union (EU), together 
with products used in gene therapy and regenerative medicine (Schneider et al. 
2010). 
 
In the EU GMP guideline (Eudralex Volume 4, directive 2003/94/EC), the 
principles and responsibilities for ATMP manufacturing are described 
(Eudralex GMP guidelines Vol 4 2017). Manufacturing is supervised in EU 
countries by the European Medicines Agency (EMA) and in Finland by the 
corresponding competent authority, The Finnish Medicines Agency, Fimea. The 
corresponding authority in the USA is the FDA, which supervises 
pharmaceutical manufacturing. FDA regulations for manufacturing food and 
drugs have been collected on part 21 (FDA CFR part 21 2013). 
 
The GMP and other regulatory activities aim at the safety of the patient. 
Regulations and recommendations have arisen from serious incidents that have 
occurred in the past, where careless action and non-standardized procedures 
have led to severe sequelae. The manufacturer must carefully characterize the 
factors affecting the quality and safety of the final product. These factors include 
the raw materials (donors/cells), process parameters and processing conditions, 
potency and characteristics of the product, as well as the stability during storage 
and delivery (Eudralex GMP guidelines Part IV 2017; FDA CFR part 21 2013).  
 
The objective of GMP regulation is to ensure that the product is pure, safe, 
and efficacious. Both Eudralex and FDA guidelines recommend a risk-based 
approach when evaluating the safety issues and to utilize research to assess the 
risks; the manufacturer should expose the product to the conditions, which 
could reveal any unexpected quality and safety issues since several parameters 
may affect the characteristics and functionality of the final product (Eudralex 






1.2.5 MANUFACTURING SCALES 
 
Cell therapy products can be manufactured on a non-industrial scale, which 
produces a few to multiple patient doses in one batch, depending on the culture 
system or on an industrial scale, where hundreds to thousands of patient doses 
are produced in one batch (Galipeau and Sensebé 2018). For treating a patient 
with GvHD, a dose of 1-2x106 cells per 1 kg patient body weight is often 
administered (Bartmann et al. 2007; Chinnadurai et al. 2017; Galipeau and 
Sensebé 2018). A large industry-sponsored phase III clinical trial infused 2x106 
cells/1 kg patient body weight twice per week for four weeks (Galipeau and 
Sensebé 2018). 
 
Currently, most clinical-grade MSCs are manufactured on a non-industrial 
scale (Naji et al. 2019).  High cell yields can be obtained by upscaling the culture 
to bioreactors (Haack-Sørensen et al. 2018; Russell et al. 2018; Mizukami and 
Swiech 2018). The advantage of bioreactors is that culture conditions are highly 
controlled and adjustable, whereas for example, the oxygen level in planar 
systems such as in culture flasks or cell stacks cannot be continuously monitored 
and controlled (Mizukami and Swiech 2018). In a bioreactor, the culturing 
temperature, the proportion of dissolved oxygen, and pH in the culture can be 
set to an optimal level (Sensebé et al. 2013; Mizukami and Swiech 2018). In the 
culturing of MSCs, the bioreactor types mostly used are mono- and multilayer 
bioreactors, hollow fiber bioreactors, stirred tanks, or wave bioreactors, with 
microcarrier and perfusion systems (Mizukami and Swiech 2018). However, the 
challenge in the manufacturing of MSCs in bioreactors is the difficulty in 
detecting confluency as well as observing cell morphology, and therefore 
monitoring the proportion of senescent cells becomes important (Chinnadurai 
et al. 2017).  
1.2.6 QUALITY PARAMETERS  
 
Manufacturing of ATMPs requires aseptic processing throughout the 
manufacturing to ensure product sterility since the product cannot be sterilized 
by autoclaving or filtering. Therefore, high requirements have been set for the 
facilities, equipment, human resources, and controlling the manufacturing 
process. In-process controls and quality control analyses must be designed to 
measure the proper parameters to ensure the safety and potency of the product. 
 
Testing of donors for possible viral infections is crucial for obtaining a sterile 
cell culture. Although regulations for manufacturing do not include 
consideration of the donor’s age, an appropriate limit should be considered 
since increasing donor age exhibits a strong correlation with decreasing 





There are differences in opinions about the benefits of immunosuppression 
assays as a release criterion for product potency. A potency assay should 
demonstrate the biological activity of the product and be based on the intended 
use in the clinical application. However, there is no specific criterion for the 
immunosuppressive potency assay due to the complexity of MSCs’ 
immunomodulatory mechanisms. Therefore, ISCT recommends an assay 
matrix including quantitative RNA and proteome analyses to complement the 
immunosuppression assay (Galipeau et al. 2015; Viswanathan et al. 2019). 
 
MSCs have a limited lifespan, and because senescence is accompanied by 
typical changes, which may impair both the characteristics and functionality of 
the cells, the aging of the cells during processing should be monitored. BM-
derived MSC cultures originate from a relatively small volume of BM, which 
contains a minor population of MSCs. The MSC culture must be expanded 
extensively to obtain high yields of early passage cells. During the expansion, 
MSCs exhaust a large proportion of their division potential, especially during 
the formation of the primary culture (DiGirolamo et al. 1999).  
 
Monitoring the PD number during culturing is the primary control for 
cellular aging (Cristofalo et al. 1998; Wagner et al. 2010), but the 
implementation of a screening method for senescence would be necessary for 
the production process. Bertolo et al. suggested a senescence score based on 
evaluation of PD number, morphological, physiological and genetic markers as 
well as testing of senescence specific markers such as counting the proportion 
of senescence-associated beta-galactosidase (SA-β-gal) positive cells, and 
expression levels of cyclin-dependent kinase inhibitors p16 and p21 (Bertolo et 
al. 2016). Epigenetic changes can be analyzed for monitoring aging in clinical-
grade cell cultures since aging-related methylation patterns accumulate in MSCs 
(Bork et al. 2010; Peffers et al. 2016). 
 
MSCs do not seem to be prone to spontaneous transformation during culture, 
but chromosomal aneuploidy may occur without transformation (Tarte et al. 
2010). According to one study, aneuploidy often occurs in senescent cells 
(Estrada et al. 2013). Genetic stability is routinely monitored from the MSC 
products by performing a karyotype analysis. However, the method is very 
inaccurate and cannot detect premalignant clonal changes (Barkholt et al. 
2013).  
 
Cryopreservation of the cells is essential to produce off-the-shelf MSC 
products. Cryopreservation holds a variety of benefits such as timely delivery 
and dosing of the product on the clinic side and better planning and control of 
the manufacturing. However, the risks and benefits associated with 
cryopreservation of MSCs have been a matter of debate since MSCs have 
exhibited a marked reduction of functionality after freezing and thawing. MSCs 




Reaction (IBMIR) or the complement system after thawing (François et al. 
2012a; Moll et al. 2014a). 
1.3 CELLULAR AGING AND SENESCENCE 
Aging is a complex and continuous process starting from the embryonal 
development stage and continuing throughout the lifespan of the organism, 
resulting eventually in declining functional capabilities. At the organismal level, 
aging encompasses the accumulation of senescence to such an extent, where it 
can be observed as changes in an organism's phenotype and functionality. In 
addition, the likelihood of aging-related severe diseases, such as degenerative 
diseases or cancer, increases during the lifetime (Childs et al. 2015). At the 
cellular level, senescence is seen as the permanent arrest of cell division as a 
result of accumulating cellular damage (Hayflick 1965). The finite lifespan of 
mammalian cells was first described by Leonard Hayflick and co-workers in 
1961 when they cultured normal diploid human fibroblasts (Hayflick and 
Moorhead 1961). In the senescence state, the cells lose their ability to divide but 
remain alive and metabolically active (Itahana et al. 2001). Hayflick and co-
workers discovered the replicative senescence, which is considered as “natural 
aging” and described an upper limit of 50 doublings for fibroblasts (Hayflick and 
Moorhead 1961). Senescent cells express morphological, metabolic, and 
functional changes deviating from young or pre-senescent cells (Sethe et al. 
2006; Kuilman et al. 2010; Mets and Verdonk 1981).  
 
In the Hayflick model, growth arrest has been named as the M1 phase during 
cell culturing (Wei and Sedivy 1999). The typical characteristics of M1 are the 
flattened morphology and enlarged cell size as well as accumulated lysosomal 
content, which can be observed as increased β-galactosidase activity (Stein et al. 
1999). In the M1 phase, the length of telomeres has eroded to critical lengths 
(Wei and Sedivy 1999). In experiments, where cell cycle regulators pRb and p53 
have been inactivated, the erosion of telomeres continued together with cell 
division and concurrently with extensive cell death until cells enter the crisis 
phase M2 (Wei and Sedivy 1999). If senescence mechanisms are inactivated, and 
telomerase is activated, cells can bypass the crisis phase. In the crisis phase, 
disrupted telomere structures reveal the chromosome ends, which are repaired 
by the end-joining of the chromosome ends, which is followed by a continuous 
cycle of chromosome breakage and joining (de Lange T. 2009). A bypassed crisis 
phase may lead to immortalization of the cells and a malignant transformation 





Figure 7. Hayflick model of a cell culture leading to a senescence state M1 and the crisis phase M2. 
After initiating the cell culture and logarithmic growth phase, when diploid somatic cells have reached 
the ”Hayflick limit” of 50 doublings, the cells will either enter the senescence phase M1 or die if the 
proportion of accumulated DNA damage is high. During the M1, the telomeres have reached their 
critical length, and genetic instability has become increased. If mechanisms leading to senescence 
state (cell cycle arrest) are not functional due to inhibition or mutations, and if telomerase is re-
activated, the cell may bypass the crisis phase M2 and become immortal (Wei and Sedivy 1999). 
Senescence is not homogenous in a cell culture and may begin earlier in a subset 
of cells. However, eventually, cell cycle arrest and other senescence 
characteristics are synchronized as a result of a multistep process (Alcorta et al. 
1996). Cells will finally die at the end of the senescence phase. Gosselin et al. 
showed that cells do not express apoptotic markers during senescent death, but 
die of high macroautophagic activity, causing the damage of cellular 




Senescence is essentially a mechanism to protect the organism from damage 
originating from replicative exhaustion, various stressors, or cancer. Damaged 
or aberrant cells are led to senescence before malignancy develops. However, 
senescence is an example of a phenomenon called antagonistic pleiotropy, 
where initially beneficial features can turn into mechanisms which may lead to 
aggravated damage in cells and tissues and finally to aging-related degenerative 
diseases or the development and progression of cancer (Kirkwood and Austad 
2000). The main reason for the controversial nature of senescence may be 




cells secrete a wide range of cytokines, chemokines, and proteolytic enzymes, 
which have been connected to various aging-related changes and molecules that 
support tumor growth (Coppé et al. 2010). Senescence can be either beneficial 
or detrimental, depending on the context.  
1.3.1 SENESCENCE PROGRAMS 
 
Replicative senescence is considered as natural aging, which is due to the loss of 
proliferative potential or replicative exhaustion of the cell and is dependent on 
telomere length (Hayflick and Moorhead 1961; Harley et al. 1990). The gradual 
shortening of telomeres and the accumulation of DNA damage lead to 
replicative senescence (Allsopp et al. 1992; von Zglinicki 2002; di Fagagna et al. 
2003; Harley et al. 1990).  
 
Stress-induced senescence can be triggered by various extrinsic factors such 
as irradiation (UV, gamma), chemotherapeutic drugs, low or high temperatures, 
oxidative stress, and lack of nutrients in the cell culture (Davalos et al. 2010; 
Toussaint et al. 2000). When cells are isolated and cultured in vitro, they are 
exposed to conditions differing from their natural environment such as high 
oxygen levels, lower temperatures, an artificial culture medium containing 
variable concentrations of nutrients, and a different surrounding cell 
environment (Sherr and DePinho 2000). One or more of these stress factors can 
induce a “culture shock” and trigger stress-induced senescence (Sherr and 
DePinho 2000).  
 
Oncogene-induced senescence (OIS) is induced due to the activation of an 
oncogene (Serrano et al. 1997). Stress-induced senescence, as well as oncogene-
induced senescence, are independent of telomere length (Davalos et al. 2010). 
Telomere length independency of stress-induced senescence has been described 
in mice, whose cells express telomerase continuously, in contrast to human cells 
(Prowse and Greider 1995).  
1.3.2 MANIFESTATION OF PROGRESSED AGING AND SENESCENCE 
 Cell cycle arrest 
The cell cycle is a stringently controlled process that produces two daughter cells 
from one cell. Cyclins are the primary regulators of the cell cycle, which in a 
complex with cyclin-dependent kinases (CDKs), phosphorylate the 
Retinoblastoma protein (pRb). CDKs are needed for the transition of the cell 
cycle from G1 phase to the synthesis phase, and Cyclin-CDK complexes are 




families; the INK family (p15INK4b, p16INK4a, p18INK4c, and p19INK4d)  and the 
Cip/Kip/Waf family including p21Cip1, p27Kip1, and p57Kip2 (Sherr and Roberts 
1999). 
 
p16INK4a (later p16), and p21Cip1 (later p21) are the major players in the 
initiation of cellular senescence (Alcorta et al. 1996; Stein et al. 1999). These 
inhibitors act both independently and in parallel to inhibit phosphorylation of 
pRb (Stein et al. 1999; Ben-Porath and Weinberg 2005). Both inhibitors are 
used as markers for progressed aging and senescence since their expression 
increases markedly upon advanced aging (Krishnamurthy et al. 2004; Alcorta 
et al. 1996). P16 is a particularly robust biomarker and is expressed in almost all 
presenescent and senescent tissues (Krishnamurthy et al. 2004), except in skin 
cells, which do not express detectable levels of p16 (Dimri et al. 2000). 
Generally, p16 mRNA levels correlate strongly with protein synthesis, and 
protein p16 displays a strong correlation with the accumulation of β-
galactosidase activity and increasing cell size (Dimri et al. 1995; Stein et al. 
1999). Other p16 family proteins are not markedly expressed in aged tissues 
(Krishnamurthy et al. 2004).  
 
Although p16 and p21 are both activators of senescence, the expression of p21 
is regulated by a different pathway i.e. through phosphorylation of p53 
(Lundberg and Weinberg 1999). The P21 level becomes rapidly elevated if cells 
are treated with DNA damaging agents (Stein et al. 1999) and it is also 
upregulated in response to many stress signals, DNA damage and oncogene 
activation, mediated through the tumor suppressor p53 (Stein et al. 1999; Ben-
Porath and Weinberg 2005). 
 
p16 is essential to complete the senescence state and to keep the cell cycle 
arrested (Stein et al. 1999). When cells are entering senescence, the levels of p21 
increase faster than that of p16, and the highest expression is reached earlier. 
The expression of p16 is not observable in early passage cells but is elevated 
rapidly after the logarithmic growth phase (Alcorta et al. 1996; Stein et al. 1999; 
Hara et al. 1996). P21 expression declines rapidly after the initiation of 
senescence, while p16 remains high for at least two months to maintain cell cycle 
arrest (Stein et al. 1999).  
 Morphological changes 
 
Continuously cultured cells experience dramatic changes in their morphology 
and size. Mets and Verdonk have described the morphological changes 
occurring during long term culturing in BM-derived stromal cell culture (Mets 
and Verdonk 1981). They identified two distinct cell morphologies from the 
cultures, type I representing the typical small and spindle-shaped fibroblast-like 




mainly of type I cells, while with passaging, the proportion of type II cells 
increased, and that of type I cells declined. When the culture senesced, it 
consisted mainly of type II cells. Prockop et al. have also identified different 
morphologies and proliferative properties in MSC colonies. MSCs could be 
grouped according to their division potential, cell size, and morphology 
(Prockop et al. 2001).  
 
Many investigators have reported that senescent cells are enlarged when 
compared to early passage cells (Baxter et al. 2004; Stenderup et al. 2003; 
Mauney et al. 2004). Senescent cells show a spread morphology with filopodia 
and stress fibers (Mauney et al. 2004; Stenderup et al. 2003). The increase in 
cell size is due to the overproduction of vimentin, which causes the 
reorganization of intracellular intermediate filaments (Nishio and Inoue 2005). 
The caveolin-1 status also contributes to cell enlargement by regulating focal 
adhesion kinase activation, and by inducing the formation of stress fibers, 
lamellipodia, and filopodia (Cho et al. 2004).  
 Accumulation of beta-galactosidase and lipofuscin 
 
The first marker used to detect senescence from cell cultures was β-
galactosidase, a lysosomal enzyme capable of cleaving β-D-galactose, which is 
expressed at pH 6 upon cell aging (Dimri et al. 1995). Due to the strong 
correlation with aging, this form of β-galactosidase was termed Senescence 
associated β-galactosidase (SA-β-Gal), to distinguish it from another form of β-
galactosidase active at pH 4-4.5 (Krishna et al. 1999). SA-β-gal is expressed by 
senescent fibroblasts and skin keratinocytes, but not in young or presenescent 
cells. It is also absent from quiescent fibroblasts, terminally differentiated 
keratinocytes and immortalized cells (Dimri et al. 1995). However, although SA-
β-gal has been used as a general marker for senescence, it is not specific for 
senescence, and therefore it is insufficient to be applied as the only marker for 
senescence. The expression of SA-β-gal increases in immortalized cells after 
serum starvation, after treatment with hydrogen peroxide (Yang and Hu 2005; 
Dumont et al. 2000) or in confluent fibroblast culture irrespective of the cell 
passage (Severino et al. 2000; Yang and Hu 2005). It has been proposed that an 
aging-related increase in β-galactosidase activity is more likely due to the 
increasing of lysosomal content upon aging than the accumulation of a 
senescence-specific form of β-gal (Kurz et al. 2000). However, the use of β-
galactosidase as a marker for senescence is a golden standard method which can 
be used together with other markers, nonetheless the limitations of the assay 
should be considered when interpreting the results. The β-galactosidase activity 
also reflects the in vitro aging but does not provide information on the in vivo 





Lipofuscin, which is a dense yellow-brown inclusion, is present in SA-β-gal 
positive cells (Georgakopoulou et al. 2013). Lipofuscin is formed from damaged 
cell components such as aggregates of oxidized proteins, lipids, and metals and 
is also called “the aging pigment” since it accumulates in the cytoplasm with 
cellular aging (Brunk and Terman 2002). Lipofuscin can be detected by 
fluorescence microscopy or flow cytometry due to its autofluorescent property, 
but it has not yet been applied widely to MSCs (Georgakopoulou et al. 2013). 
Lipofuscin accumulation correlates with increasing cell size, SA-β-galactosidase 
activity, and p16 expression, but not with p21 expression or telomere length. 
Therefore, it has been suggested that lipofuscin could be utilized in the detection 
of stress-induced senescence (Bertolo et al. 2019). 
 Telomere attrition 
 
Telomeres are protective nucleoprotein structures located at the ends of 
chromosomes and are composed of TTAGGG tandem repeats and a guanine rich 
3’ overhang.  Telomeric DNA is bound to a complex multiprotein structure, 
shelterin (or telosome), which consists of a T-loop DNA structure with several 
bound protein complexes (Figure 8.). Shelterin forms a protective structure and 
also regulates telomere length (Liu et al. 2004; de Lange 2005; Moyzis et al. 
1988). Human telomere lengths vary between 4-15 kb depending on the cell 
type. Since telomeres shorten at every cell division, they have been considered 
as indicative of the cells’ division history and thus of its replicative potential 
(Harley et al. 1990; Allsopp et al. 1992). Telomere length is controlled by 
telomerase activity during embryonal development and in immortal or cancer 
cells (Wright et al. 1996; Vaziri and Benchimol 1998). 
 
 Oxidative stress is another factor affecting telomere shortening (von 
Zglinicki 2002). Oxidative damage is not induced by extrinsic oxygen by itself 
but is caused by the reactive oxygen species produced in mitochondria (Passos 
et al. 2007). Telomere repeats, and especially the 3’ overhang, rich in guanine 
bases, are highly sensitive to oxidative damage and, therefore, are susceptible to 
ROS-induced DNA strand breaks (Oikawa and Kawanishi 1999). The repair of 
oxidative damage in telomere sequences is less efficient than in the rest of the 
genome (Petersen et al. 1998). The study of Passos et al. showed that senescent 
fibroblasts had shorter telomeres, dysfunctional mitochondria, higher ROS 
levels, and more DNA double strand breaks than early passage fibroblasts 








Figure 8. Structure of human telomeres and shelterin complex. The figure is modified from  
(Calado and Young 2009, O'Sullivan and Karlseder 2010). 
 Epigenetic modifications 
 
Modifications in DNA methylation, chromatin organization, posttranslational 
modifications of histones, and non-coding RNAs are essential contributors to 
cellular aging and senescence (Franzen et al. 2016). These epigenetic changes 
occur at various levels and include reduced levels of the core histones, altered 
patterns of histone posttranslational modifications and DNA methylation, 
replacement of canonical histones with histone variants, and altered non-coding 
RNA expression (Franzen et al. 2016). Gene expression patterns may change as 
a response to culture conditions, but genetic changes are relatively stable 
(Wagner et al. 2016). Currently, the best understood and measurable aging-
related epigenetic modification is the DNA methylation at specific cytosine 
guanine dinucleotide sites (CpG), which become either hypomethylated or 
hypermethylated with aging (Bork et al. 2010).     
 Senescence-associated secretory profile 
 
One characteristic of senescent cells is that they do not proliferate but remain 
metabolically active. Senescent cells have undergone various metabolic changes 
in protein expression and secretion and express a senescence messaging 
secretome (Kuilman and Peeper 2009), also called the Senescence-associated 
Secretory Profile (SASP) (Coppé et al. 2008). The secretion of SASP factors 
occurs when severe DNA damage triggers senescence. Cells with SASP produce 
a large variety of soluble signaling factors such as cytokines, chemokines and 




components. SASP factors enable senescent cells to modify their 
microenvironment, and many of them also stimulate tumor growth and 
progression (Coppé et al. 2010; Davalos et al. 2010).  
1.3.3 AGING-RELATED ALTERATIONS IN THE CHARACTERISTICS 
AND FUNCTIONALITY OF MSCS 
 
Since they are diploid somatic cells, MSCs have a restricted lifespan, where 
progressed aging is evident as the reduced proliferative capacity and reduced 
functional properties (Stenderup et al. 2003; Bieback et al. 2012; Turinetto et 
al. 2016). Donor’s age and clinical history, as well as individual genetic variation, 
have been identified as major sources for the variability of MSCs in clinical use 
(Wu et al. 2014; Ho et al. 2008). The donor’s age negatively affects the count of 
original CFUs and MSCs proliferative potential in culture as well as the cells’ 
differentiation and immunosuppressive capacities (Wu et al. 2014; Banfi et al. 
2000; Stenderup et al. 2003; Stolzing et al. 2008; Ross et al. 2000).  
 
MSCs undergo approximately 30-40 PDs in cell culture (Wagner et al. 2010). 
Advanced aging manifests as reduced proliferation and thus lengthened 
doubling times (De Witte et al. 2017; Stenderup et al. 2003). MSCs undergo 
dramatic morphological changes upon aging as they are converted from small 
and spindle-shaped cells into enlarged cells with a flattened appearance with 
irregular shapes and granularity (Mets and Verdonk 1981; Stenderup et al. 
2003). The aging-related loss of differentiation capacity has been shown in 
several studies; however, controversial results have been presented depending 
on whether all three differentiation directions are reduced or if the osteogenic 
or adipogenic potential is retained in some conditions (Banfi et al. 2000; Ross 
et al. 2000; Digirolamo et al. 1999; Bruder et al. 1997). An impaired 
differentiation potential upon aging seems to be, however, independent of the 
culture supplement used (Bieback et al. 2012). 
 
  In several reports, the immunomodulatory effects of MSCs have been 
reported to be markedly reduced upon aging, where a significant defect in 
inhibiting T-cell proliferation and cytokine secretion was seen in vitro 
(Chinnadurai et al. 2017; De Witte et al. 2017; Sepúlveda et al. 2014). The 
immunosuppressive properties are attenuated partly because of defective 
kynurenine production, thus indicating deficient IDO activity (Chinnadurai et 
al. 2017). Sepulveda et al. observed that MSCs, which failed to produce a 
therapeutic effect against GvHD in a clinical trial, had similarly regulated genes 
as senescent MSCs (Sepúlveda et al. 2014)   
 
MSCs have a low risk of transformation to malignant cells during culture, and 
no tumors have been reported in clinical trials (Lalu et al. 2012). However, 




et al. 2010), and aneuploidy has been correlated with senescence (Estrada et al. 
2012). Telomere attrition at a constant rate has been observed in most studies 
but has been found not to be dependent on which culture supplements were 
used (Bieback et al. 2009; De Witte et al. 2017). However, whether telomerase 
is expressed in MSC cultures remains a topic of debate. Most studies have not 
found telomerase expression in MSCs, but some investigators have reported 
telomerase activity in rat MSCs, human fetal MSCs and in one highly 
proliferative human BM-MSC subset (Lee et al. 2003; Fu et al. 2001; Schieker 
et al. 2004).  
 
MSCs exhibit aging-related changes in their transcriptional profile (Wagner 
et al. 2008). One study reported 583 differently expressed genes between young 
and senescent cells, and another study detected over 5000 genes and 31 miRNAs 
that were differentially expressed in young and senescent cells (Noh et al. 2010; 
Wagner et al. 2008). However, there are many reports that genes regulating cell 
death, chromatin assembly, and vacuolization are upregulated in senescent 
cells, while genes involved in the cell cycle, cell growth, DNA repair, and 
metabolism are upregulated in young cells (Noh et al. 2010; Wagner et al. 2008).  
 
Although MSCs are not tumorigenic per se, they contribute actively to the 
tumor microenvironment (Skolekova et al. 2016; Zhu et al. 2006). Senescent 
MSCs express SASP factors, which promote tumor formation and progression 
and particularly robust expression of SASP-related genes encoding IL-6, IL-8, 
MCP-2, CCL5 (Rantes), GM-CSF, MMP3 and ICAM-1 have been observed 
(Minieri et al. 2015; Skolekova et al. 2016; Davalos et al. 2010). With respect to 
the SASP factors, IL-6 is expressed at the highest levels and is known to promote 
tumor cell proliferation and migration (Di et al. 2014). Replicative senescent 
MSCs have been reported to undergo a 40-fold increase in IL-6 secretion in 
comparison to early passage cells (Di et al. 2014). IL-6 secreting MSCs produced 
large and highly vascularized tumors in a mouse xenograft model, and other 
studies have indicated that senescent MSCs display increased tumor cell 
resistance to cisplatin treatment in vivo (Skolekova et al. 2016; Di et al. 2014). 
Karnoub et al. reported that MSCs promoted metastasis in breast cancer cells 
and that the contributing factor between MSCs and breast cancer cells was 
identified as CCL5 (Karnoub et al. 2007; Davalos et al. 2010). Elsawa et al. 
revealed a functional correlation between the secretion of CCL5 and IL-6 






Figure 9. Functional alterations of senescent MSCs. The figure has been modified from (Turinetto 
et al. 2016). 
1.4 CRYOPRESERVATION OF MSCS 
1.4.1 CRITICAL PARAMETERS IN CRYOPRESERVATION 
 
If one wishes to manufacture MSCs as off-the-shelf products, then the cells need 
to be cryopreserved. Cryopreservation of cells aims to halt cell metabolism 
during the storage period at extremely low (-196 - -150°C) temperatures while 
being able to restore cell viability and functionality after thawing. Success in 
cryopreservation is dependent on several critical parameters such as cooling 
rate, selection of a cryoprotective agent, and rate of thawing (Marquez-Curtis et 
al. 2015). Different cell types tolerate freezing differently; for example, 
embryonic stem cells are highly vulnerable to freezing, whereas adult stem cells 
endure cryopreservation relatively well (Hunt 2011). However, the conditions 
for freezing should be optimized for every cell type because cryopreservation has 
been associated with various forms of cellular damage (McGann et al. 1988). An 
optimal cooling rate is crucial for cell survival since too slow cooling results in 
extracellular ice formation, mitochondrial damage, high salt concentration 
outside the cell, and thus cell shrinkage due to osmotic stress. Too fast cooling 
rate results in plasma membrane damage and the formation of intracellular ice, 
which causes physical damage to the cell (McGann et al. 1988; Mazur 1970) 





Figure 10. Physical events in cells during freezing. When a cell is cooled approximately to -5 °C, 
both intracellular and extracellular spaces are supercooled but not yet frozen. Between -5°C and -10 
°C the supercooled water will flow out from the cell due to the increase in its chemical potential. If the 
temperature is further lowered, extracellular ice formation begins, but the intracellular space remains 
supercooled and unfrozen because the plasma membrane restrains the intracellular ice formation. 
Whether cooling injuries occur depends on the cooling rate below -10 °C.  According to Mazur’s two-
factor hypothesis, if an optimal cooling rate is not applied, the cells will be damaged because of 
water’s transport rates (Mazur 1970).  
 Freezing damages in cells are minimized by using cryoprotective agents 
(CPAs), which reduce formation of intracellular ice crystals by different 
mechanisms. The CPAs can be divided into penetrating and non-penetrating 
agents. Examples of penetrating CPAs are dimethyl sulfoxide (DMSO), glycerol, 
ethylene glycol, and propylene glycol (1,2-propanediol) (Lovelock and Bishop 
1959), and examples of non-penetrating CPAs are for example sucrose, glucose, 
and trehalose (McGann 1978).  
1.4.2 EFFECT OF CRYOPRESERVATION ON THE CHARACTERISTICS 
AND FUNCTIONALITY OF MSCS 
 
Despite the use of cryoprotective agents, cells experience significant physical 
and biological stress during freezing. Generally, cryopreservation may result in 
reduced cell viability, damage to mitochondria and the plasma membrane 
(McGann et al. 1988). MSCs have been traditionally frozen in a 10% DMSO 
concentration and at a freezing rate of 1°C-5°C/min. This practice has been 
adopted from the freezing protocol used for hematopoietic stem cells but might 
not necessarily be optimal for BM-MSCs as such (Marquez-Curtis et al. 2015; 




For example, AT-derived MSCs tolerate freezing better than BM-MSCs 
(Marquez-Curtis et al. 2015).  
 
Freezing of MSCs alters the functionality of the cells both in vitro and in vivo. 
The poor immunomodulatory performance of MSCs in the first major phase III 
clinical trial conducted by Osiris Therapeutics (Martin et al. 2010; Allison 2009; 
Kebriaei et al. 2019) has been hypothesized to be due to use of cryopreserved 
instead of fresh cells (Galipeau 2013). In MSCs, freezing and thawing result in a 
disruption of the actin cytoskeleton, which affects their engraftment and homing 
ability (Chinnadurai et al. 2014b). Reduced engraftment and homing after the 
systemic injection may also be due to the use of DMSO as a CPA, which may also 
cause the enhanced clearance of the cells by IBMIR (Moll et al. 2014a; 
Hoogduijn et al. 2016; Moll et al. 2016).  
 
Thawed MSCs contain a larger proportion of apoptotic cells than a product 
composed of fresh cells. Cryopreserved MSCs are susceptible to T-cell mediated 
apoptosis compared to fresh cells (Chinnadurai et al. 2016). Exposure to T-cell 
mediated killing might be due to alterations in the structure of the plasma 
membrane, intracellular pH, or mitochondrial function (Chinnadurai et al. 
2016). Frozen and thawed MSCs have a reduced ability to suppress T cell 
proliferation in vitro correlating with a deficient activity of IDO enzyme after 
thawing (François et al. 2012a; Chinnadurai et al. 2014a; Moll et al. 2014a). The 
deficient IDO activity is caused by the heat shock response induced by freezing 
and thawing (François et al. 2012a).  
 
Freezing has been suggested to damage membrane proteins, which are 
glycosylated after translation, and this modification facilitates the recognition of 
MSCs by the complement system after systemic injection (Yong et al. 2017; Moll 
et al. 2014a). Mitochondrial injury results in accumulated oxidative stress, 
which in turn damages DNA and especially telomeres and thus accelerates aging 
(Pollock et al. 2015; Honda et al. 2001).  
 
High donor age and increased in vitro age of MSCs before freezing affected 
the post-thaw viability and functionality negatively in the study conducted by 
Pollock et al. (Pollock et al. 2015). However, Andrzejewska et al. found that 
donor age did not affect the morphology, growth kinetics, gene expression 
profiles, pro-angiogenic, or immunosuppressive potential or the trilineage 
differentiation capacity of biobanked MSCs (Andrzejewska et al. 2019).  
 
It has been suggested the optimal way to restore the functionality of MSCs 
after thawing, could be either pre-licensing the cells with IFN-γ before freezing 
or by recovering the cells in 24-hour culture after thawing (François et al. 2012a; 
Chinnadurai et al. 2016). Pre-licensing has been shown to improve the 
immunosuppressive properties of MSCs but not to rescue the homing ability of 




recovery of MSCs with a short culture period with or without IFN-γ priming 
after thawing restored the immunosuppressive capacity of MSCs after the heat 
shock response (François et al. 2012a).    
 
A reduction in the DMSO concentration used for MSC cryopreservation did 
not, however, affect the T-cell driven apoptosis (Chinnadurai et al. 2016). 
Another study, which explored the effects of DMSO-free osmolyte-based 
freezing medium formulation consisting of sucrose, glycerol or isoleucine, 
prevented the disruption of the actin cytoskeleton, promoted cryoprotective 






2 AIMS OF THE STUDY 
 
This study aimed: 
 
 
1. To establish an optimal animal serum-free culture system for clinical-
grade MSC production (I, II) 
 
2. To compare the osteogenic differentiation capacity of MSCs in animal 
serum-free and fetal bovine serum supplemented 2D- and 3D-culture 
systems (I). 
 
3. To examine the aging of MSCs in the established animal serum-free 
clinical-grade culture system (II, III, IV). 
 
4. To develop an imaging-based method to screen cellular aging from 
clinical-grade MSC cultures, and to study the correlation of 
morphological changes to senescence-associated markers (III). 
 
5. To study the utilization of additional freezing steps in the clinical-grade 
manufacturing of MSCs and to evaluate the potential effects on the 





















3 MATERIALS AND METHODS 
3.1 ETHICS 
 
This study and all donor protocols were approved by the Ethical Committee of 
the Hospital District of Helsinki and Uusimaa, Finland. Human BM-MSCs were 
collected from healthy volunteer donors after written informed consent.  
 
3.2 METHODS 
3.2.1 ESTABLISHMENT OF THE PRIMARY CULTURES AND CULTURE 
EXPANSION OF THE MSCS 
 
All MSC primary cultures were established from BM-derived mononuclear cell 
(BM-MNC) fractions, which were isolated from 20-40 ml bone aspirates 
collected from healthy volunteer donors. Mononuclear cell fractions were 
isolated by Ficoll-Paque density gradient centrifugation after which the cells 
were seeded at a density 400 000 cells/cm2 on 55 cm2 plates (I) or 75 cm2 (II-
IV) flasks and were incubated for 72 hours at +37°C/5% CO2 in an ambient 
oxygen concentration, except in publication II, were MSCs were cultured in 3% 
and ambient oxygen. 
  
After a 72-hour incubation period, non-adherent cells were removed by 
careful washing, and the culture medium was changed. Culturing of the primary 
passage was continued until the cultures reached 80% confluence. In the 
subsequent passages, MSCs were seeded at a density of 1000 cells/cm2.  At every 
passaging, MSC cultures were washed with DPBS and detached with either 
Trypsin-EDTA (I) or TrypLE CTS (II-IV).  Upon culturing, the culture medium 
was changed twice every week, and passages were detached when confluence 
reached 80-90%. The cells were characterized according to the ISCT criteria 
(Dominici et al. 2006). 
 
For the colony-forming unit assay (CFU-F), MNCs were seeded onto 6-well 
plates (9.6 cm2). Cells for the CFU-F assay were cultured similarly to the primary 
culture. Culturing was continued up to 14 days before staining with 0.1% crystal 
violet in ethanol. Colonies larger than 2 mm were counted to obtain the original 
CFU-F count in the BM aspirate. The original CFU-F count was used to calculate 
the population doubling number spent during the primary passage (passage 0). 




(NH/N1), where NH is the number of harvested cells/cm2, and N1 is the number 
of seeded cells/cm2. At the primary passage (p0), the CFU-F count from the 
CFU-F assay was used as the seeded cell density.  Population doubling time was 
calculated as the length of each culture passage (days) divided by PDs attained 
during each passage.  
3.2.1 CULTURE SYSTEMS FOR MSCS 
 PL1 supplemented basal medium (II, III, IV) 
 
Platelet lysate 1 (PL1) was prepared according to the protocol devised by 
Schallmoser et al. (Schallmoser et al. 2007). For the preparation of PL1, 2-13 
pooled PRP units were frozen and thawed twice, and the resulting lysate was 
used at 10% concentration in the culture medium (Table 2.). Each used PRP unit 
was produced by pooling buffy coats from four individual blood donations with 
one unit of AB plasma (both from Finnish Red Cross Blood Service). Residual 
leukocytes were removed by filtration before freezing at -20 °C and subsequent 
thawing in a +37 °C water bath. The basal culture medium was prepared from 
DMEM low glucose with GlutaMax (Life Technologies), 100 U/ml penicillin and 
100 µg/ml streptomycin and with 40 IU/ml porcine heparin (Heparin LEO® 
5000 IE/KY/ml, Leo Pharma, Sweden) (Table 3.). Prepared PL1 was 
functionally tested in MSC culture before use. When the culture system was 
translated into a clinical-grade process in the cleanroom, antibiotics were 
omitted from the culture medium. MSCs were plated at a density of 1000 
cells/cm2. 
 PL2 supplemented basal medium (I, II) 
 
Platelet lysate 2 (PL2) was prepared from four platelet units not valid for patient 
use due to exceeding their expiry date (Finnish Red Cross Blood Service, 
Helsinki, Finland). The protocol for preparation of PL2 was modified from the 
protocol proposed by Doucet et al. (Doucet et al. 2005). Platelet concentrates, 
stored in platelet additive solution (30% SSP (MacoPharma, Langen, Germany), 
were collected by centrifugation and suspended in Octaplas® AB plasma 
(Octapharma AG, Switzerland) to a density of 300×109 platelets/ml.  Platelets 
were lysed by five freeze-thaw cycles using an ultra-low freezer at -80 °C and a 
+37°C water bath. The lysate was then centrifuged at 3200g for 20 minutes, and 
the supernatant was collected. The supernatant was named as the PL2 
supplement and was used at a 0.5% concentration as a culture medium 
supplement together with 2.5%  AB plasma (Octaplas), 100 U/ml penicillin and 




5000 IE/KY/ml, Leo Pharma, Sweden) (Table 3.). The growth promotion 
efficiency of the PL2 was tested in MSC reference culture before use. Lysates 
promoting cell expansion, with at least with the cell numbers observed in FBS 
supplemented reference culture, were selected for use. The MSCs were plated at 
a density of 1000 cells/cm2. 
 
Table 3. Composition of platelet lysates used as basal medium supplements. 
Supplement Platelet 









in the culture 
medium 







et al. 2007) 
2 0.1×109/ml 
lysed platelets 





low glucose with 
GlutaMax  
10% AB plasma 
(FRCBS) 
40 IU/ml heparin  













(Doucet et al. 
2005)  
5 15×109 /ml lysed 
platelets 









40 IU/ml heparin 
100 U/ml penicillin 
100 µg/ml 
streptomycin 
 *Penicillin and streptomycin were not used in clinical-grade MSC cultures processed in the 
cleanroom. 
 Correspondence of the PL supplement abbreviations used in 
publications 
 
PL1 was prepared according to the protocol described in section 3.2.1.1 and in 
Table 3. and corresponds to the abbreviation PRP (platelet-rich plasma) used in 




and in Table 3. and corresponds to the abbreviation PLP (platelet lysate and 
plasma) used in publication I.  
 2D and 3D cultures for osteogenic differentiation assays (I) 
 
For both 2D and 3D culture systems, MSCs were cultured in FBS supplemented 
culture medium and in PL2 supplemented medium. The basal medium used 
consisted of low-glucose DMEM supplemented with 100 U/ml penicillin, 100 
ug/ml streptomycin (EuroClone, S.p.A. P.IVA, Italy) and 2 mM L-glutamine 
(EuroClone). For medium supplemented with FBS, heat inactivated FBS 
optimized for MSC culturing was used at a 10% concentration (StemCell 
Technologies, Vancouver, Canada). For animal serum-free cultures, the basal 
medium was supplemented with 0.5% PL2 and 2.5% AB plasma (Octaplas®, 
Octapharma).  
 
For 2D cultures, the cells from p2 were seeded at a density of 5 000 cells/cm² 
onto 9.5 cm diameter (55 cm2) cell culture plates. Osteogenic differentiation was 
initiated when the culture confluence reached 70%. Differentiation was 
continued for 28 days. For 3D cultures, 25×10³ cells from p2 were inoculated in 
75 µl of culture medium into the scaffold matrix composed of 7×7×10 mm 
Spongostan® collagen scaffold (Ferrosan, Søeborg Denmark) and were 
cultured on 24-well plates. After an adhesion period of 6 hours, 1 mL of 
expansion medium was added to each well. On the following day, the culture 
medium was replaced with the osteogenic differentiation medium, and 
differentiation was continued for up to 28 days. 
 
The increase in cell number during differentiation was assessed by harvesting 
the 2D cultured cells with trypsin-EDTA and counted by using the Coulter Cell 
Counter (Beckmann Coulter Life Sciences, IN, USA). Cells cultured in the 3D 
system were harvested by dissolving the collagen scaffolds with collagenase B (1 
mg/ml) (Roche, Mannheim, Germany) and then counting the cell numbers. 
 Culturing of MSCs for image analysis (III) 
 
MSCs from donors 1-3 were cultured in small-scale culture format (75 cm2 and 
175 cm2 cell culture flasks). Continuous culturing was performed in 75 cm2 
flasks, and 175 cm2 flasks were used in passages p1, p3, p5, pSEN (senescent 
passages) to obtain sufficient cell numbers for the assays. Cells from donors 4-6 
were cultured in a large-scale format, using 2-layer Cell Stacks (Corning) with 
1272 cm2 culturing area. Basal medium supplemented with PL1 was used as a 
culture medium in both culture formats (Table 3.). The cells were seeded at 




image analysis, cells were seeded at 3000 cells/cm2 in 6-well culture plates for 
further fixation and staining.  
 Cell cultures for studying the interim freezing steps (IV) 
 
Cell culturing for publication IV mimicked the cell culturing procedures 
according to the clinical protocol as precisely as possible. Cell culturing was 
performed using 2-layer cell stacks (Corning). The basal medium corresponds 
to the clinical protocol (PL1 supplemented medium, Table 3.), with the 
exception that it was supplemented with 100 U/ml penicillin and 100 µg/ml 
streptomycin. Cells were plated at density 1000 cells/cm2 and harvested when 





3.2.2 SUMMARY OF METHODS USED IN PUBLICATIONS I-IV 
 
Detailed methods used in Publications I-IV are listed in Table 4.  
Table 4. Methods used in Publications I-IV. 
Method Publication 
Cell isolation methods 
Isolation of MSCs from the BM by density gradient centrifugation I-IV 
Cell culturing 
FBS supplemented culture for BM-MSCs I, II 
PL1 supplemented culture  II-IV 
PL2 supplemented culture  I-II 
Colony-forming unit-fibroblast assay (CFU-F) I-IV 
Characterization assays 
Osteogenic differentiation  





Oil Red O staining 





Alcian Blue staining 
 
II 
Flow cytometric analysis of surface antigens 
CD14, CD19, CD45, CD73, CD34, CD90, CD105 








Immunosuppression assay  
MSCs co-cultured with CFSE stained responder cells 
Flow cytometric analysis using CFSE staining 
II, IV 
II, IV 
Assessment of osteogenic differentiation in 2D and 3D matrices 
Alkaline phosphatase activity assay (Colorimetric pNPP Alkaline 
Phosphatase assay) 
Formation of collagen matrix (Sirius Red staining)  
Formation of a mineralized matrix (Alizarin Red staining) 
Analysis of calcium deposition (spectrophotometric measurement 
using Cresolphthalein Complexone assay) 









Determination of cell surface area 
Image analysis using HCS CellOmics platform  III-IV 
Aging biomarkers  
Quantitative analysis of SA-β-galactosidase activity 
Western blot analysis of the expression of p16INK4a and p21Cip1/Waf 








3.2.3 IMAGING-BASED METHOD TO DETERMINE AGING-RELATED 
CHANGES IN CELL MORPHOLOGY 
 
An imaging-based method to detect and quantify aging-related morphological 
changes of MSCs was devised and optimized in publication III; it was also 
utilized in publication IV. The development and optimization of the method, 
sample preparation, imaging, and data analysis are described in detail below. 
Results from the imaging analysis are presented in the Results section.  
 Sample preparation for the imaging analysis  
 
BM-MSCs for the study were derived from six clinical-grade cultures and were 
cultured in the research laboratory starting from passage one until senescence 
(pSEN). Samples for the imaging analysis were taken from every other passage 
until cells reached the senescence state defined as maintaining a less than 30% 
confluence for two consecutive weeks and expressing the typical morphological 
characteristics of senescent cells.  The MSCs were seeded at a density of 3000 
cells/cm2 on 6-well plates suitable for imaging purposes and were allowed to 
attach and spread for 48 hours. The cells were fixed with 4% paraformaldehyde 
and were stored at +4°C under 0.02% sodium azide/PBS until staining and 
imaging. Before imaging, the cells were permeabilized first with 1% Tx-100/PBS 
for subsequent staining of the nuclei with 0.125 µg/ml DAPI (Sigma, MO, USA) 
and the cytoplasm with 1 µg/ml Cell Mask Deep Red stain (Life Technologies, 
USA). 
 Image calibration and settings for image acquisition  
 
The images were acquired using a high content screening microscope (Cell 
Insight, Thermo Scientific, IL, USA) using a 10× objective (Olympus, Japan). A 
630 nm filter for the signal acquisition was used for Cell Mask and 386 nm for 
DAPI. For defining settings for image calibration and image acquisition, several 
test MSCs were cultured, fixed, stained, and imaged according to the protocol. 
Calibration data was analyzed several times, and parameters for image gating 
were set manually after each iteration. The gating parameters were the 
minimum object size, the threshold signal intensity was when two objects are 
considered separate, and the threshold for finding an object’s edge. An object 
was considered as a cell when it contained only one nucleus and was included 
entirely within the imaging field. The lowest size limit of 765 µm2 was set to 
include only objects larger than the limit. Smaller objects were considered as 
debris after optimization. Careful optimization resulted in the final imaging 
protocol yielding only a few false positives and a moderate level of false 




because of dye bleaching, and the first imaging field was used for the 
adjustment. The imaging protocol was run automatically, and the image was 
focused after every tenth image to maintain uniform and comparable focus 
throughout the imaging. 
 Image acquisition and data analysis 
 
Three to six wells of 6-well plates were imaged for the analysis resulting in 999-
1998 images per channel at each run. Imaging was started from the center of the 
well and proceeded in a spiral-like fashion to minimize the optical distortion 
caused by the convexity of the well.   
 
Collected images were analysed using Cell Omics Morphology Explorer 
software (v4, Thermo Scientific), and nine morphological parameters were 
selected for further analysis; length, width, area, and perimeter (size 
parameters) and perimeter to area ratio, length to width ratio, boxed frame 
ratio, convex hull area ratio, and convex hull perimeter ratio (shape 
parameters).  
 
The imaging data was first cleaned by removing outliers by excluding the 
proportion of the smallest and largest measurements for every parameter. 
However, even after data cleaning, the distributions of the data were remarkably 
non-normal. To normalize the distributions for subsequent analysis, the Box-
Cox transformation was applied for each parameter. Differences between the 
data groups (morphological parameters) were analysed by applying either one- 
or two-way analysis of variance (ANOVA). If the paired differences were 
statistically significant with more than 95% confidence, Bonferroni-corrected 
Student’s t-test was used as a post-test. The hypothesis of two distributions of 
two samples being the same was tested using the Kolmogorov-Smirnov 
distribution test.   
 
To determine the correlation coefficients between the cell surface area 
measurements (after outlier removal) and the senescence-associated markers, 
the Pearson correlation analysis was performed. Results of the correlation 
analysis were visualized by a heat map and a principal component analysis by 
using the R language.   
3.2.4 TERMINAL RESTRICTION FRAGMENT ANALYSIS TO ASSESS 
TELOMERE LENGTH 
 
Mean telomere lengths were measured by Southern blot analysis of terminal 




frozen cell pellets was purified using the Qiagen DNAeasy Blood and Tissue Kit 
(Qiagen, MD, USA) and was further precipitated with sodium acetate and 
ethanol. The integrity of the purified DNA was evaluated by electrophoresis on 
a 1% agarose gel. Telomere length analysis was performed from triplicate 
samples using a TeloTAGGG Telomere Length Assay Kit (Roche, Switzerland). 
For each sample, 2 µg of extracted genomic DNA was digested using the RsaI 
and HinfI enzymes and electrophoresed in a 0.8% agarose gel 125 V (4 V/cm) 
for 4.5 hours. The separated DNA was transferred to a positively charged nylon 
membrane (Roche, Switzerland) by Southern blotting using 20x saline-sodium 
citrate buffer (SSC), after which the transferred DNA was crosslinked at 120 
µJ/cm2 using UV light (UVP CL-100, UK). The blot was hybridized overnight 
with a Digoxigenin (DIG)-labeled telomere-specific probe (TTAGGG), which 
was subsequently detected using an alkaline phosphatase-labeled anti-DIG 
antibody and CDP-Star chemiluminescent substrate. The signal from the 
detection reaction was exposed to autoradiography film (GE Healthcare, WI, 
USA). The average length (kilobase pairs, kbp) of the telomeric terminal 
restriction fragments was calculated using ImageJ analysis software (National 
Institute of Health (NIH)) and Excel software (Microsoft, WA, USA) according 
to mean TRF= Σ (ODi × Li) / Σ (ODi) where ODi is optical density and Li is the 
length of the TRF at position i. TRF signals between 3 and 20 kbp were used in 





3.2.5 FLOW CHART OF THE FREEZING STEPS AND SAMPLE 
COLLECTION USED IN PUBLICATION IV 
 
To study the impact of interim freezing steps on the basic manufacturing 
parameters and MSC functionality, samples were collected according to the 
following plan:  
 
Figure 11. Sampling of the MSC cultures in the interim freezing study. According to the validated 
process for clinical-grade manufacturing, the cell product is frozen once and thawed just before use 
in the clinic. MSCs frozen either in passage 0 (primary passage) or in passage 1 and in passage 2 
were compared to the culture passages of the clinical product. MSCs culture frozen at every passage 
were used to monitor the effects of serial freezing on proliferative potential. 
Cell yield and viability were monitored at every passage as well as the PD 
number. Cell viability and recovery were determined after thawing at p2.  
 Functionality assays 
 
Functionality assays such as differentiation to osteogenic and adipogenic 
lineages and T-cell proliferation assay were performed on the clinical product 
and the sample cells before and after freezing at passage 2. 
 
In the osteogenic differentiation assay, MSCs were seeded at a density of 1000 
cells/cm2 on six-well cell culture plates and cultured with PL1 supplemented 
basal medium containing 100 IU/ml penicillin and 100 µg/ml streptomycin 
until 70% confluence. Osteogenic differentiation was induced with 0.1 µM 
dexamethasone (Dexamethasone, BioXtra, Sigma), 50 µM ascorbic acid 
(Ascorbic acid 2-phosphate, Sigma) and with 10 mM β-glycerophosphate 




the differentiation medium until the formation of visible calcium phosphate 
precipitate was observed. MSCs were fixed with 4% paraformaldehyde (PFA), 
and the calcium phosphate precipitate was stained using von Kossa staining.  
 
For the adipogenic differentiation assay, MSCs were seeded at a density of 
1000 cells/cm2 on six-well culture plates and were cultured with PL1 
supplemented basal medium with 100 IU/ml penicillin and 100 µg/ml 
streptomycin until 70–100% confluence. Adipogenic differentiation was 
induced for 3-4 days period with an induction medium consisting of αMEM 
GlutaMax, 10% inactivated FBS, 20 mM Hepes, 100 U/ml penicillin and 
streptomycin (all compounds from Gibco, Life Technologies). The medium was 
supplemented with the induction cocktail containing  0.1 mM indomethacin 
(Sigma), 44 µg/ml 3-isobutyl methyl-xanthine (IBMX-22∗), 0.5 µg/ml insulin 
(Insulin-0.25∗) and 0.4 µg/ml dexamethasone (DM-200∗) (∗Preadipocyte 
Differentiation Medium Supplement Pack, PromoCell, Italy). Control cells were 
only maintained in the induction medium without the induction cocktail. 
Adipogenic differentiation was finalized by culturing the MSCs in the terminal 
differentiation medium consisting of the induction medium supplemented with 
0.1 mM indomethacin (Sigma), 0.5µg/ml insulin (Insulin-0.25∗) and 3.0 µg/ml 
ciglitazone (Ciglitazone-1.5∗) (∗Preadipocyte Differentiation Medium 
Supplement Pack) for 2–4 weeks until visible lipid droplets could be observed. 
The cells were fixed with 4% PFA and stained using Sudan III. 
 
T-cell proliferation assay was performed using thawed PBMCs from two 
donors and with thawed MSCs either with a 2-4 hours recovery period in a 
culture or with a 24h culture recovery. Co-cultures with the CFSE labeled 
PBMCs and MSCs were activated using an activation cocktail containing CD3 
and CD28 antibodies. An IDO inhibitor, 1-Methyl-L-Tryptophan, was used in 
every assay to verify IDO inhibition.     
3.2.6 STATISTICAL ANALYSES 
 
The results in publication I are presented as mean ± standard deviation. 
Statistical significance was evaluated with two-tailed Student’s t-test, and 
p<0.05 was considered as significant. In publication II, all data was presented 
as mean ± standard deviation. Two-way ANOVA and Tukey’s post hoc tests were 
used to evaluate statistical significance, p <0.05 was considered significant. In 
publication III, the statistical analyses used to analyze acquired imaging data 
have been described in detail in 3.2.3. due to the complexity of the analyses. The 
results reporting the activity of the SA-β-gal marker are presented as mean ± 
standard deviation. Bonferroni-corrected Student’s t-test has been used to 
evaluate statistical significance in differences in measured β-gal activities. 
P<0.05 was considered statistically significant. In publication IV, a two-tailed 




groups. One-way ANOVA with either Bonferroni’s multiple comparisons test or 
Brown-Forsythe test was applied when comparing multiple groups after 
measurement of cell surface areas. Differences were considered statistically 





The results presented here are a summary of the most important findings of this 
study. The results are presented in a more detailed manner in the original 
publications.  
4.1.1 PL SUPPORT OSTEOGENIC DIFFERENTIATION EQUALLY WITH 
FBS IN 2D AND 3D SYSTEMS (I) 
 
In the first publication, we explored the differences in the osteogenic 
differentiation of MSCs between two supplements, FBS or PL2. We also 
investigated whether the extent of osteogenic differentiation varied between a 
2D plate culture compared to differentiation performed in the 3D system, 
represented by a gelatin scaffold sponge. PL2 cultures in this study were not 
completely animal component-free, since heparin was used as a culture medium 
additive, and the gelatin scaffold was porcine in origin. However, both products 
have been approved for human medical use and are routinely used in the clinic. 
 
When MSCs were cultured in 2D plate culture, cell numbers in PL2 
supplemented culture were observed to increase 3.5-fold by day 7 after initiation 
of differentiation but remained constant until the end of the twenty-eight-day 
experiment. In FBS supplemented 2D cultures, the cells proliferated throughout 
the differentiation period (Figure 12A.) resulting in markedly higher total cell 
numbers than in PL2 supplemented cultures (FBS: 140 460 ± 17 793 cells/well 
and PL2: 39 000 ± 4258 cells/well, p<0.01). In 3D cultures, where the cells were 
seeded to Spongostan® matrix, equal cell numbers were counted at the end of 
the differentiation for both supplements (FBS; 73 993 ±17 862 cells, PL2; 78 047 








Figure 12. Cell proliferation in 2D and 3D differentiation systems. A) FBS supplemented cultures 
proliferated throughout the culturing, whereas PL2 supplemented 2D culture ceased to proliferate 
after day 7 (c. p<0.01). B) 3D differentiation system resulted in equal cell numbers for MSCs cultured 
with both supplements (a. difference statistically non-significant). (Castrén et al. 2015). Permission 
for reprint from BioMed Central, Nature Publishing. 
The mRNA level of Runx2 was assessed by RT-PCR analysis of the mRNA 
copies. FCS supplemented the 2D plate culture showed a marked increase in the 
mRNA level on day 9, whereas the level of Runx2 in PL2 culture increased later, 
on day 14. However, 2D culture systems with both supplements resulted in 
almost equal levels of Runx2 on day 21 (Figure 13 A.). In 3D culture, peaks on 
day 9 and on day 14 were also observed for FBS and PL2 supplemented cultures, 
respectively, although the peaks resulted in a higher number of mRNA copies 
than in 2D system (Figure 13D.).  
 
Osteocalcin (OCN), a marker for late osteogenic differentiation, was shown to 
increase steeply in the 2D system after day 5 for FBS and after day 14 for PL2 
but resulted in a slightly higher level in PL2 supplemented cells than in cells 
cultured with FBS (Figure 13C.). In the 3D system, OCN levels peaked with both 
supplements on day 10 but were markedly higher in the FBS supplemented 






Figure 13. mRNA copies of Runx2 and OCN were determined by quantitative RT-PCR for A) Runx2 
in 2D differentiation system B) Runx2 in 3D system C) OCN in 2D culture D) OCN in the 3D system. 
(Castrén et al. 2015). Permission for reprint from BioMed Central, Nature Publishing. 
In summary, MSCs cultured with the FBS supplement showed slightly higher 
cell numbers during differentiation in the 2D culture system than MSCs from 
PL2 supplemented culture. The 3D system where cell cultures were maintained 
in a gelatin scaffold favored cell proliferation, and differences in cell numbers 
between differently supplemented cultures did not exist any longer. The 
determination of expression levels of osteogenic markers that are required to 
initiate and maintain osteogenic differentiation resulted in similar expression 
levels in both differentiation systems with both supplements. However, MSCs 
grown in FBS supplemented cultures showed earlier expression of these 
markers. 
4.1.2 3D DIFFERENTIATION SYSTEM SUPPORTS FORMATION OF 
MINERALIZED MATRIX AND CALCIUM DEPOSITION WITH PL 
AND FBS (I) 
 
Alkaline phosphatase (ALP), known to be an essential factor required for the 




matrix, was assessed by two different methods; by measuring the ALP activity 
using a colorimetric assay, but also by determining the number of mRNA copies 
by quantitative RT-PCR. MSCs in PL2 supplemented 2D cultures showed 
increasing ALP activity measured by the assay kit on day 4 (0.27±0.01 ng/well) 
compared to FBS supplemented culture (0.13±0.02 ng/well) (p<0.01) (Figure 
14A.). Although ALP showed a high concentration for early differentiation in the 
PL2 cultures, the activity declined after that and subsequently remained low. In 
the FBS supplemented cultures, ALP activity displayed a peak on day 7 and 
remained high throughout the experiment (Figure 14A.). In 3D cultures, slightly 
higher ALP activity was observed in the PL2 cultures on day 7 than in the FBS 
supplemented cultures (PL2 0.012±0.003 ng/well; FBS 0.007±0.002 ng/well, 
difference not significant). On day 14, the ALP activity had further increased in 
the PL2 cultures (PL2 0.027±0.006 ng/well; FBS 0.009± 0.002 ng/well, 
p<0.05) (Figure 14B.). Quantitative RT-PCR analysis revealed a steady increase 
of ALP mRNA in 2D cultures with both supplements, a steeper increase was seen 
after day 15 (Figure 14C.). In 3D cultures, mRNA analysis showed an earlier but 
a modest peak of ALP mRNA in FBS supplemented culture. However, a marked 
increase in the expression of ALP in PL2 supplemented culture was observed on 
day 15, with the highest number of mRNA copies being detected on d21 (Figure 
14D.). 
 
Figure 14. The activity of ALP in A) 2D system, B) 3D system for PL2, and FBS supplemented 
differentiation system. The number of ALP mRNA copies determined by quantitative RT-PCR 
analysis for C) 2D system and D) 3D differentiation systems with PL2 and FBS. (Castrén et al. 




The ability of differentiated MSCs to form collagen matrix and mineralized 
matrix was assessed by staining cells from 2D and 3D differentiation systems 
with Sirius Red stain for a collagen matrix and with Alizarin Red stain for a 
mineralized matrix. Staining was quantified by determining the optic density 
(OD) from the stained samples. Sirius red staining for the collagen matrix 
showed more intense staining for FBS in the 2D system on both analyzed days; 
day 14 and day 21, than for PL2 supplemented samples (Figure 15A.). When the 
formation of the mineralized matrix was detected in a 2D system using Alizarin 
Red staining, PL2 supplemented cells displayed intensive staining on days 14 
and 21, and MSCs from FBS culture showed equal staining with PL2 culture on 
day 21 (Figure 15B.). The result was confirmed by determining the calcium 
deposition of the matrix by measuring the dissolved calcium concentration from 
the medium. The PL2 supplemented culture showed high levels of dissolved 
calcium in comparison to FBS culture indicating efficient calcium deposition of 
the mineralized matrix. Cryosection from the 3D matrix showed equal staining 
for PL2 and FBS supplemented cells, and the result was also confirmed by 
quantitation of deposited calcium level (Figure 15C. and D.).  
 
Figure 15. Detection of formation of collagen matrix and mineralized matrix from the differentiation 
systems. A) Sirius Red staining of MSCs from the 2D system shows more intensive staining for FBS 
supplemented MSCs. B) Alizarin Red staining indicates the formation of a mineralized matrix. PL2 
supplemented culture shows intensive staining on both day 14 and day 21, whereas OD for FBS 
supplemented cells is equal to PL2 on day 21. C) Calcium deposition in the 2D system shows slightly 
higher deposition for PL2 culture and D) in the 3D system; both supplements show uniform deposition 
of calcium. The deposition level in the 3D system is higher than in the 2D system (Castrén et al. 




In summary, MSCs differentiated in the 3D system with PL2 resulted in a 
larger number of ALP mRNA copies and a higher ALP activity than FBS 
supplemented cells. MSCs from the PL2 supplemented 3D system also produced 
a mineralized matrix earlier than FBS supplemented cells and deposited calcium 
equally with FBS supplemented cells in the 3D differentiation system. 
4.1.3 PL PROVIDES EFFICIENT SUPPORT FOR MSC PROLIFERATION 
UNDER AN AMBIENT OXYGEN CONCENTRATION (II) 
 
To find the optimal culture medium supplement, which would provide good 
support for cell proliferation, we compared two human platelet lysate-based 
supplements, PL1 and PL2, to FBS. We also tested whether a lowered oxygen 
level (3%) would have a beneficial impact on cell proliferation and 
immunosuppressive properties as compared to the ambient oxygen level. PLs 
were prepared using two different protocols, the most noticeable difference 
being that platelet granules were released using two freeze-thaw cycles in PL1 
while PL2 was prepared using five cycles. Culture medium compositions also 
varied (see Methods 3.2.1 and Table 3.).  
 
 When cells from PL1, PL2, and FBS supplemented cultures were compared, 
a statistically significant difference in total cell yield count could not be observed 
between the differently enriched cultures (p=0.42). However, PL1 
supplemented culture produced the highest extrapolated cell yield from 20 ml 
BM aspirate when compared to the other supplements (Figure 16A.). Produced 
cell yield with PL1 under ambient oxygen was 6.31×109±9.82×109 cells, and 
under 3% oxygen, the yield was 4.81×109 ± 6.78×109 cells. The numbers of 
cumulative PDs in PL1 supplemented MSC cultures were also higher with both 
oxygen concentrations when compared to the other two cultures. Cumulative 
PDs in PL1 cultures with 3% oxygen resulted in slightly higher PD numbers, 
23.4±2.5 PD, while in ambient oxygen concentration, the PD count was 
22.4±2.9 PDs. Culturing with PL1 supplement resulted in the shortest PD time, 
especially under 3% oxygen, where the doubling time was 1.7±0.3 days. The 
doubling time with PL1 in ambient oxygen was 2.1±0.5 days. The PD time was 
significantly shorter in cultures with PL1 than in MSCs supplemented with PL2 
regardless of oxygen concentration (p=0.015). Still, a statistically significant 
difference between PL1 and FBS in PD time was not observed (Figure 17A.). To 
conclude, supplement PL1 resulted in a significantly shorter doubling time than 
PL2 supplemented MSCs. However, PL1 supplemented culture did not produce 
significantly higher cell numbers than the other cultures. Slightly shorter 
doubling times were observed with PL1 supplemented cells exposed to 3% 
oxygen than those exposed to ambient oxygen. 
 
PL2 and FBS cultures originated from the same 16 BM donors and were 




culture ceased to proliferate after 46 PDs (Figure 16C.); in comparison, the PL2 
supplemented culture resulted in the earliest cessation of cell proliferation at p6 
after 27 PD. In these cultures, aging-related morphological changes could be 
observed already after passages 3 or 4, when evaluated by routine microscopy 
(S. Oja unpublished observations). MSCs from culture supplemented with FBS 
continued proliferating until p9 and 38 PDs (Figure 16D.).  
 
 
Figure 16. The effect of platelet lysates PL1, PL2, and FBS A) on cell yields and B) cumulative PD 
numbers in cells exposed to 3% and 20% oxygen concentrations. C) Growth kinetics of PL1 
supplemented MSCs under ambient oxygen conditions D) Growth kinetics of PL2 and FBS 
supplemented MSCs under ambient oxygen conditions. Cell culture in Figure 16C. originate from a 
different donor than cells in Figure 16D., which are from the same donor and have been cultured in 
parallel  (Laitinen et al. 2016a). Permission for reprint from Springer Nature Publishing.  
To compare the functionality of the differently supplemented cells, we tested 
their immunosuppressive capacity in the T-cell proliferation assay. We found 
that PL1 supplemented MSC suppressed T-cell proliferation equally with PL2 
and FBS supplemented cells (Figure 17B.). When immunosuppression of PL1 
supplemented cells in different oxygen concentrations were compared, the 
suppressive property was slightly better in 20% oxygen than at a lower oxygen 
level. However, FBS supplemented cells suppressed proliferation better if 
cultured under in vitro hypoxia. Cells grown in the PL2 supplemented medium 
did not perform as well as PL1 or FBS in the proliferation assay, but when 
cultured under reduced oxygen conditions, the immunosuppressive potential of 






Figure 17. Impact of oxygen concentrations on MSCs A) doubling time and B) immunosuppressive 
properties. The oxygen concentration does not affect doubling time at the primary passage (p0), but 
at p1, doubling times with PL2 are markedly longer than in cultures supplemented with PL1, 
regardless of the oxygen concentration. PL1 and FBS does not show a statistically significant 
difference in doubling times. Differences in the immunosuppressive capacity between cells cultured 
with different supplements and in different oxygen concentrations are not statistically significant 
(Laitinen et al. 2016a). Permission for reprint from Springer Nature Publishing. 
Thus, in summary, PL1 performs well as a supporter of cell proliferation 
regardless of the used oxygen levels. PL1 can produce slightly higher cell 
numbers within two culture passages than PL2 or FBS and within a shorter time. 
Hypoxia does not offer any significant benefit to MSCs cultured with PL1 in the 
T-cell suppression assay. PL1 cultured cells suppress T cell proliferation, as 
efficiently as cells that have been grown in FBS supplemented culture.    
4.1.4 AGING-RELATED CHANGES IN CELL SIZE CAN BE DETECTED 
AND QUANTIFIED BY USING IMAGING-BASED MORPHOLOGY 
ANALYSIS (III) 
 
To study aging-related changes in cell morphology, cells from six healthy donors 
were cultured in PL1 supplemented cultures mimicking clinical-grade MSC 
cultures. MSCs were cultured starting from the primary passage until the 
cessation of the culture. Cessated cultures showed less than 30% confluence 
after two weeks of culturing and displayed the typical phenotypic characteristics 
of senescent cells, such as flattened morphology and irregular cell shapes, and 
granularity. The samples for the imaging analysis and experiments detecting the 
expression of senescence markers p16INK4a, p21Cip1/Waf1, and β-galactosidase were 






From the stained imaging samples, the total number of collected imaging 
fields was 999–1998 (examples of imaging fields are shown in Figure 18A.). 
Collected imaging data was processed using Cell Omics Morphology Explorer 
software. From the collected data, we selected nine morphology-related 
parameters, which would describe the aging-related changes for further 
analysis. The chosen parameters included both size and shape parameters. 
Imaging data of cell morphology was collected from 313,141 cells in total. 
However, before the subsequent analyses, we first cleaned the data by removing 
5% of the smallest and largest values. These removed outliers were due to 
interpretation errors of the imaging software; in some imaging fields, debris had 
been interpreted as cells and overlapping cells as one large cell. After the outlier 
removal, the analysis was continued with 281,827 cells.  
 
To select the morphological parameter, which could be best associated with 
the PD number, we performed linear fitting for each morphological parameter 
as an explanatory variable for the PD to a first-degree model. We also tested the 
donor and passage subgroup mean values and standard deviations by using 
them as explanatory variables. The resulting R2 coefficients for the models were 
highest for the size parameters such as cell area, perimeter, length, and width. 
When testing the standard deviations of the groups, R2 values (correlations) 
were even higher than the mean values, resulting in R2 values of 48% for cell 
area, 47% for length, 43% for perimeter, and 38% for width. Of these 
parameters, based on the correlations and the fact that cell area is the 
parameter, which is visually monitored by many operators during routine cell 
culturing, we selected cell surface area as the primary parameter to describe 
aging-related changes in cell morphology.   
 
From the measured cell surface area values, we observed that MSCs at 
passages 1 and 3 were surprisingly uniform in terms of their size; the cell surface 
area for MSCs at p1 was 1827±329 µm2 and the area at p3 was 2353±386 µm2. 
A rapid enlargement of cell size was seen at p5 when the cell surface area had 
doubled as compared to p1 and reached 4198±1628 µm2. Cell area at senescent 
passages (pSEN) had increased on average by 4.8-fold when compared to p1, 
resulting in a cell surface area of 8744±2494 µm2 (Figure 18B.-D.). At p5, MSCs 
had undergone approximately 28-35 population doublings. Earlier enlargement 
of cell size was seen with one donor only after 25 PDs at p5 (Figure 18D.). Linear 
and logarithmic distributions of cell sizes show the uniform cell size at p1 and 
p3 but a shift towards larger cell size starting at p5. The population of smaller 





Figure 18. A.) Examples of the imaged cell cultures from passages p1, p3, p7, and p8 and recognition 
by the imaging software according to preset rules. Recognized and accepted cells are marked as 
green lines and recognized, and excluded cells are magenta lines. The correctness of the recognition 
was visually checked during the run, and during analysis, interpretation errors were reduced by data 
cleaning. B) Histograms of the distributions of cell sizes in different passages revealed a clear shift 
of the cell size towards enlarged phenotype at passage 5. C) When the mean cell area was plotted 
against culture passages (p1, p3, p5, pSEN) and D) PD number, a rapid increase in cell size could 
be observed, and the PD range for the increase could be determined (Oja et al. 2018). Permission 
for reprint from Stem Cell Research and Therapy/Nature Publishing. 
4.1.5 RAPID INCREASE IN CELL SURFACE AREA CORRELATES WITH 
THE EXPRESSION OF SENESCENCE-ASSOCIATED MARKERS (III) 
 
An increase in the expression of the classical senescence markers p16, p21, and 
β-galactosidase occurred concurrently with the increase in cell area (Figure 19.). 
The expression of p21 showed a pattern typical of replicative senescence; the 
peak in the p21 level was seen before the p16 peak, but its level rapidly decreased 
after p16 had reached its highest level. The highest level of expression of p16 was 
seen at p7, having approximately a 30-fold increase as compared to p1 (Figure 
19A.). The activity of β-galactosidase increased significantly at passage 5 and 
continued to increase at passage 7 (for both, p<0.001). Constant i.e. not 
accelerated, telomere shortening was observed in the cell cultures during 






Figure 19. Correlation of senescence-associated markers with cell surface area. A) An example of a 
western blot analysis of the expression of cell cycle regulating cyclin-dependent kinase inhibitors, 
p16, and p21 from one donor.  B) The activity of Senescence-associated β-galactosidase in different 
culture passages. The difference between p1-p3 and p5 and p7 is statistically significant p<0.001 C) 
Correlation of mean cell area with the senescence-related markers is visualized by a heat map, and 
D) by principal component analysis (Oja et al. 2018). Permission for reprint from Stem Cell Research 
and Therapy/Nature Publishing. 
Visualization of Pearson correlation coefficients by the heat map and the 
principal component analysis reveals that the expression of p16 and β-
galactosidase increase together with the cell surface area, indicating that cell 
proliferation had ceased and that β-galactosidase was accumulating in the cells 
upon culturing. These three parameters correlated negatively with the 
population doubling rate (PD/Day) and the mean telomere length, indicating 
that with progressive aging, mean telomere length had shortened, and more 
time was consumed in cell doubling. The expression of p21 did not seem to 
correlate with the other parameters in the PC analysis, however the typical 
expression pattern of p21 is shown in Figure 19A; a phenomenon that has also 
been reported by others (Alcorta et al. 1996; Stein et al. 1999), which explains 






4.1.6 ONE TO TWO FREEZING STEPS DO NOT ALTER THE BASIC 
MANUFACTURING PARAMETERS IN PASSAGE 2 MSCS (IV) 
 
To produce the clinical product according to the manufacturing protocol at 
FRCBS, MSCs need to be culture-expanded until passage 2, when they are 
harvested and frozen. In this study, surplus cells produced during processing, at 
passages 0 and 1, were frozen and thawed (interim frozen cells) and further 
cultured until passage 2, when they were harvested and frozen again. Cell 
aliquots were thawed after the second freezing, and after that, viabilities and cell 
recovery were determined (Figure 20.).   
 
Figure 20. The effect of interim freezing steps on A) the cell yield at passage 2 before freezing, B) 
cumulative PD count at passage 2, C) viability after thawing at p2 and D) proportion of living cells at 
p2 after thawing, compared to the clinical product (cells frozen once) (Oja et al. 2019). Permission 
for reprint from Frontiers of Immunology/Frontiers Media. 
Both cell aliquots with interim freezing steps (p0 or p1) produced slightly 
higher cell numbers at passage 2, as did the unfrozen cells (Figure 20A.), 
however, the difference in the cell yields between unfrozen cells and the interim 
frozen cell aliquots were not statistically significant. During the expansion, all 
cell aliquots underwent approximately 25 PDs until passage 2, when cells were 
harvested for the second freezing step (Figure 20B.). The cell viability after 
thawing at p2 was high, over 90% in all cell aliquots (Figure 20C.). Cell recovery 




recovery was over 80%, and differences between recoveries were statistically 
nonsignificant (Figure 20D.).    
4.1.7 AGING-RELATED REDUCTION IN PROLIFERATION AND 
CHANGES IN MORPHOLOGY ARE NOT ACCELERATED AFTER 
ADDITIONAL FREEZING STEPS (IV) 
 
MSCs, which have undergone 2 freezing steps, did not cease to proliferate earlier 
than the clinical product (frozen once at p2) at passages that are relevant for 
clinical-grade production. The control cultures that were frozen at every passage 
displayed a markedly diminished expansion potential, ceasing to proliferate 
after 35 PD. Exhaustion of the control culture was attained at passage 5, while 
other cell aliquots proliferated at least until passage 6. Differences in 
proliferation kinetics between unfrozen cells, cell aliquots frozen once (clinical 
product), and cells frozen twice, were not evident until p5 (Figure 21A. and 
21D.). Cell aliquots, which were either unfrozen, frozen once or frozen twice, did 
not show any statistically significant differences in the number of cumulative 
PDs at passages 4 or 5. However, cells frozen at every passage had undergone 
significantly more PDs at these passages as compared to cell aliquots which were 
unfrozen, frozen once or twice (p < 0.01) (Figure 21B.).  
 
Figure 21. A) Growth kinetics from unfrozen MSC culture and cultures, which have been frozen once 
(clinical product), twice or at every passage. B) The difference in cumulative PD numbers between 
unfrozen, frozen once and frozen twice cell aliquots in passages 4 and 5 is not statistically significant. 
C) Cell surface areas of unfrozen MSCs and cells frozen once or twice are uniform at p1 and p3. D) 
An example of growth kinetics from one BM-MSC batch when unfrozen cells were compared to cell 





In these experiments, we utilized the imaging-based screening method, which 
was established and described in publication III, to screen for cellular aging. Due 
to the robust analysis and a strong correlation of changes in cell size with the 
expression of aging-related markers, other assays to study aging were not 
applied. Data from the imaging analysis indicated that cell surface areas in 
samples from p1-p3 remained small (2000-3000 µm2) and uniform despite the 
number of freezing steps. The small size of the cells at p1 and p3 and the rapid 
increase in cell size at p5 indicated that MSCs at early passages did not express 
senescence-associated markers at significant levels yet. Evidence of variability 
in cell sizes began to show at p5 after 30 PDs, with cells frozen twice, showing 
larger cell sizes as unfrozen cells. The differences in cell surface areas between 
unfrozen cells and cells frozen twice were not, however, statistically significant.  
4.1.8 MOST OF THE FUNCTIONALITY OF THE MSCS IS PRESERVED 
AFTER ONE TO TWO FREEZING STEPS (IV) 
 
The functionality of the MSCs before freezing and after thawing at passage 2 was 
assessed in osteogenic and adipogenic differentiation assays (Figure 22.) and in 
a T-cell suppression assay (Figure 23.). We observed that osteogenic and 
adipogenic potentials were retained in the frozen cell aliquots and the clinical 
product, irrespective of the timing of the freezing steps. However, differentiation 
in this study was not quantified but only observed by visual examination (Figure 
22.).   
Figure 22. Osteogenic and adipogenic differentiation before and after freezing at p2. All samples 
show differentiation to both lineages. Differentiation analyses are quantitative and show only the 




The ability of unfrozen and interim frozen MSCs to suppress T-cell 
proliferation was studied using the T-cell proliferation assay. When MSCs with 
one (clinical product) or two freezing steps were compared, they could both 
suppress T-cell proliferation (one freezing p<0.001, and two freezing steps p0 
and p1 <0.05) (Figure 23A.). However, when the immunosuppressive properties 
of fresh MSCs and frozen cells were compared, an approximately 50% reduction 
was seen in the suppression of T -cell proliferation (p<0.001) (Figure 23B.).  
 
Figure 23. A) The ability of MSCs with one or two freezing steps to suppress T-cell proliferation 
before and after freezing at p2. B) Approximately 50% reduction in immunosuppressive capacity was 
seen in MSCs after freezing and thawing when compared to fresh cells (Oja et al. 2019). *p<0.005, 
***p<0.001. Permission for reprint from Frontiers of Immunology/Frontiers Media. 
To summarize, additional freezing steps at early passages, p0 and p1, did not 
alter the basic manufacturing parameters such as cell viability, cell yield, or total 
cumulative PD count, but showed excellent recovery and viability after thawing. 
Cell surface areas in unfrozen and interim frozen cells displayed uniform cell 
sizes, and an aging-related increase in cell sizes was seen at p5, which was not, 
however, the relevant passage count in our culture protocol. The small cell sizes 
in early passages are indicative of the absence or minor expression of aging-
related markers. Osteogenic- and adipogenic differentiation assays showed 
comparable differentiation potential of interim frozen cells to their unfrozen 
counterparts. T-cell proliferation assay revealed a reduced suppression capacity 
of frozen and thawed cells compared to fresh cells, but the equal capacity of cells 





This study was initiated in 2007 at a time when there was worldwide interest in 
MSC research and the development of clinical-grade products. Laboratories had 
moved on from basic research to the establishment and optimization of culture 
conditions for clinical-grade manufacturing. MSCs held great promise in 
therapeutic use, and they were thought to be the long-awaited answer to treating 
many immunological disorders and tissue injuries. MSC research was supported 
by the promising results emerging from pre-clinical experiments and the early 
clinical trials conducted by Lazarus and Le Blanc (Lazarus et al. 2005; Le Blanc 
et al. 2004). However, a major setback occurred in 2009 when an advanced 
phase III clinical trial (NCT00366145) for steroid refractory GvHD was 
performed using MSCs (Prochymal®). The results from the trial found almost 
no difference between the study groups (overall response, OR 82%) and placebo 
(OR73%) (Martin et al. 2010; Kebriaei et al. 2019).  
 
Our study was initiated at the time when optimal culturing conditions for 
clinical manufacturing were being sought. Furthermore, we aimed to establish 
and optimize an animal serum-free culture system for the production of clinical-
grade MSCs. Before the process development for clinical-grade manufacturing, 
we evaluated the growth and functionality supporting properties of two 
differently prepared PLs and compared them to FBS, which at that time was the 
standard supplement for cell cultures. In parallel with the testing of PLs, we 
determined the efficiency of osteogenic differentiation in PL supplemented and 
in FBS supplemented cultures, both in 2D and 3D culture systems. After 
establishing our facility for manufacturing, we concentrated on establishing and 
optimizing an imaging-based method to screen the cell products for alterations 
in their cell morphology, e.g. for the progressive signs of aging typical for MSCs. 
Monitoring of aging in the MSC cultures is a critical quality attribute since MSCs 
are known to lose their functionality with aging and to exhibit unwanted 
alterations in their characteristics and secretory profile. Finally, we sought to 
upscale our manufacturing process by using interim freezing steps to exploit 
surplus cells from previous process steps to utilize as far as possible the valuable 
starting material from BM aspirates received from voluntary donors.   
5.1.1 PL PROVIDES AN EFFICIENT SUPPORT FOR CLINICAL-GRADE 
MSC CULTURES 
 
Culture supplements PL1 and PL2 were prepared using two different protocols, 
which contained different numbers of freeze-thaw cycles: two cycles for PL1 
(according to Schallmoser et al. 2007), and five for PL2 (modified from Doucet 




because FBS supplementation had been the former standard. We found that 
MSCs cultured in PL1 supplemented medium could produce equal cell numbers 
with shorter doubling times compared to cultures with PL2 supplement or FBS, 
regardless of the oxygen level. PL2 supplement showed a reduced ability to 
support cell proliferation than PL1 or FBS. Cells produced with PL1 also showed 
an equal ability for suppression of T-cell proliferation as FBS supplemented cells 
whereas PL2 supplemented cells had a weaker ability to suppress T-cell 
proliferation. No marked difference was observed between ambient or low 
oxygen level to immunosuppression with PL1 supplemented cells, but MSCs 
from PL2 supplemented culture showed a slight improvement in their 
suppression capacity with the 3% oxygen level. 
 
An increased proliferation rate, a decreased doubling time, delayed 
senescence and equally maintained functional properties of PL supplemented 
MSCs compared to FBS supplemented cultures have been shown in multiple 
studies (Doucet et al. 2005; Müller et al. 2006; Schallmoser et al. 2007; Avanzini 
et al. 2009; Griffiths et al. 2013). However, the composition of PL and the role 
of growth-promoting factors in the supplement is not entirely understood. 
Although most of the studies report at least similar functionality of PL to FBS, 
one study claimed that culturing MSCs with PL may alter the expression of some 
essential MSC surface molecules and impair their ability to suppress T-cell and 
NK-cell proliferation and cytotoxicity. That report also detected a reduced 
production of PGE2 but increased secretion of IL-6, IL-8, and Rantes 
(Abdelrazik et al. 2011).  These cytokines have also been associated with the 
detrimental effects of the SASP profile related to progressed aging (Davalos et 
al. 2010; Lunyak et al. 2017). 
 
The properties of PL may modulate the culture of MSCs in many ways; for 
example, the age of the blood donors has been shown to have an impact on the 
functionality of PL, and platelets from young donors have been reported to 
possess better growth-promoting properties than platelets from older donors 
(Lohmann et al. 2012).  
 
An adequate number of freeze-thaw cycles to release platelet α-granules has 
been a topic of debate, varying from 1 to at least 4, with most of the published 
studies favoring 1-3 freeze-thaw cycles (Doucet et al. 2005; Kocaömer et al. 
2007; Schallmoser et al. 2007; Capelli et al. 2007; Strandberg et al. 2017). We 
chose to test five freeze-thaw cycles in parallel with two cycles to explore the 
possibility of releasing a maximal concentration of growth-promoting factors. 
Strandberg et al. tested the release of growth factors after 1, 3, 5, 10, and 30 
freeze-thaw cycles and found that the optimal number of freeze-thaw cycles 
seemed to be 3-5 to release selected growth factors such as isoforms of PDGF, 
EGF, FGF, and TGF-β1 (Strandberg et al. 2017). Our study did not, however, 
find support for five freeze-thaw cycles with our preparation method. We 




promoting factors may have been degraded, resulting in lower proliferation-
promoting properties. In addition, Fekete et al. showed that inhibition of PDFG-
BB, bFGF, and TGF-β1 in the culture medium resulted in a loss of cell 
proliferation (Fekete et al. 2012, 2014).  
 
We observed an earlier cessation of PL2 supplemented cultures than the 
other cultures, and during routine microscopy, aging-related morphological 
changes in PL2 cultures could be seen already after p4 in some cultures. Zhang 
and coworkers reported that PDGF-BB protected MSCs from senescence and 
apoptosis and this improved their immunosuppressive properties. In their 
study, MSCs were isolated from patients with immune thrombocytopenia (ITP) 
(Zhang et al. 2015). The senescence of the ITP-MSCs was shown to be mediated 
through the p53/p21 pathway (Zhang et al. 2016), which can also be activated in 
stress-induced senescence such as that induced by suboptimal culturing 
conditions in a nutrient-poor culture medium (Toussaint et al. 2000). 
Degradation of PDGF-BB due to five freeze-thaw cycles may explain the earlier 
signs of senescence in PL2 supplemented MSCs. We observed a slight 
improvement in the proliferation of PL2 supplemented cell culture under a 3% 
oxygen concentration. This may indicate that the load of stress factors caused by 
the degradation of PDGF-BB may have been reduced in 3% oxygen and thus 
enabled faster proliferation. 
 
Another deviating factor than the number of freeze-thaw cycles between the 
lysates was the origin of the platelets being used. PL1 was derived from blood 
product production where fresh platelets were suspended in fresh AB plasma, 
whereas PL2 was prepared from expired platelet products, which were no longer 
valid for patient use. The study of Jonsdottir-Buch et al. did not, however, find 
any difference in growth-promoting properties between lysates produced of 
fresh platelets and lysates where expired platelets were utilized (Jonsdottir-
Buch et al. 2013). Because fresh platelet products are valuable in clinical use, 
expired products should be considered to be favored in the preparation of PL 
supplements, as proposed by Astori et al. and Jonsdottir-Buch et al. (Astori et 
al. 2016; Jonsdottir-Buch et al. 2013).   
 
A large variety of methods to produce PL supplements for clinical-grade 
culture have been published differing in terms of the origin of the platelets, 
components of the supplements and techniques to release platelet α-granules 
(Doucet et al. 2005; Schallmoser et al. 2007; Kocaömer et al. 2007; Lange et al. 
2007). Currently, there are no standardized protocols or requirements to 
prepare PL supplements for MSC manufacturing, and neither is there any 
requirement for the assay of the contents of cytokines, chemokines, or growth 
factors etc. We used our in-house standardized quality criteria for the used PLs 
with clear release criteria involving donor test results, the number of platelets, 
and residual leucocytes. Standardized preparation methods and defined release 




MSC products. Uniform procedures would provide better comparability 
between products manufactured by different facilities and would decrease the 
lot-to-lot variation of lysates and MSC products.   
5.1.2 CULTURING OF MSCS WITH REDUCED OXYGEN DOES NOT 
CONFER ANY MARKED BENEFIT TO CELL EXPANSION OR 
FUNCTIONALITY AT LOW PASSAGE NUMBERS  
 
The use of in vitro hypoxic conditions is known to improve cell proliferation and 
to decelerate aging of MSCs in several culture settings, since a 3% oxygen 
concentration is physiological for BM-MSCs  (Grayson et al. 2006; Fehrer et al. 
2007; von Zglinicki et al. 1995). A lower oxygen concentration during in vitro 
expansion has also been shown to improve the differentiation capacity of MSCs 
(Fehrer et al. 2007). In our study, it did not affect the growth-promoting 
performance of the PL1 whether cells were cultured under ambient oxygen or 
under 3% oxygen conditions. We could also not observe any statistically 
significant difference in the immunosuppressive capacities between the MSCs 
at lower the oxygen level. A lower oxygen concentration seemed, however, to 
slightly improve the performance of PL2, because the doubling time was 
markedly shorter for PL2 under 3%, than under ambient oxygen. A slight 
improvement in the immunosuppression was also observed with the 3% oxygen 
concentration; however, the difference was not statistically significant.  
 
Grayson et al. and Estrada et al. have reported markedly improved cell 
expansion at lower oxygen levels as compared to culturing in a 20% oxygen 
concentration (Grayson et al. 2007; Estrada et al. 2012). Estarada et al. 
suggested that the ambient oxygen level, which is non-physiological for MSCs, 
causes a metabolic shift from glycolysis to oxidative phosphorylation and thus 
results in increased amounts of ROS in the MSC cultures. An elevated ROS level 
is known to affect genetic stability and telomere length in long-term culture 
(Estrada et al. 2012, 2013). Our study compared cell yields, doubling times, and 
PD numbers in the early passages, p0-02, and did not evaluate the differences 
in long-term cultures. Our results indicate that with the early passage numbers 
which are relevant to our manufacturing protocol, MSCs cultured under 
ambient oxygen performed equally well as cells cultured under lower oxygen 
concentrations. In addition, the experiments performed by Grayson et al. and 
Estrada et al. only detected differences between different oxygen conditions 
after p2 culture (Grayson et al. 2007; Estrada et al. 2012). In a plate culture 
system, such as ours, oxygen levels are controlled by inserting nitrogen to the 
incubator. However, cells are exposed to ambient oxygen during medium 
replacement, passaging, and harvest. Maintaining a lower oxygen concentration 
in a plate culture system is also a financial issue, and therefore we chose to 






Controlling the oxygen level would, however, be beneficial if cell expansion 
were to be continued significantly further than p2. MSCs for the industry-
sponsored phase II/III clinical trial with Prochymal®, were expanded until p5 
(Martin et al. 2010; Prasad et al. 2011; Galipeau 2013). With these passage 
numbers, the utilization of closed bioreactors, with oxygen control and 
continuous monitoring of the metabolism, could help to improve the quality and 
functionality of the cell products.  
 
Due to the ability to produce equal cell numbers with FBS culture in a shorter 
time, PL1 was selected for process development to establish a clinical-grade 
culturing process for the MSCs. Since lowering of oxygen level did not confer 
any significant benefit for PL1 supplemented culture, cell cultures were 
continued to be expanded under an ambient oxygen level using a 5-stack plate 
culture system. 
5.1.3  PL IS AN EQUALLY GOOD SUPPORTER OF OSTEOGENIC 
DIFFERENTIATION AS FBS 
 
The ability to induce differentiation of clinical-grade MSCs in an animal serum-
free culture system would improve the safety of the therapy due to minimizing 
the risk of animal-derived pathogens and xenoimmunization reactions 
(Heiskanen et al. 2007; Cervenakova et al. 2011; Van der Valk et al. 2018) as well 
as enhancing the proliferation and differentiation of MSCs (Xia et al. 2011; Zaky 
et al. 2008). MSCs used for bone regeneration should retain their osteogenic 
properties after transplantation, or maintain their paracrine activity to secrete 
factors supporting bone healing (Birmingham et al. 2012). The four essential 
parameters for MSCs to be used for bone regeneration are 1) sufficient cell 
proliferation after transplantation to the target tissue, 2) the expression, and 
activity of alkaline phosphatase (ALP), as well as 3) the expression of other 
osteogenic markers and 4) the ability to produce collagen matrix able to deposit 
calcium (Birmingham et al. 2012). A 3D matrix together with cultured MSCs has 
been shown to support osteogenic differentiation and bone regeneration when 
compared to a matrix with fresh BM (Petite et al. 2000; Sogo et al. 2007; Kasten 
et al. 2008).  
 
In our study, MSCs proliferated better in a FBS supplemented 2D plate 
culture than with PL2, but in the 3D gelatin matrix, both supplements supported 
cell proliferation equally throughout the experiment. FBS and PL2 were also 
found to promote equally well the osteogenic differentiation of MSCs. However, 
there were temporal differences in the expression of differentiation-related gene 
expression. In the 2D culture system, mRNA levels increased earlier in FBS 
supplemented cultures than in PL2. Nonetheless, both supplements eventually 




culture. The 3D differentiation system was found to induce an earlier expression 
of osteogenic markers than the 2D system, during days 10-15; however, the 
highest ALP expression was seen on day 21 for PL2 supplemented culture. The 
expression levels of ALP and OCN were more robust in the 3D system than in 
2D culture.  
 
The findings of other workers confirm that PL is an effective supporter of 
osteogenic differentiation in MSC cultures and is comparable to FBS (Chevallier 
et al. 2010; Xia et al. 2011; Kasten et al. 2008; Vogel et al. 2006; Warnke et al. 
2013). Chevallier et al. reported better proliferation of MSCs with PL as 
compared to FBS. ALP expression was found to be higher in MSCs cultured with 
PL. However, differences in the expression of other osteogenic markers such as 
Runx2 or OCN were not statistically significant between PL and FBS (Chevallier 
et al. 2010). The study of Kasten et al. showed that when MSCs were introduced 
to the 3D scaffold and were fed with freshly prepared PL, cell proliferation was 
significantly improved. However, no improvement in differentiation was found 
(Kasten et al. 2008). One of the root causes which introduced variability into the 
results of cell proliferation was identified as the use of different PL lots. The 
results reported by Warnke et al. are in agreement with our findings that PL 
provides an equal support for osteogenic differentiation as FBS and also that 
differentiation in the 3D matrix was more effective than in 2D plate culture 
(Warnke et al. 2013).  
 
Bone fractures may be the type of tissue injury that is amenable to treatment 
with MSCs. Bone is a tissue which is able to regenerate without scarring unless 
the lesion is too large or bone formation has been interrupted by surgical 
operations (Petite et al. 2000). Autologous bone engraftment has been the 
primary choice for regeneration, but invasive methods to obtain the bone grafts 
and the risk of complications have limited the availability of this kind of therapy 
(Petite et al. 2000). Different methods to treat bone injuries have been 
exploited; autologous BM aspirate injected into the injury site, sometimes mixed 
with a supporting matrix before injection or mononuclear cells that have been 
isolated from the BM aspirate, culture-expanded and introduced into the matrix 
and are then engrafted to the injury site (Stanovici et al. 2016). The latter two 
approaches, i.e. where cells and matrix are used, have achieved the best results 
in experimental bone regeneration. However, the problem in cell-based grafts is 
the lack of vascularization. The newest applications have aimed at the 
vascularization of the cell-based grafts, for example, by 3D printing (Stanovici 
et al. 2016). However, a more important issue in tissue regeneration than the 
ability of MSCs to form bone may be the ability of the explants to exert paracrine 
effects which support bone healing in concert with osteoblast activity  (Strioga 
et al. 2012; Almalki and Agrawal 2016). 
 
Our study revealed that osteogenic differentiation is efficient in a 3D matrix 




perform poorly when compared to PL1 (Laitinen et al. 2016a). We hypothesize 
that the difference between FBS and PL would have been greater if PL1 should 
have been used as a supplement. To conclude, it is possible to achieve our aim 
to replace FBS as a culture supplement for MSCs intended for bone regeneration 
with culture expanded MSCs supplemented with PL. The osteogenic 
differentiation of these cells, especially when introduced to the 3D matrix, is 
comparable to cells grown in FBS supplemented cultures. 
5.1.4 MONITORING OF CELLULAR AGING IN MSC CULTURES 
 
Monitoring of advanced aging and senescence in MSC cultures is essential to 
evaluate the proliferative potential and functionality of the cells since aging is 
known to alter the characteristics and reduce the potency of the MSCs. In the 
third publication of this study, we established and optimized an imaging-based 
screening method to detect and quantify cell morphology and revealed that cell 
surface area was the best morphological parameter that described the aging-
related changes. We also demonstrated that a rapid increase in cell surface area 
clearly correlated with the expression of classical senescence-associated 
markers. We succeeded in establishing a screening method that could reliably 
be used to detect cells expressing the primary markers for senescence, and thus 
we utilized this method also in our subsequent experiments.  
 
Monitoring of MSCs in vitro aging and its impact on their functional 
properties is considered one of the cornerstones of quality control of the MSC 
products (Bieback et al. 2019; Menard et al. 2013; Barkholt et al. 2013). The 
basic measure for MSCs’ aging is the determination of the cumulative PD count. 
We found that when the PD count was measured with our culture standards, an 
enlarged cell size could be detected in one sample already after 25 PDs. This 
sample originated from a 40-year-old donor, while the other MSCs in the study 
originated from donors in their early 20s. It is reasonable to hypothesize that 
donor age may have had an impact on the early cessation of the culture. 
However, the careful analysis of Andrzejewska et al. suggests that donor age 
does not impact on the in vitro aging of cultured cells (Andrzejewska et al. 2019). 
Our finding is, however, an important reminder that senescent cells can be 
found even in the MSC cultures with relatively low PD numbers. Therefore, 
routine monitoring of cell size should be implemented in the manufacturing 
process. All MSCs where cell area was quantified (publications III and IV) were 
derived from clinical-grade production and did not show any significant 
expression of senescence-related markers during the passages 1-3 (PDs 35 or 
lower).  
 
In addition to counting cumulative PD numbers, changes in cell size have 
been known to be an indicative phenotypic characteristic of progressed aging in 




and morphology and the occurrence of cellular senescence were conducted by 
Hayflick (Hayflick and Moorhead 1961) and Mets and Verdonk (Mets and 
Verdonk 1981). Later, Prockop et al. and Katsube et al. separated MSCs 
according to their size and studied the correlation of cell size to culture 
characteristics and functionality (Colter et al. 2010; Katsube et al. 2008). There 
are also other experiments reporting that the size and morphology of the MSCs 
are predictive for their osteogenic and adipogenic differentiation potential, 
proliferative activity as well as their immunosuppressive capacity (Marklein et 
al. 2016; Klinker et al. 2017; Lo Surdo et al. 2013; Sasaki et al. 2014).  
 
Our finding that a rapid increase in cell surface area displayed a strong 
correlation with the senescence markers is novel and opens the possibility to 
develop an in-process monitoring method for altered cell size further and thus 
to establish a first-step online screening method for senesced cells. Although 
there are different methods that are commonly used to study cellular aging, such 
as measurement of telomere length, β-galactosidase activity, or expression of 
cell cycle inhibitory proteins, these are not optimal for being implemented as 
quality control assays into clinical-grade manufacturing processes instead they 
are rather research tools. The senescence-associated DNA methylation 
signature based on six specific CpG sites (SA-DNAm), is an accurate method for 
detecting senescent cells from the cultures (Bork et al. 2010; Koch et al. 2012; 
Schellenberg et al. 2014). However, that method is laborious and may not be 
suitable for monitoring the culture during processing.  
 
Imaging-based screening methods have been successfully applied to the 
monitoring of MSC cultures (Marklein et al. 2016; Klinker et al. 2017; Sasaki et 
al. 2014). These studies, where a morphology analysis has been combined with 
sophisticated computational methods, report that differentiation and 
immunosuppressive potential could be reliably predicted. Sasaki et al. described 
a label-free imaging method, which could be implemented into clinical-grade 
cell culturing without invasive handling (Sasaki et al. 2014). In addition, our 
approach could be further developed into a label-free method that could detect 
cells from images taken with a phase-contrast microscope. The detection of 
enlarged cells when combined with a classification analysis could be performed 
using deep learning-based prediction models (Sasaki et al. 2014; Chen et al. 
2016; Mencattini et al. 2020). A bioreactor with a multilayer planar culture 
system combined with integrated cameras is already available for clinical-grade 
manufacturing. By utilizing these systems, screening method for senescent cells 






5.1.5 FREEZE OR NOT TO FREEZE – HOW TO RESOLVE THE 
FUNCTIONALITY QUESTION? 
 
Cryopreservation is a necessary step in producing MSCs as off-the-shelf 
products. The freezing step allows the storage of products and means that 
released products will have a well-timed distribution to the clinic. Protocols to 
freeze MSCs have been adopted from those techniques applied in the freezing of 
HSCs but these might not be optimal for MSCs (Marquez-Curtis et al. 2015). 
Recent reports have shown that the immunomodulatory abilities of MSCs are 
either abolished or markedly reduced after freezing and thawing (François et al. 
2012a; Pollock et al. 2015; Moll et al. 2014a). The reason for the reduced 
functionality has been identified to be impaired IDO activity due to the heat 
shock response, although this could be rescued either by 24-48 hours culturing 
or by IFN-γ treatment (François et al. 2012a). Freezing may also alter the surface 
topology of the MSCs and thus make the cells susceptible to rejection by IBMIR 
and clearance by the complement system (Moll et al. 2014b, 2011). The 
disruption of the actin cytoskeleton structure caused by freezing and thawing 
has been shown to impair the ability of MSCs for engraftment and homing 
(Chinnadurai et al. 2014b). These freezing-related injuries may also be avoided 
by recovering MSCs in cell culture after thawing.  
 
We investigated if additional freezing steps would affect the basic 
manufacturing parameters such as cell yield and viability, and the functional 
properties of MSCs. The ability to utilize additional freezing steps would provide 
flexibility to the manufacturing process and enable more effective production of 
“off-the-shelf” MSC products. Additional freezing steps would also provide a 
crucial possibility to create a master cell bank system and thus to produce more 
patient doses from the same starting material. Our results showed that two 
interim freezing steps did not alter the basic manufacturing parameters when 
compared to a clinical product which had been frozen only once in passage 2. 
We observed an approximately halving of the immunosuppressive capacity 
regardless of the number or point of the freezing steps.  
 
In contrast to the report of Francois et al., in our experiments, MSCs’ 
suppressive ability in T cell proliferation assay could not be improved by culture 
rescue (François et al. 2012a). However, when different experimental settings 
were used to confirm the observation, we found that minor changes in the assay 
protocol did change the readouts of the T-cell proliferation. This observation 
questions the value of this commonly used method as a measure of functionality 
for the clinical product. 
 
The post-thaw functionality and practices to cryopreserve MSCs have been a 
topic of intensive debate, and alternatives have been sought to maintain the 
functionality of MSCs during cryostorage. The critical parameters in 




rate (McGann et al. 1988). Furthermore, the contact time with DMSO before 
freezing and after thawing is important to consider and should be maintained 
under one hour. Overexposure to DMSO results in the degradation of membrane 
integrity, impaired attachment, and altered immunophenotype (Morris et al. 
2016).   
 
Cell fitness before cryostorage should be ensured by careful monitoring of 
cumulative PDs and searching for signs of progressed aging since immune 
functionality is known to be reduced by aging due to the impairment of IDO 
production in MSCs (Chinnadurai et al. 2017). In addition, choice of tissue 
source may improve the potency of MSC products, for example, MSCs from 
birth-related tissues such as placenta or UC have been claimed to have a better 
proliferative potential and immunomodulatory properties than BM-MSCs (Jin 
et al. 2013; Heo et al. 2016).  If MSCs are to be cultured on an industrial-scale, 
it is more than likely that cell products will contain some proportion of senescent 
MSCs, especially after five culture passages, as was the case with the MSCs 
cultured for the Prochymal® study (Kebriaei et al. 2009). Chinnadurai and 
colleagues have shown that IFN-γ treatment could revive the impaired immune 
functionality of MSCs due to their senescence  (Chinnadurai et al. 2017).  Our 
results demonstrate that early passage cells from young donors can be frozen 
during the manufacturing process, and expansion can be continued without any 
reduction in their viability or proliferative capacity. The findings by Moll and 
others also emphasized that passage 1-2 MSCs resulted in better clinical 
outcomes after thawing than MSCs from subsequent passages (Moll et al. 
2014a).   
 
We did not observe aging-related changes in interim frozen cells with two 
freezing steps. Only serial freezing with more than four freezing steps impaired 
cell proliferation. In addition to the mechanical stress caused by freezing, DMSO 
penetrates through cell membranes and leaves transient pores in the membrane 
(McGann et al. 1988). DMSO also alters mitochondrial integrity, which may 
increase the production of reactive oxygen species and thus damage encoding 
DNA and telomeres (Morris et al. 2016; von Zglinicki 2002; Passos et al. 2007).  
 
 Most studies that have explored the effects of freezing on MSCs have used 
DMSO as a cryoprotective agent. Pollock et al. found that DMSO-free freezing 
solution formulations improved MSCs post-thaw viability and functionality. 
DMSO-free formulations were also able to prevent the disruption of the actin 
cytoskeleton and thus improve engraftment and homing of MSCs (Pollock et al. 
2017). However, Chinnadurai et al. did not observe any post-thaw improvement 
with a DMSO-free cryosolution (Chinnadurai et al. 2016). Pre-licensing of MSCs 
with IFN-γ before freezing resulted in improved inhibition of T-cell proliferation 
and reduced the susceptibility to lysis by activated PBMCs. Nonetheless, pre-
licensed MSCs did not completely rescue the lung-homing defect caused by 





Several investigators have suggested that treatment with fresh MSCs seems 
to be the most effective approach (Chinnadurai et al. 2016; François et al. 2012a; 
Moll et al. 2014b; Burand et al. 2017). However, in order to be able to ensure 
systematic manufacturing and well-timed distribution and, most importantly, 
to mitigate the risks of post-thaw handling if MSCs are cultured at the clinic-side 
after product release, it is evident that off-the-shelf MSCs would provide the 
safest option for the patient. Testing of new cryosolution formulations and 
optimizing other crucial freezing parameters may provide new ways to improve 









































In this study, we established and tested an animal serum-free culture system for 
obtaining clinical-grade MSCs. We evaluated the ability of two differently 
prepared PLs to support the proliferation and functionality of MSCs at a lowered 
oxygen concentration (3%) and an ambient oxygen concentration. We observed 
that PL1 prepared from fresh plasma and platelets using two freeze-thaw cycles 
could produce an equal number of MSCs as a culture supplemented with FBS, 
but at a shorter time. Furthermore, the ability to suppress T-cell proliferation in 
ambient oxygen level was comparable to FBS supplemented cells. Based on the 
results of that experiment, the process development for clinical-grade 
manufacturing of BM-MSCs was continued with PL1. Culturing of MSCs with 
lowered oxygen level did not confer any major benefit in the expansion or 
functionality of early passage MSCs, and therefore, cell culturing under an 
ambient oxygen concentration was also continued. 
 
We aimed to compare the ability of MSCs to support osteogenic 
differentiation in 2D and 3D matrices supplemented with either FBS or PL2.  We 
demonstrated that PL2 supplemented MSCs could support osteogenic 
differentiation equally well as in a FBS culture, especially in the 3D 
differentiation system. We observed temporal differences in the expression of 
osteogenic markers. However, both supplementation systems resulted in an 
equal expression level of osteogenic markers and similar functionality during 
the research period. 
 
After the establishment of clinical-grade manufacturing for MSCs, we 
developed an imaging-based screening method to recognize and quantify aging-
related changes in cell size. We found that MSCs in passages 1-3 were small and 
had a uniform at size, but a rapid increase was evident at passage 5; this occurred 
concurrently with a highly increased level of expression of senescence-related 
markers. The studied cell cultures were derived from clinical-grade cultures. 
Our study did not find enlarged cell sizes before p5 (35 PDs) in most of the 
cultures.  
 
Finally, we explored the possibility of upscaling MSC manufacturing by using 
interim freezing steps during the manufacturing process, at passages p0 and p1, 
to obtain more products from the same starting material. We evaluated the 
effects of the additional freezing steps on the primary manufacturing 
parameters and found that when early passage cells were being processed, 
additional freezing steps did not alter the characteristics of the MSCs or greatly 
influence their functionality. However, we also found that the ability to suppress 
T-cell proliferation was markedly but equally reduced in the clinical product and 





In conclusion, this thesis has provided knowledge which can be utilized in 
developing solutions for regenerative therapy as well as for quality control, 





This study was carried out in the Institute of Biomedicine of the University of 
Helsinki and in the Finnish Red Cross Blood Service in Helsinki. This study was 
financially supported by Väre Foundation for Pediatric Cancer Research 
(formerly Nona and Kullervo Väre Foundation), Finnish Red Cross Blood 
Service state research funding (EVO grants), and Advanced Cell Therapy Centre 
budget funding. This study has also gained financial support from the 
Foundation for Pediatric Research (Lastentautien tutkimussäätiö). I am deeply 
grateful for the financial possibilities to carry out this work. I especially wish to 
thank Chairman Sakari Arkio from the Väre Foundation for his support and 
encouragement.  
 
I am grateful to the Chief Executive of the Blood Service, Professor Martti 
Syrjälä, Adj. Professor Jarkko Ihalainen, Adj. Professor Kari Aranko, and 
Professor Jukka Partanen for providing such excellent working facilities and 
such inspirational research colleagues. It has been a privilege to be able to work 
at the Blood Service.   
 
I am deeply grateful to my thesis supervisors, Adj. Professor Matti Korhonen 
and Adj. Professor Johanna Nystedt and wish to express my warmest thanks for 
all the years we have worked together. Both of you played significant roles in my 
supervision; without you, this study and thesis wouldn’t have been possible.  
 
I want to warmly thank the reviewers of this thesis, Dr. Guido Moll and Adj. 
Professor Susanna Narkilahti, for their time and thorough revision. Their 
contribution was valuable and helped me to reach the next level.  
    
I thank my thesis committee members, Professor Susanna Miettinen and 
Professor Elina Ikonen for their views and encouraging comments throughout 
the work. 
 
I thank the Research Training Programme of Helsinki University Hospital for 
Children and Adolescents for the research community, training, and also for a 
travel grant during the first years of this study. I especially want to thank 
Professor Markku Heikinheimo for his support and encouragement.  
 
I wish to express my gratitude and warmest thanks to all of my co-authors for 
their contributions to the publications. I thank especially Dr. Anita Laitinen and 
Dr. Eeva Castrén for allowing me to be a part of their projects, and Adj. Professor 
Antti Penttilä for his extensive expertise with the statistical analyses. His 
contribution was crucial to the success of the imaging study. I thank Pauno 




method. I also thank Dr. Tanja Kaartinen, Dr. Lotta Kilpinen, and MSc. Marja 
Ahti, for their valuable work and contribution to the analyses and authorship in 
the shared publications. I thank Adj. Professor Saara Laitinen, for her 
inspiration, participation, and help in integrating me into the Blood Service.  
 
I thank Margit Sädekari, Riitta Malinen, and Piia Loponen from Blood Service 
for professional secretarial support. I thank Ewen MacDonald for the revision of 
the language of this thesis. 
 
I thank the technical staff of the R&D Department and the Advanced Cell 
Therapy Centre for their excellent work; Birgitta Rantala, Sirkka Hirschovitz-
Gertz, Susanna Räsänen, Iris Tallus, Satu Happonen, and Johanna Matikainen.  
You all are highly skilled and working with you was always both inspiring and 
fun. You are the best help that a researcher can have!  
 
I thank my work community at the Department of Anatomy; Pauno, Ariel, Eeva, 
Heidi, Pipsa Kaipainen, Marja-Leena Piiroinen, Hanna Wennäkoski, Outi 
Rauanheimo and Reijo Karppinen.  
 
I want to thank my work community at Blood Service; Ani, Erja, Johanna, Tanja, 
Gitta, Sirkka, Suski, Lotta A., Lotta K., and  Lotta S., Jan, Annu, Pilvi, Kaarina, 
Joni, Sisko, Paula, Iris, Satu H., Johanna M., Ulla, Ilja, Teija, Heli and Tiia, for 
all the fun and inspiring moments during lunch and coffee breaks and outside 
the workplace. I have always had such a lovely time with you and a lot of laughs! 
Especially I want to thank you all for the comfort and support when my father 
died suddenly in 2017.  
 
I thank my new colleagues at FinVector; Piia, Kaisa, Päivi, Lucia, and Lisette 
(”Lucette”), Katriina, Silja, Kati, and Maija for support and inspiring 
discussions. You have shared with me these last moments in the completion of 
the thesis. I thank Dr. Minna Karhinen and Adj. Professor Tuija Kekarainen for 
the encouragement to finalize my degree.  
 
I warmly thank my close friends; Maarit, Anne, Terhi, Tanja-Maria and Satu for 
your friendship and support during all these years.   
 
I thank my parents, Kristiina and Timo Franssi, and my sister Salla Franssi, for 
their endless love and belief in me. I dedicate this thesis to my father’s memory.  
 
Finally, my super thanks go to my own family; my husband Joni and our 
beautiful and bright children, Ella and Emil. Thank you for your love and 
understanding during the writing of this thesis. Our children have been born 
and raised along with this study. It has been wonderful to see that also the next 
generation is interested in cells and the wonders of nature. Ella and Emil, 





Thank you, Joni, for your professional help with the imaging and statistical 
analyses, and for inspiring discussions about science. As a scientist yourself, you 
have always shown understanding about my work. In our private life, thank you 
for your love and support! I love you!    
 








Abdelrazik H, Spaggiari GM, Chiossone L, Moretta L. 2011. Mesenchymal stem cells expanded 
in human platelet lysate display a decreased inhibitory capacity on T- and NK-cell 
proliferation and function. Eur J Immunol 41: 3281–3290. 
Abo-Aziza FAM, Zaki AA. 2017. The impact of confluence on bone marrow mesenchymal stem 
(BMMSC) proliferation and osteogenic differentiation. Int J Hematol Stem Cell Res 11: 
121–132. 
Aggarwal S, Pittenger MF. 2005. Human mesenchymal stem cells modulate allogeneic immune 
cell responses. Blood 105: 1815–1822. 
Al-Najar M, Khalil H, Al-Ajlouni J, Al-Antary E, Hamdan M, Rahmeh R, Alhattab D, Samara O, 
Yasin M, Abdullah A Al, et al. 2017. Intra-articular injection of expanded autologous bone 
marrow mesenchymal cells in moderate and severe knee osteoarthritis is safe: A phase I/II 
study. J Orthop Surg Res 12. 
Alcorta DA, Xiong Y, Phelps D, Hannon G, Beach D, Barrett JC. 1996. Involvement of the cyclin-
dependent kinase inhibitor p16 (INK4a) in replicative senescence of normal human 
fibroblasts. Biochemistry 93: 13742–13747. 
Alfaifi M, Eom YW, Newsome PN, Baik SK. 2018. Mesenchymal stromal cell therapy for liver 
diseases. J Hepatol 68: 1272–1285. 
Algeri M, Conforti A, Pitisci A, Starc N, Tomao L, Bernardo ME, Locatelli F. 2015. Mesenchymal 
stromal cells and chronic inflammatory bowel disease. Immunol Lett 168: 191–200. 
Allison M. 2009. Genzyme backs Osiris, despite Prochymal flop. Nat Biotechnol. 
Allsopp RC, Vaziri, Homayoun, Patterson, Christopher; Glodstein S, Younglai E V, Bruce 
Futcher A, Greidert CW, Harley CB. 1992. Telomere length predicts replicative capacity of 
human fibroblasts. 89: 10114–10118. 
Almalki SG, Agrawal DK. 2016. Key transcription factors in the differentiation of mesenchymal 
stem cells. Differentiation 92: 41–51.  
Álvarez-Viejo M, Menéndez-Menéndez Y, Otero-Hernández J. 2015. CD271 as a marker to 
identify mesenchymal stem cells from diverse sources before culture. World J Stem Cells 
7: 470. 
Andrzejewska A, Catar R, Schoon J, Qazi TH, Sass FA, Jacobi D, Blankenstein A, Reinke S, 
Krüger D, Streitz M, et al. 2019. Multi-Parameter Analysis of Biobanked Human Bone 
Marrow Stromal Cells Shows Little Influence for Donor Age and Mild Comorbidities on 
Phenotypic and Functional Properties. Front Immunol 10. 
Arai F, Hirao A, Ohmura M, Sato H, Matsuoka S, Takubo K, Ito K, Koh GY, Suda T. 2004. 
Tie2/angiopoietin-1 signaling regulates hematopoietic stem cell quiescence in the bone 
marrow niche. Cell 118: 149–161. 
Astori G, Amati E, Bambi F, Bernardi M, Chieregato K, Schäfer R, Sella S, Rodeghiero F. 2016. 
Platelet lysate as a substitute for animal serum for the ex-vivo expansion of mesenchymal 
stem/stromal cells: Present and future. Stem Cell Res Ther 7: 1–8.  
Augello A, Tasso R, Negrini SM, Amateis A, Indiveri F, Cancedda R, Pennesi G. 2005. Bone 
marrow mesenchymal progenitor cells inhibit lymphocyte proliferation by activation of the 
programmed death 1 pathway. Eur J Immunol 35: 1482–1490. 
Avanzini MA, Bernardo ME, Cometa AM, Perotti C, Zaffaroni N, Novara F, Visai L, Moretta A, 
Del Fante C, Villa R, et al. 2009. Generation of mesenchymal stromal cells in the presence 
of platelet lysate: A phenotypic and functional comparison of umbilical cord blood- and 
bone marrow-derived progenitors. Haematologica. 
Baddoo M, Hill K, Wilkinson R, Gaupp D, Hughes C, Kopen GC, Phinney DG. 2003. 
Characterization of mesenchymal stem cells isolated from murine bone marrow by 
negative selection. J Cell Biochem. 
Baker M. 2016. Reproducibility: Respect your cells! Nature. 
Ball LM, Bernardo ME, Roelofs H, Lankester A, Cometa AM, Egeler RM, Locatelli F, Fibbe WE. 




lymphocyte recovery and may reduce the risk of graft failure in haploidentical 
hematopoietic stem-cell transplantation. Blood 110: 2764–2767. 
Banfi A, Muraglia A, Dozin B, Mastrogiacomo M, Cancedda R, Quarto R. 2000. Proliferation 
kinetics and differentiation potential of ex vivo expanded human bone marrow stromal 
cells: Implications for their use in cell therapy. Exp Hematol 28: 707–715. 
Barkholt L, Flory E, Jekerle V, Lucas-Samuel S, Ahnert P, Bisset L, Büscher D, Fibbe WE, 
Foussat A, Kwa M, et al. 2013. Risk of tumorigenicity in mesenchymal stromal cell-based 
therapies - Bridging scientific observations and regulatory viewpoints. Cytotherapy 15: 
753–759. 
Bartmann C, Rohde E, Schallmoser K, Pürstner P, Lanzer G, Linkesch W, Strunk D. 2007. Two 
steps to functional mesenchymal stromal cells for clinical application. Transfusion 47: 
1426–1435. 
Bartunek J, Behfar A, Dolatabadi D, Vanderheyden M, Ostojic M, Dens J, El Nakadi B, Banovic 
M, Beleslin B, Vrolix M, et al. 2013. Cardiopoietic stem cell therapy in heart failure: The C-
CURE (cardiopoietic stem cell therapy in heart failURE) multicenter randomized trial with 
lineage-specified biologics. J Am Coll Cardiol 61: 2329–2338. 
Batorov E V., Shevela EY, Tikhonova MA, Batorova DS, Ushakova GY, Sizikova SA, 
Sergeevicheva V V., Gilevich A V., Kryuchkova I V., Ostanin AA, et al. 2015. Mesenchymal 
stromal cells improve early lymphocyte recovery and T cell reconstitution after autologous 
hematopoietic stem cell transplantation in patients with malignant lymphomas. Cell 
Immunol 297: 80–86. 
Baxter MA, Wynn RF, N. JS, Wraith JE, Fairbairn LJ, Bellatuono I. 2004. Study of Telomere 
Length Reveals Rapid Aging of Human Marrow Stromal Cells following In Vitro 
Expansion. Stem Cells 22: 675–682. 
Becherucci V, Piccini L, Casamassima S, Bisin S, Gori V, Gentile F, Ceccantini R, De Rienzo E, 
Bindi B, Pavan P, et al. 2018. Human platelet lysate in mesenchymal stromal cell expansion 
according to a GMP grade protocol: A cell factory experience. Stem Cell Res Ther 9. 
Ben-Porath I, Weinberg RA. 2005. The signals and pathways activating cellular senescence. Int 
J Biochem Cell Biol 37: 961–76. 
Benvenuto F, Ferrari S, Gerdoni E, Gualandi F, Frassoni F, Pistoia V, Mancardi G, Uccelli A. 
2007. Human Mesenchymal Stem Cells Promote Survival of T Cells in a Quiescent State. 
Stem Cells 25: 1753–1760. 
Bernal A, Arranz L. 2018. Nestin-expressing progenitor cells: function, identity and therapeutic 
implications. Cell Mol Life Sci 75: 2177–2195. https://doi.org/10.1007/s00018-018-2794-
z. 
Bernardo ME, Avanzini MA, Perotti C, Cometa AM, Moretta A, Lenta E, Del Fante C, Novara F, 
De Silvestri A, Amendola G, et al. 2007a. Optimization of in vitro expansion of human 
multipotent mesenchymal stromal cells for cell-therapy approaches: Further insights in 
the search for a fatal calf serum substitute. J Cell Physiol 211: 121–30. 
Bernardo ME, Avanzini MA, Perotti C, Cometa AM, Moretta A, Lenta E, Del Fante C, Novara F, 
Zuffardi O, Maccario R, et al. 2006. Platelet-Lysate for In Vitro Expansion of Human 
Multipotent Mesenchymal Stromal Cells in Approaches of Cell-Therapy. Blood. 
Bernardo ME, Ball LM, Cometa AM, Roelofs H, Zecca M, Avanzini MA, Bertaina A, Vinti L, 
Lankester A, MacCario R, et al. 2011. Co-infusion of ex vivo-expanded, parental MSCs 
prevents life-threatening acute GVHD, but does not reduce the risk of graft failure in 
pediatric patients undergoing allogeneic umbilical cord blood transplantation. Bone 
Marrow Transplant 46: 200–207. 
Bernardo ME, Emons JAM, Karperien M, Nauta AJ, Willemze R, Roelofs H, Romeo S, Marchini 
A, Rappold GA, Vukicevic S, et al. 2007b. Human mesenchymal stem cells derived from 
bone marrow display a better chondrogenic differentiation compared with other sources. 
Connect Tissue Res. 
Bertolo A, Baur M, Guerrero J, Pötzel T, Stoyanov J. 2019. Autofluorescence is a Reliable in vitro 
Marker of Cellular Senescence in Human Mesenchymal Stromal Cells. Sci Rep 9. 
Bertolo A, Mehr M, Janner-Jametti T, Graumann U, Aebli N, Baur M, Ferguson SJ, Stoyanov J 
V. 2016. An in vitro expansion score for tissue-engineering applications with human bone 




Beyth S, Borovsky Z, Mevorach D, Liebergall M, Gazit Z, Aslan H, Galun E, Rachmilewitz J. 
2005. Human mesenchymal stem cells alter antigen-presenting cell maturation and 
induce T-cell unresponsiveness. Blood 105: 2214–9. 
Bianco P, Cao X, Frenette PS, Mao JJ, Robey PG, Simmons PJ, Wang CY. 2013. The meaning, 
the sense and the significance: Translating the science of mesenchymal stem cells into 
medicine. Nat Med 19: 35–42. 
Bieback K, Brinkmann I. 2010. Mesenchymal stromal cells from human perinatal tissues: From 
biology to cell therapy. World J Stem Cells 2: 81. 
Bieback K, Hecker A, Kocaömer A, Lannert H, Schallmoser K, Strunk D, Klüter H. 2009. Human 
alternatives to fetal bovine serum for the expansion of mesenchymal stromal cells from 
bone marrow. Stem Cells 27: 2331–2341. 
Bieback K, Hecker A, Schlechter T, Hofmann I, Brousos N, Redmer T, Besser D, Klter H, Mller 
AM, Becker M. 2012. Replicative aging and differentiation potential of human adipose 
tissue-derived mesenchymal stromal cells expanded in pooled human or fetal bovine 
serum. Cytotherapy 14: 570–583. 
Bieback K, Kern S, Kocaömer A, Ferlik K, Bugert P. 2008. Comparing mesenchymal stromal 
cells from different human tissues: Bone marrow, adipose tissue and umbilical cord blood. 
Biomed Mater Eng 18: 71–76. 
Bieback K, Kinzebach S, Karagianni M. 2011. Translating research into clinical scale 
manufacturing of mesenchymal stromal cells. Stem Cells Int 2010. 
Bieback K, Kuçi S, Schäfer R. 2019. Production and quality testing of multipotent mesenchymal 
stromal cell therapeutics for clinical use. Transfusion 59: 2164–2173. 
Bieback K, Netsch P. 2016. Isolation, culture, and characterization of human umbilical cord 
blood-derived mesenchymal stromal cells. In Methods in Molecular Biology. 
Bigot N, Mouche A, Preti M, Loisel S, Renoud ML, Le Guével R, Sensebé L, Tarte K, Pedeux R. 
2015. Hypoxia Differentially Modulates the Genomic Stability of Clinical-Grade ADSCs 
and BM-MSCs in Long-Term Culture. Stem Cells 33: 3608–3620. 
Birmingham E, Niebur GL, Mchugh PE, Shaw G, Barry FP, McNamara LM. 2012. Osteogenic 
differentiation of mesenchymal stem cells is regulated by osteocyte and osteoblast cells in 
a simplified bone niche. Eur Cells Mater 23: 13–27. 
Bonab MM, Sahraian MA, Aghsaie A, Karvigh SA, Hosseinian SM, Nikbin B, Lotfi J, Khorramnia 
S, Motamed MR, Togha M, et al. 2012. Current Stem Cell Autologous Mesenchymal Stem 
Cell Therapy in Progressive Multiple Sclerosis: An Open Label Study. Res Ther 7: 407–
414. 
Bork S, Pfister S, Witt H, Horn P, Korn B, Ho AD, Wagner W. 2010. DNA methylation pattern 
changes upon long-term culture and aging of human mesenchymal stromal cells. Aging 
Cell 9: 54–63. 
Bosnakovski D, Mizuno M, Kim G, Takagi S, Okumura M, Fujinaga T. 2005. Isolation and 
multilineage differentiation of bovine bone marrow mesenchymal stem cells. Cell Tissue 
Res 319: 243–53. 
Bruder SP, Jaiswal N, Haynesworth SE. 1997. Growth kinetics, self-renewal, and the osteogenic 
potential of purified human mesenchymal stem cells during extensive subcultivation and 
following cryopreservation. J Cell Biochem 64: 278–294. 
Brunk UT, Terman A. 2002. Lipofuscin: Mechanisms of age-related accumulation and influence 
on cell function. Free Radic Biol Med 33: 611–619. 
Burand AJ, Gramlich OW, Brown AJ, Ankrum JA. 2017. Function of Cryopreserved 
Mesenchymal Stromal Cells With and Without Interferon-γ Prelicensing is Context 
Dependent. Stem Cells 35: 1437–1439. 
Burnouf T, Goubran HA, Chen TM, Ou KL, El-Ekiaby M, Radosevic M. 2013. Blood-derived 
biomaterials and platelet growth factors in regenerative medicine. Blood Rev 27: 77–89. 
Burova E, Borodkina A, Shatrova A, Nikolsky N. 2013. Sublethal oxidative stress induces the 
premature senescence of human mesenchymal stem cells derived from endometrium. Oxid 
Med Cell Longev. 
Cai J, Wu Z, Xu X, Liao L, Chen J, Huang L, Wu W, Luo F, Wu C, Pugliese A, et al. 2016. 
Umbilical Cord Mesenchymal Stromal Cell with Autologous Bone Marrow Cell 




Label Clinical Study to Assess Safety and Impact on Insulin Secretion. Diabetes Care 39: 
149–157. 
Cao Y, Ding Z, Han C, Shi H, Cui L, Lin R. 2017. Efficacy of Mesenchymal Stromal Cells for 
Fistula Treatment of Crohn’s Disease: A Systematic Review and Meta-Analysis. Dig Dis Sci 
62: 851–860. 
Capelli C, Domenghini M, Borleri G, Bellavita P, Poma R, Carobbio A, Micò C, Rambaldi A, Golay 
J, Introna M. 2007. Human platelet lysate allows expansion and clinical grade production 
of mesenchymal stromal cells from small samples of bone marrow aspirates or marrow 
filter washouts. Bone Marrow Transplant 40: 785–91. 
Caplan AI. 2008. All MSCs Are Pericytes? Cell Stem Cell 3: 229–230. 
Caplan AI. 1991. Mesenchymal stem cells. J Orthop Res 9: 641-650J. 
Caplan AI. 2017. New MSC: MSCs as pericytes are Sentinels and gatekeepers. J Orthop Res 35: 
1151–1159. 
Carlsson PO, Schwarcz E, Korsgren O, Le Blanc K. 2015. Preserved β-cell function in type 1 
diabetes by mesenchymal stromal cells. Diabetes 64: 587–592. 
Castello LM, Leone M, Adamini A, Castiglia S, Mareschi K, Ferrero I, De Gobbi Marco †, 
Carnevale-Schianca F, Fagioli F, Berger M. 2018. Analysis of Mesenchymal Stromal Cell 
Engraftment After Allogeneic HSCT in Pediatric Patients: A Large Multicenter Study. 
Castrén E, Sillat T, Oja S, Noro A, Laitinen A, Konttinen YT, Lehenkari P, Hukkanen M, 
Korhonen M. 2015. Osteogenic differentiation of mesenchymal stromal cells in two-
dimensional and three-dimensional cultures without animal serum. Stem Cell Res Ther 6. 
Castro-Malaspina H, Gay R., Resnick G, Kapoor N, Meyers P, D C, McKenzie S, Broxmeyer H, 
Moore MA. 1980. Characterization of human bone marrow fibroblast colony-forming cells 
(CFU-F) and their progeny. Blood 56: 289–301. 
Cervenakova L, Akimov S, Vasilyeva I, Yakovleva O, McKenzie C, Cervenak J, Piccardo P, Asher 
DM. 2011. Fukuoka-1 strain of transmissible spongiform encephalopathy agent infects 
murine bone marrow-derived cells with features of mesenchymal stem cells. Transfusion 
51: 1755–1768. 
CFR - Code of Federal Regulations Title 21. 2013. Current Good Manufacturing Practice For 
Finished Pharmaceuticals. Part 211 Curr Good Manuf Pract Finish Pharm. 
Chen CL, Mahjoubfar A, Tai LC, Blaby IK, Huang A, Niazi KR, Jalali B. 2016. Deep Learning in 
Label-free Cell Classification. Sci Rep 6. 
Chen L, Tredget EE, Wu PYG, Wu Y, Wu Y. 2008. Paracrine factors of mesenchymal stem cells 
recruit macrophages and endothelial lineage cells and enhance wound healing. PLoS One. 
Chen X, Wang C, Yin J, Xu J, Wei J, Zhang Y, Del Cañizo MC. 2015. Efficacy of mesenchymal 
stem cell therapy for steroid-refractory acute graft-versus-host disease following allogeneic 
hematopoietic stem cell transplantation: A systematic review and meta-analysis. PLoS One 
10. 
Chevallier N, Anagnostou F, Zilber S, Bodivit G, Maurin S, Barrault A, Bierling P, Hernigou P, 
Layrolle P, Rouard H. 2010. Osteoblastic differentiation of human mesenchymal stem cells 
with platelet lysate. Biomaterials 31: 270–278. 
Chiesa S, Morbelli S, Morando S, Massollo M, Marini C, Bertoni A, Frassoni F, Bartolomé ST, 
Sambuceti G, Traggiai E, et al. 2011. Mesenchymal stem cells impair in vivo T-cell priming 
by dendritic cells. Proc Natl Acad Sci U S A 108: 17384–17389. 
Childs BG, Durik M, Baker DJ, Van Deursen JM. 2015. Cellular senescence in aging and age-
related disease: From mechanisms to therapy. Nat Med 21: 1424–1435. 
Chinnadurai R, Copland IB, Garcia MA, Petersen CT, Lewis CN, Waller EK, Kirk AD, Galipeau 
J. 2016. Cryopreserved Mesenchymal Stromal Cells Are Susceptible to T-Cell Mediated 
Apoptosis Which Is Partly Rescued by IFNγ Licensing. Stem Cells 34: 2429–2442. 
Chinnadurai R, Copland IB, Patel SR, Galipeau J. 2014a. IDO-Independent Suppression of T 
Cell Effector Function by IFN-γ–Licensed Human Mesenchymal Stromal Cells. J Immunol 
192: 1491–1501. 
Chinnadurai R, Garcia MA, Sakurai Y, Lam WA, Kirk AD, Galipeau J, Copland IB. 2014b. Actin 
cytoskeletal disruption following cryopreservation alters the biodistribution of human 
mesenchymal stromal cells in vivo. Stem Cell Reports 3: 60–72. 




Galipeau J. 2017. Immune dysfunctionality of replicative senescent mesenchymal stromal 
cells is corrected by IFNg priming. Blood Adv 1: 628–643. 
Cho KA, Sung JR, Yoon SO, Ji HP, Jung WL, Kim HP, Kyung TK, Ik SJ, Sang CP. 2004. 
Morphological adjustment of senescent cells by modulating caveolin-1 status. J Biol Chem 
279: 42270–42278. 
Chow DC, Wenning LA, Miller WM, Papoutsakis ET. 2001. Modeling pO 2 Distributions in the 
Bone Marrow Hematopoietic Compartment. I. Krogh’s Model. 81: 675–84. 
Chullikana A, Majumdar A Sen, Gottipamula S, Krishnamurthy S, Kumar AS, Prakash VS, Gupta 
PK. 2015. Randomized, double-blind, phase I/II study of intravenous allogeneic 
mesenchymal stromal cells in acute myocardial infarction. Cytotherapy 17: 250–261. 
Cohneim JF. 1867. Ueber Entzündung und Eiterung. Arch Pathol Anat Pysiol Klin Med 40: 1–
79. 
Colter DC, Sekiya I, Prockop DJ. 2010. Identification of a subpopulation of rapidly and renewing 
multipotential in colonies of human marrow stromal cells. Proc Natl Acad Sci U S A 98: 
7841–7845. 
Connick P. 2012. Autologous mesenchymal stem cells for the treatment of secondary progressive 
multiple sclerosis: an open-label phase 2a proof-of-concept study. Artic Lancet Neurol 11: 
150–56. 
Coppé J-P, Desprez P-Y, Krtolica A, Campisi J. 2010. The Senescence-Associated Secretory 
Phenotype: The Dark Side of Tumor Suppression. Annu Rev Pathol Mech Dis 5: 99–118. 
Coppé J-P, Patil CK, Rodier F, Sun Y, Muñoz DP, Goldstein J, Nelson PS, Desprez PY, Campisi 
J. 2008. Senescence-associated secretory phenotypes reveal cell-nonautonomous 
functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol 6: 2852–68. 
Corcione A, Benvenuto F, Ferretti E, Giunti D, Cappiello V, Cazzanti F, Risso M, Gualandi F, 
Mancardi GL, Pistoia V, et al. 2006. Human mesenchymal stem cells modulate B-cell 
functions. Blood 107: 367–372. 
Crippa S, Bernardo ME. 2018. Mesenchymal Stromal Cells: Role in the BM Niche and in the 
Support of Hematopoietic Stem Cell Transplantation. HemaSphere 2: e151. 
Crisan M, Corselli M, Chen WCW, Péault B. 2012. Perivascular cells for regenerative medicine. 
J Cell Mol Med 16: 2851–2860. 
Crisan M, Yap S, Casteilla L, Chen CW, Corselli M, Park TS, Andriolo G, Sun B, Zheng B, Zhang 
L, et al. 2008. A Perivascular Origin for Mesenchymal Stem Cells in Multiple Human 
Organs. Cell Stem Cell. 
Cristofalo VJ, Allen RG, Pignolo RJ, Martin BG, Beck JC. 1998. Relationship between donor age 
and the replicative lifespan of human cells in culture: A reevaluation. Proc Natl Acad Sci 
U S A. 
da Silva Meirelles L, Caplan AI, Nardi NB. 2008. In Search of the In Vivo Identity of 
Mesenchymal Stem Cells. Stem Cells 26: 2287–2299. 
da Silva Meirelles L, Chagastelles PC, Nardi NB. 2006. Mesenchymal stem cells reside in 
virtually all post-natal organs and tissues. J Cell Sci 119: 2204–2213. 
Davalos AR, Coppé J-P, Campisi J, Desprez PY. 2010. Senescent cells as a source of 
inflammatory factors for tumor progression. Cancer Metastasis Rev 29: 273–283. 
Dazzi F, Ramasamy R, Glennie S, Jones SP, Roberts I. 2006. The role of mesenchymal stem cells 
in haemopoiesis. Blood Rev 20: 161–171. 
De Almeida DC, Ferreira MRP, Franzen J, Weidner CI, Frobel J, Zenke M, Costa IG, Wagner W. 
2016. Epigenetic Classification of Human Mesenchymal Stromal Cells. Stem Cell Reports 
6: 168–175. http://dx.doi.org/10.1016/j.stemcr.2016.01.003. 
De Bari C, Dell’Accio F, Tylzanowski P, Luyten FP. 2001. Multipotent mesenchymal stem cells 
from adult human synovial membrane. Arthritis Rheum. 
de Lange T. 2009. How Telomeres Solve the End-Protection Problem. Science (80- ) 326: 948. 
de Lange T. 2005. Shelterin: The protein complex that shapes and safeguards human telomeres. 
Genes Dev 19: 2100–10. 
De Witte S, Lambert E, Merino A, Strini T, Douben H, O’Flynn L, Elliman SJ, de Klein A, 
Newsome P, Baan CC, et al. 2017. Aging of bone marrow– and umbilical cord–derived 
mesenchymal stromal cells during expansion. Cytotherapy 19: 798–807. 




O, Baudoux E, Hannon M, et al. 2017. Infusion of mesenchymal stromal cells after 
deceased liver transplantation: A phase I-II, open-label, clinical study. J Hepatol 67: 47–
55. www.misot.eu. 
Devine SM, Bartholomew AM, Mahmud N, Nelson M, Patil S, Hardy W, Sturgeon C, Hewett T, 
Chung T, Stock W, et al. 2001. Mesenchymal stem cells are capable of homing to the bone 
marrow of non-human primates following systemic infusion. Exp Hematol. 
Dezawa M, Ishikawa H, Itokazu Y, Yoshihara T, Hoshino M, Takeda SI, Ide C, Nabeshima YI. 
2005. Developmental biology: Bone marrow stromal cells generate muscle cells and repair 
muscle degeneration. Science (80- ) 309: 314–317. 
Dhere T, Copland IB, Garcia M, Chiang KY, Chinnadurai R, Prasad M, Galipeau J, Kugathasan 
S. 2016. The safety of autologous and metabolically fit bone marrow mesenchymal stromal 
cells in medically refractory Crohn’s disease – a phase 1 trial with three doses. Aliment 
Pharmacol Ther 44: 471–481. 
di Fagagna A, Reaper PM, Clay-Farrace L, Fiegler H, Carr P, von Zglinicki T, Saretzki G, Carter 
NP, Jackson SP. 2003. A DNA damage checkpoint response in telomere-initiated 
senescence. Nature 426: 194–198. 
Di GH, Liu Y, Lu Y, Liu J, Wu C, Duan HF. 2014. IL-6 secreted from senescent mesenchymal 
stem cells promotes proliferation and migration of breast cancer cells. PLoS One 9. 
Di Nicola M, Carlo-Stella C, Magni M, Milanesi M, Longoni PD, Matteucci P, Grisanti S, Gianni 
AM. 2002. Human bone marrow stromal cells suppress T-lymphocyte proliferation 
induced by cellular or nonspecific mitogenic stimuli. Blood 99: 3838–43. 
Digirolamo CM, Stokes D, Colter DC, Phinney DG, Class R, Prockop DJ. 1999. Propagation and 
senescence of human marrow stromal cells in culture: A simple colony-forming assay 
identifies samples with the greatest potential to propagate and differentiate. Br J 
Haematol 107: 275–281. 
Dimri GP, Itahana K, Acosta M, Campisi J. 2000. Regulation of a Senescence Checkpoint 
Response by the E2F1 Transcription Factor and p14ARF Tumor Suppressor. Mol Cell Biol 
20: 273–285. 
Dimri GP, Leet X, Basile G, Acosta M, Scorrt G, Roskelley C, Medrano EE, Linskensi M, Rubeljii 
I, Pereira-Smithii O, et al. 1995. A biomarker that identifies senescent human cells in 
culture and in aging skin in vivo (replicative senescence/tumor suppression/18-
galactosidase) Communicated by Arthur. Cell Bioiogy 92: 9363–9367. 
Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini FC, Krause DS, Deans RJ, 
Keating A, Prockop DJ, Horwitz EM. 2006. Minimal criteria for defining multipotent 
mesenchymal stromal cells. The International Society for Cellular Therapy position 
statement. Cytotherapy. 
Dormont D. 1999. Transmissible spongiform encephalopathy agents and animal sera. Dev Biol 
Stand. 
Dotoli GM, De Santis GC, Orellana MD, De Lima Prata K, Caruso SR, Fernandes TR, Rensi 
Colturato VA, Kondo AT, Hamerschlak N, Simões BP, et al. 2017. Mesenchymal stromal 
cell infusion to treat steroid-refractory acute GvHD III/IV after hematopoietic stem cell 
transplantation. Bone Marrow Transplant 52: 859–862. 
Doucet C, Ernou I, Zhang Y, Llense JR, Begot L, Holy X, Lataillade JJ. 2005. Platelet lysates 
promote mesenchymal stem cell expansion: A safety substitute for animal serum in cell-
based therapy applications. J Cell Physiol 205: 228–236. 
Du Rocher B, Mencalha AL, Gomes BE, Abdelhay E. 2012. Mesenchymal stromal cells impair 
the differentiation of CD14++ CD16- CD64+ classical monocytes into CD14++ CD16+ 
CD64++ activate monocytes. Cytotherapy 14: 12–25. 
Dubois B, Bridon JM, Fayette J, Barthélémy C, Banchereau J, Caux C, Brière F. 1999. Dendritic 
cells directly modulate B cell growth and differentiation. J Leukoc Biol. 
Duijvestein M, Vos ACW, Roelofs H, Wildenberg ME, Wendrich BB, Verspaget HW, Kooy-
Winkelaar EMC, Koning F, Zwaginga JJ, Fidder HH, et al. 2010. Autologous bone marrow-
derived mesenchymal stromal cell treatment for refractory luminal Crohn’s disease: 
Results of a phase I study. Gut 59: 1662–1669. 
Dumont P, Burton M, Chen QM, Gonos ES, Frippiat C, Mazarati JB, Eliaers F, Remacle J, 




stresses in normal human fibroblast. Free Radic Biol Med 28: 361–373. 
Elahi KC, Klein G, Avci-Adali M, Sievert KD, Macneil S, Aicher WK. 2016. Human mesenchymal 
stromal cells from different sources diverge in their expression of cell surface proteins and 
display distinct differentiation patterns. Stem Cells Int 2016. 
Elsawa SF, Novak AJ, Ziesmer SC, Almada LL, Hodge LS, Grote DM, Witzig TE, Fernandez-
Zapico ME, Ansell SM. 2011. Comprehensive analysis of tumor microenvironment 
cytokines in Waldenstrom macroglobulinemia identifies CCL5 as a novel modulator of IL-
6 activity. Blood 118: 5540–5549. 
English K, Barry FP, Field-Corbett CP, Mahon BP. 2007. IFN-γ and TNF-α differentially regulate 
immunomodulation by murine mesenchymal stem cells. Immunol Lett 110: 91–100. 
Erices A, Conget P, Minguell JJ. 2000. Mesenchymal progenitor cells in human umbilical cord 
blood. Br J Haematol. 
Estrada JC, Albo C, Benguría A, Dopazo A, López-Romero P, Carrera-Quintanar L, Roche E, 
Clemente EP, Enríquez JA, Bernad A, et al. 2012. Culture of human mesenchymal stem 
cells at low oxygen tension improves growth and genetic stability by activating glycolysis. 
Cell Death Differ 19: 743–755. 
Estrada JC, Torres Y, Benguría A, Dopazo A, Roche E, Carrera-Quintanar L, Pérez RA, Enríquez 
JA, Torres R, Ramírez JC, et al. 2013. Human mesenchymal stem cell-replicative 
senescence and oxidative stress are closely linked to aneuploidy. Cell Death Dis 4. 
European comission. 2017. EudraLex The Rules Governing Medicinal Products in the European 
Union: Guidelines on Good Manufacturing Practice specific to Advanced Therapy 
Medicinal Products. 4. 
Fadeel B, Åhlin A, Henter JI, Orrenius S, Hampton MB. 1998. Involvement of caspases in 
neutrophil apoptosis: Regulation by reactive oxygen species. Blood 92: 4808–18. 
Fehrer C, Brunauer R, Laschober G, Unterluggauer H, Reitinger S, Kloss F, Gülly C, Gaßner R, 
Lepperdinger G. 2007. Reduced oxygen tension attenuates differentiation capacity of 
human mesenchymal stem cells and prolongs their lifespan. Aging Cell 6: 745–757. 
Fekete N, Gadelorge M, Frst D, Maurer C, Dausend J, Fleury-Cappellesso S, Mailnder V, Lotfi 
R, Ignatius A, Sensebé L, et al. 2012. Platelet lysate from whole blood-derived pooled 
platelet concentrates and apheresis-derived platelet concentrates for the isolation and 
expansion of human bone marrow mesenchymal stromal cells: Production process, 
content and identification of active comp. Cytotherapy 14: 540–554. 
Fekete N, Rojewski M, Lotfi R, Schrezenmeier H. 2014. Essential components for Ex vivo 
proliferation of mesenchymal stromal cells. Tissue Eng - Part C Methods 20: 129–139. 
Fisher SA, Cutler A, Doree C, Brunskill SJ, Stanworth SJ, Navarrete C, Girdlestone J. 2019. 
Mesenchymal stromal cells as treatment or prophylaxis for acute or chronic graft-versus-
host disease in haematopoietic stem cell transplant (HSCT) recipients with a 
haematological condition. Cochrane Database Syst Rev 2019. 
Fitzsimmons REB, Mazurek MS, Soos A, Simmons CA. 2018. Mesenchymal stromal/stem cells 
in regenerative medicine and tissue engineering. Stem Cells Int 2018. 
Forbes GM, Sturm MJ, Leong RW, Sparrow MP, Segarajasingam D, Cummins AG, Phillips M, 
Herrmann RP. 2014. A phase 2 study of allogeneic mesenchymal stromal cells for luminal 
crohn’s disease refractory to biologic therapy. Clin Gastroenterol Hepatol 12: 64–71. 
François M, Copland IB, Yuan S, Romieu-Mourez R, Waller EK, Galipeau J. 2012a. 
Cryopreserved mesenchymal stromal cells display impaired immunosuppressive 
properties as a result of heat-shock response and impaired interferon-γ licensing. 
Cytotherapy 14: 147–152. 
François M, Romieu-Mourez R, Li M, Galipeau J. 2012b. Human MSC suppression correlates 
with cytokine induction of indoleamine 2,3-dioxygenase and bystander M2 macrophage 
differentiation. Mol Ther 20: 187–195. 
Franzen J, Wagner W, Fernandez-Rebollo E. 2016. Epigenetic Modifications upon Senescence 
of Mesenchymal Stem Cells. Curr Stem Cell Reports 16: 183–191. 
Friedenstein A. 1976. Fibroblast precursors in normal and irradiated mouse hematopoietic 
organs. Exp Hematol 4: 274. 
Fu W-Y, Lu Y-M, Piao Y-J. 2001. Differentiation and telomerase activity of human mesenchymal 




Galipeau J. 2020. Mesenchymal Stromal Cells for Graft-versus-Host Disease: A Trilogy. Biol 
Blood Marrow Transplant 26: e89–e91. https://doi.org/10.1016/j.bbmt.2020.02.023. 
Galipeau J. 2017. Reply: “Function of Cryopreserved Mesenchymal Stromal Cells With and 
Without Interferon-γ Prelicensing Is Context Dependent.” Stem Cells 35: 1440–1441. 
Galipeau J. 2013. The mesenchymal stromal cells dilemma-does a negative phase III trial of 
random donor mesenchymal stromal cells in steroid-resistant graft-versus-host disease 
represent a death knell or a bump in the road? Cytotherapy 15: 2–8. 
Galipeau J, Krampera M, Barrett J, Dazzi F, Deans RJ, DeBruijn J, Dominici M, Fibbe WE, Gee 
AP, Gimble JM, et al. 2015. International Society for Cellular Therapy perspective on 
immune functional assays for mesenchymal stromal cells as potency release criterion for 
advanced phase clinical trials. Cytotherapy 18: 151–159. 
Galipeau J, Sensebé L. 2018. Mesenchymal Stromal Cells: Clinical Challenges and Therapeutic 
Opportunities. Cell Stem Cell 22: 824–833. 
Galleu A, Riffo-Vasquez Y, Trento C, Lomas C, Dolcetti L, Cheung TS, Von Bonin M, Barbieri L, 
Halai K, Ward S, et al. 2017. Apoptosis in mesenchymal stromal cells induces in vivo 
recipient-mediated immunomodulation. Sci Transl Med 9: 1–11. 
Gao S, Mao F, Zhang B, Zhang L, Zhang X, Wang M, Yan Y, Yang T, Zhang J, Zhu W, et al. 2014. 
Mouse bone marrow-derived mesenchymal stem cells induce macrophage M2 polarization 
through the nuclear factor-κB and signal transducer and activator of transcription 3 
pathways. Exp Biol Med 239: 366–375. 
Garcia-Olmo D, Herreros D, Pascual I, Pascual JA, Del-Valle E, Zorrilla J, De-La-Quintana P, 
Garcia-Arranz M, Pascual M. 2009. Expanded adipose-derived stem cells for the treatment 
of complex perianal fistula: A phase ii clinical trial. Dis Colon Rectum 52: 79–86. 
Geißler S, Textor M, Kühnisch J, Könnig D, Klein O, Ode A, Pfitzner T, Adjaye J, Kasper G, Duda 
GN. 2012. Functional Comparison of Chronological and In Vitro Aging: Differential Role 
of the Cytoskeleton and Mitochondria in Mesenchymal Stromal Cells. PLoS One 7. 
Gerosa F, Baldani-Guerra B, Nisii C, Marchesini V, Carra G, Trinchieri G. 2002. Reciprocal 
activating interaction between natural killer cells and dendritic cells. J Exp Med 195: 327–
33. 
Ghannam S, Pène J, Torcy-Moquet G, Jorgensen C, Yssel H. 2010. Mesenchymal Stem Cells 
Inhibit Human Th17 Cell Differentiation and Function and Induce a T Regulatory Cell 
Phenotype. J Immunol 185: 302–312. 
Gimbel M, Ashley RK, Sisodia M, Gabbay JS, Wasson KL, Heller J, Wilson L, Kawamoto HK, 
Bradley JP. 2007. Repair of alveolar cleft defects: Reduced morbidity with bone marrow 
stem cells in a resorbable matrix. J Craniofac Surg 18: 895–901. 
Glenn JD, Whatenby K. 2014. Mesenchymal stem cells: Emerging mechanisms of 
immunomodulation and therapy. World J Stem Cells 6: 526. 
Glennie S, Soeiro I, Dyson PJ, Lam EWF, Dazzi F. 2005. Bone marrow mesenchymal stem cells 
induce division arrest anergy of activated T cells. Blood 105: 2821–7. 
Gosselin K, Deruy E, Martien S, Vercamer C, Bouali F, Dujardin T, Slomianny C, Houel-Renault 
L, Chelli F, De Launoit Y, et al. 2009. Senescent keratinocytes die by autophagic 
programmed cell death. Am J Pathol 174: 423–435. 
Goujon E. 1869. Recersches expérimentales sur les propriétés physiologiques de la moelle des 
os. J Anat Physiol 6: 399–412. 
Grau-Vorster M, Laitinen A, Nystedt J, Vives J. 2019. HLA-DR expression in clinical-grade bone 
marrow-derived multipotent mesenchymal stromal cells: A two-site study. Stem Cell Res 
Ther 10. 
Grayson WL, Zhao F, Bunnell B, Ma T. 2007. Hypoxia enhances proliferation and tissue 
formation of human mesenchymal stem cells. Biochem Biophys Res Commun 358: 948–
953. 
Grayson WL, Zhao F, Izadpanah R, Bunnell B, Ma T. 2006. Effects of hypoxia on human 
mesenchymal stem cell expansion and plasticity in 3D constructs. J Cell Physiol 207: 331–
339. 
Grégoire C, Ritacco C, Hannon M, Seidel L, Delens L, Belle L, Dubois S, Vériter S, Lechanteur C, 
Briquet A, et al. 2019. Comparison of mesenchymal stromal cells from different origins for 





Gregory CA, Singh H, Perry AS, Prockop DJ. 2003. The Wnt signaling inhibitor Dickkopf-1 is 
required for reentry into the cell cycle of human adult stem cells from bone marrow. J Biol 
Chem 278: 28067–28078. 
Griffiths S, Baraniak PR, Copland IB, Nerem RM, McDevitt TC. 2013. Human platelet lysate 
stimulates high-passage and senescent human multipotent mesenchymal stromal cell 
growth and rejuvenation in vitro. Cytotherapy 15: 1469–1483. 
Gronthos S, Mankani M, Brahim J, Robey PG, Shi S. 2000. Postnatal human dental pulp stem 
cells (DPSCs) in vitro and in vivo. Proc Natl Acad Sci U S A. 
Gstraunthaler G, Lindl T, Van Der Valk J. 2013. A plea to reduce or replace fetal bovine serum 
in cell culture media. Cytotechnology 65: 791–3. 
Haack-Sørensen M, Juhl M, Follin B, Harary Søndergaard R, Kirchhoff M, Kastrup J, Ekblond 
A. 2018. Development of large-scale manufacturing of adipose-derived stromal cells for 
clinical applications using bioreactors and human platelet lysate. Scand J Clin Lab Invest 
78: 293–300. https://doi.org/10.1080/00365513.2018.1462082. 
Hara E, Uzman JA, Dimri GP, Nehlin JO, Testori A, Campisi J. 1996. The helix-loop-helix 
protein Id-1 and a retinoblastoma protein binding mutant of SV40 T antigen synergize to 
reactivate DNA synthesis in senescent human fibroblasts. Dev Genet 18: 161–172. 
Hare JM, Fishman JE, Gerstenblith G, DiFede Velazquez DL, Zambrano JP, Suncion VY, Tracy 
M, Ghersin E, Johnston P V., Brinker JA, et al. 2012. Comparison of allogeneic vs 
autologous bone marrow-derived mesenchymal stem cells delivered by transendocardial 
injection in patients with ischemic cardiomyopathy: The POSEIDON randomized trial. 
JAMA - J Am Med Assoc 308: 2369–2379. 
Harley CB, Futcher B, Greider CW. 1990. Telomeres shorten during ageing of human fibroblasts. 
Nature. 
Hayes M, Curley G, Ansari B, Laffey JG. 2012. Clinical review: Stem cell therapies for acute lung 
injury/acute respiratory distress syndrome - hope or hype? Crit Care 16: 205. 
Hayflick L. 1965. The limited in vitro lifetime of human diploid cell strains. Exp Cell Res 37: 
614–36. 
Hayflick L, Moorhead PS. 1961. The serial cultivation of human diploid cell strains. Exp Cell Res 
25: 585–621. 
Heiskanen A, Satomaa T, Tiitinen S, Laitinen A, Mannelin S, Impola U, Mikkola M, Olsson C, 
Miller-Podraza H, Blomqvist M, et al. 2007.  N -Glycolylneuraminic Acid Xenoantigen 
Contamination of Human Embryonic and Mesenchymal Stem Cells Is Substantially 
Reversible . Stem Cells 25: 197–202. 
Heo JS, Choi Y, Kim HS, Kim HO. 2016. Comparison of molecular profiles of human 
mesenchymal stem cells derived from bone marrow, umbilical cord blood, placenta and 
adipose tissue. Int J Mol Med 37: 115–125. 
Ho AD, Wagner W, Franke W. 2008. Heterogeneity of mesenchymal stromal cell preparations. 
Cytotherapy 10: 320–330. 
Honda S, Weigel A, Hjelmeland LM, Handa JT. 2001. Induction of telomere shortening and 
replicative senescence by cryopreservation. Biochem Biophys Res Commun. 
Hoogduijn MJ, De Witte SFH, Luk F, Van Den Hout-Van Vroonhoven MCGN, Ignatowicz L, 
Catar R, Strini T, Korevaar SS, Van Ijcken WFJ, Betjes MGH, et al. 2016. Effects of Freeze-
Thawing and Intravenous Infusion on Mesenchymal Stromal Cell Gene Expression. Stem 
Cells Dev 25: 586–597. 
Horwitz EM. 2004. Dkk-1-mediated expansion of adult stem cells. Trends Biotechnol 22: 386–
388. 
Horwitz EM, Le Blanc K, Dominici M, Mueller I, Slaper-Cortenbach I, Marini FC, Deans RJ, 
Krause DS, Keating A. 2005. Clarification of the nomenclature for MSC: The International 
Society for Cellular Therapy position statement. Cytotherapy 7: 393–395. 
Hunt CJ. 2011. Cryopreservation of human stem cells for clinical application: A review. Transfus 
Med Hemotherapy 38: 107–123. 
In ’t Anker P, Scherjon S, Kleijburg-van der Keur C, de Groot-Swings G, Claas FHJ, Fibbe WE, 
Kanhai H. 2004. Isolation of Mesenchymal Stem Cells of Fetal or Maternal Origin from 




In ’t Anker P, Scherjon S, Kleijburg-van der Keur C, Noort WA, Claas FHJ, Willemze R, Fibbe 
WE, Kanhai H. 2003. Amniotic fluid as a novel source of mesenchymal stem cells for 
therapeutic transplantation. Blood 102: 1548–9. 
Itahana K, Dimri GP, Campisi J. 2001. Regulation of cellular senescence by p53. Eur J Biochem. 
Ito A, Aoyama T, Yoshizawa M, Nagai M, Tajino J, Yamaguchi S, Iijima H, Zhang X, Kuroki H. 
2015. The effects of short-term hypoxia on human mesenchymal stem cell proliferation, 
viability and p16 INK4A mRNA expression: Investigation using a simple hypoxic culture 
system with a deoxidizing agent. J Stem Cells Regenetrative Med 11: 25–31. 
Jaiswal N, Haynesworth SE, Caplan AI, Bruder SP. 1997. Osteogenic differentiation of purified, 
culture-expanded human mesenchymal stem cells in vitro. J Cell Biochem 54: 295–312. 
Jeon ES, Moon HJ, Lee MJ, Song HY, Kim YM, Bae YC, Jung JS, Kim JH. 2006. 
Sphigosylphosphorylcholine induces differentiation of human mesenchymal stem cells 
into smooth-muscle-like through a TGF-β-dependent mechanism. J Cell Sci 119: 4994–
5005. 
Jin HJ, Bae YK, Kim M, Kwon SJ, Jeon HB, Choi SJ, Kim SW, Yang YS, Oh W, Chang JW. 2013. 
Comparative analysis of human mesenchymal stem cells from bone marrow, adipose 
tissue, and umbilical cord blood as sources of cell therapy. Int J Mol Sci 14: 17986–18001. 
Jin Y, Kato T, Furu M, Nasu A, Kajita Y, Mitsui H, Ueda M, Aoyama T, Nakayama T, Nakamura 
T, et al. 2010. Mesenchymal stem cells cultured under hypoxia escape from senescence via 
down-regulation of p16 and extracellular signal regulated kinase. Biochem Biophys Res 
Commun 391: 1471–1476. 
Johnstone B, Hering TM, Caplan AI, Goldberg VM, Yoo JU. 1998. In vitro chondrogenesis of 
bone marrow-derived mesenchymal progenitor cells. Exp Cell Res 238: 265–272. 
Jonsdottir-Buch SM, Lieder R, Sigurjonsson OE. 2013. Platelet Lysates Produced from Expired 
Platelet Concentrates Support Growth and Osteogenic Differentiation of Mesenchymal 
Stem Cells. PLoS One 8. 
Kaigler D, Pagni G, Park CH, Braun TM, Holman LA, Yi E, Tarle SA, Bartel RL, Giannobile W V. 
2013. Stem cell therapy for craniofacial bone regeneration: A randomized, controlled 
feasibility trial. Cell Transplant 22: 767–777. 
Kallekleiv M, Larun L, Bruserud Ø, Hatfield KJ. 2016. Co-transplantation of multipotent 
mesenchymal stromal cells in allogeneic hematopoietic stem cell transplantation: A 
systematic review and meta-analysis. Cytotherapy 18: 172–185. 
Karnoub AE, Dash AB, Vo AP, Sullivan A, Brooks MW, Bell GW, Richardson AL, Polyak K, Tubo 
R, Weinberg RA. 2007. Mesenchymal stem cells within tumour stroma promote breast 
cancer metastasis. Nature 449: 557–563. 
Karp JM, Leng Teo GS. 2009. Mesenchymal Stem Cell Homing: The Devil Is in the Details. Cell 
Stem Cell 4: 206–16. 
Karussis D, Karageorgiou C, Vaknin-Dembinsky A, Gowda-Kurkalli B, Gomori JM, Kassis I, 
Bulte JWM, Petrou P, Ben-Hur T, Abramsky O, et al. 2010. Safety and immunological 
effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and 
amyotrophic lateral sclerosis. Arch Neurol 67: 1187–1194. 
Kasten P, Vogel J, Beyen I, Weiss S, Niemeyer P, Leo A, Luginbuhl R. 2008. Effect of platelet-
rich plasma on the in vitro proliferation and osteogenic differentiation of human 
mesenchymal stem cells on distinct calcium phosphate scaffolds: The specific surface area 
makes a difference. J Biomater Appl 23: 169–188. 
Kastrup J, Haack-Sørensen M, Juhl M, Harary Søndergaard R, Follin B, Drozd Lund L, Mønsted 
Johansen E, Ali Qayyum A, Bruun Mathiasen A, Jørgensen E, et al. 2017. Cryopreserved 
Off-the-Shelf Allogeneic Adipose-Derived Stromal Cells for Therapy in Patients with 
Ischemic Heart Disease and Heart Failure—A Safety Study. Stem Cells Transl Med 6: 
1963–1971. 
Katsube Y, Hirose M, Nakamura C, Ohgushi H. 2008. Correlation between proliferative activity 
and cellular thickness of human mesenchymal stem cells. Biochem Biophys Res Commun 
368: 256–260. 
Kebriaei P, Hayes J, Daly A, Uberti J, Marks DI, Soiffer R, Waller EK, Burke E, Skerrett D, Shpall 
E, et al. 2019. A Phase 3 Randomized Study of Remestemcel-L versus Placebo Added to 




Disease. Biol Blood Marrow Transplant. 
Kebriaei P, Isola L, Bahceci E, Holland K, Rowley S, McGuirk J, Devetten M, Jansen J, Herzig 
R, Schuster M, et al. 2009. Adult Human Mesenchymal Stem Cells Added to Corticosteroid 
Therapy for the Treatment of Acute Graft-versus-Host Disease. Biol Blood Marrow 
Transplant 15: 804–811. 
Kern S, Eichler H, Stoeve J, Klüter H, Bieback K. 2006. Comparative Analysis of Mesenchymal 
Stem Cells from Bone Marrow, Umbilical Cord Blood, or Adipose Tissue. Stem Cells 24: 
1294–1301. 
Kharaziha P, Hellström PM, Noorinayer B, Farzaneh F, Aghajani K, Jafari F, Telkabadi M, Atashi 
A, Honardoost M, Zali MR, et al. 2009. Improvement of liver function in liver cirrhosis 
patients after autologous mesenchymal stem cell injection: A phase I-II clinical trial. Eur 
J Gastroenterol Hepatol 21: 1199–1205. 
Kim J, Hematti P. 2009. Mesenchymal stem cell-educated macrophages: A novel type of 
alternatively activated macrophages. Exp Hematol 37: 1445–1453. 
Kimura M, Stone RC, Hunt SC, Skurnick J, Lu X, Cao X, Harley CB, Aviv A. 2010. Measurement 
of telomere length by the southern blot analysis of terminal restriction fragment lengths. 
Nat Protoc 5: 1596–1607. 
Kirkwood TBL, Austad SN. 2000. Why do we age? Nature. 
Klinker MW, Marklein RA, Lo Surdo JL, Wei CH, Bauer SR. 2017. Morphological features of 
IFN-γ-stimulated mesenchymal stromal cells predict overall immunosuppressive capacity. 
Proc Natl Acad Sci U S A 114: E2598–E2607. 
Koç ON, Gerson SL, Cooper BW, Dyhouse SM, Haynesworth SE, Caplan AI, Lazarus HM. 2000. 
Rapid hematopoietic recovery after coinfusion of autologous-blood stem cells and culture-
expanded marrow mesenchymal stem cells in advanced breast cancer patients receiving 
high-dose chemotherapy. J Clin Oncol. 
Kocaömer A, Kern S, Klüter H, Bieback K. 2007. Human AB Serum and Thrombin-Activated 
Platelet-Rich Plasma Are Suitable Alternatives to Fetal Calf Serum for the Expansion of 
Mesenchymal Stem Cells from Adipose Tissue. Stem Cells 25: 1270–1278. 
Koch CM, Joussen S, Schellenberg A, Lin Q, Zenke M, Wagner W. 2012. Monitoring of cellular 
senescence by DNA-methylation at specific CpG sites. Aging Cell 11: 366–369. 
Kozlowska U, Krawczenko A, Futoma K, Jurek T, Rorat M, Patrzalek D, Klimczak A. 2019. 
Similarities and differences between mesenchymal stem/progenitor cells derived from 
various human tissues. World J Stem Cells 11: 347–374. 
Krampera M, Cosmi L, Angeli R, Pasini A, Liotta F, Andreini A, Santarlasci V, Mazzinghi B, 
Pizzolo G, Vinante F, et al. 2006. Role for Interferon-γ in the Immunomodulatory Activity 
of Human Bone Marrow Mesenchymal Stem Cells. Stem Cells 24: 386–398. 
Krampera M, Glennie S, Dyson J, Scott D, Laylor R, Simpson E, Dazzi F. 2003. Bone marrow 
mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells 
to their cognate peptide. Blood 101: 3722–3729. 
Krampera M, Marconi S, Pasini A, Galiè M, Rigotti G, Mosna F, Tinelli M, Lovato L, Anghileri 
E, Andreini A, et al. 2007. Induction of neural-like differentiation in human mesenchymal 
stem cells derived from bone marrow, fat, spleen and thymus. Bone 40: 382–390. 
Krishna DR, Sperker B, Fritz P, Klotz U. 1999. Does pH 6 β-galactosidase activity indicate cell 
senescence? Mech Ageing Dev 109: 113–123. 
Krishnamurthy J, Torrice C, Ramsey MR, Sharpless NE, Kovalev GI, Su L, Al-Regaiey K. 2004. 
Ink4a/Arf expression is a biomarker of aging. J Clin Invest 114: 1299–1307. 
Kuilman T, Michaloglou C, Mooi WJ, Peeper DS. 2010. The essence of senescence. Genes Dev 
24: 2463–2479. 
Kuilman T, Peeper DS. 2009. Senescence-messaging secretome: SMS-ing cellular stress. Nat 
Rev Cancer. 
Kuo CK, Tuan RS. 2008. Mechanoactive tenogenic differentiation of human mesenchymal stem 
cells. Tissue Eng - Part A 14: 1615–1627. 
Kurtzberg J, Abdel-Azim H, Carpenter P, Chaudhury S, Horn B, Mahadeo K, Nemecek E, 
Neudorf S, Prasad V, Prockop S, et al. 2020. A Phase 3, Single-Arm, Prospective Study of 
Remestemcel-L, Ex Vivo Culture-Expanded Adult Human Mesenchymal Stromal Cells for 




Graft-versus-Host Disease. Biol Blood Marrow Transplant 26: 845–854. 
https://doi.org/10.1016/j.bbmt.2020.01.018. 
Kurtzberg J, Prasad V, Grimley MS, Horn B, Carpenter PA, Jacobsohn D, Prockop S. 2010. 
Allogeneic Human Mesenchymal Stem Cell Therapy (Prochymal®) As A Rescue Agent For 
Severe Treatment Resistant GVHD In Pediatric Patients. Biol Blood Marrow Transplant 
16: S169. http://dx.doi.org/10.1016/j.bbmt.2009.12.056. 
Kurtzberg J, Prockop S, Teira P, Bittencourt H, Lewis V, Chan KW, Horn B, Yu L, Talano JA, 
Nemecek E, et al. 2014. Allogeneic human mesenchymal stem cell therapy (Remestemcel-
L, Prochymal) as a rescue agent for severe refractory acute graft-versus-host disease in 
pediatric patients. Biol Blood Marrow Transplant 20: 229–235. 
Kurz DJ, Decary S, Hong Y, Erusalimsky JD. 2000. Senescence-associated beta-galactosidase 
reflects an increase in lysosomal mass during replicative ageing of human endothelial cells. 
J Cell Sci 113: 3613–22. 
Kuznetsov SA, Mankani MH, Robey PG. 2000. Effect of serum on human bone marrow stromal 
cells: Ex vivo expansion and in vivo bone formation. Transplantation 70: 1780–1787. 
Laitinen A, Oja S, Kilpinen L, Kaartinen T, Möller J, Laitinen S, Korhonen M, Nystedt J. 2016a. 
A robust and reproducible animal serum-free culture method for clinical-grade bone 
marrow-derived mesenchymal stromal cells. Cytotechnology 68: 891–906. 
Laitinen A, Oja S, Kilpinen L, Kaartinen T, Möller J, Laitinen S, Korhonen M, Nystedt J. 2016b. 
A robust and reproducible animal serum-free culture method for clinical-grade bone 
marrow-derived mesenchymal stromal cells. Cytotechnology 68. 
Lalu MM, Mazzarello S, Zlepnig J, Dong YY (Ryan), Montroy J, McIntyre L, Devereaux PJ, 
Stewart DJ, David Mazer C, Barron CC, et al. 2018. Safety and Efficacy of Adult Stem Cell 
Therapy for Acute Myocardial Infarction and Ischemic Heart Failure (SafeCell Heart): A 
Systematic Review and Meta-Analysis. Stem Cells Transl Med 7: 857–866. 
Lalu MM, McIntyre L, Pugliese C, Fergusson D, Winston BW, Marshall JC, Granton J, Stewart 
DJ. 2012. Safety of Cell Therapy with Mesenchymal Stromal Cells (SafeCell): A Systematic 
Review and Meta-Analysis of Clinical Trials. PLoS One 7. 
Lange C, Cakiroglu F, Spiess AN, Cappallo-Obermann H, Dierlamm J, Zander AR. 2007. 
Accelerated and safe expansion of human mesenchymal stromal cells in animal serum-free 
medium for transplantation and regenerative medicine. J Cell Physiol 213: 18–26. 
Lazarus HM, Koc ON, Devine SM, Curtin P, Maziarz RT, Holland HK, Shpall EJ, McCarthy P, 
Atkinson K, Cooper BW, et al. 2005. Cotransplantation of HLA-identical sibling culture-
expanded mesenchymal stem cells and hematopoietic stem cells in hematologic 
malignancy patients. Biol Blood Marrow Transplant 11: 389–398. 
Le Blanc K, Davies LC. 2015. Mesenchymal stromal cells and the innate immune response. 
Immunol Lett 168: 140–146. 
Le Blanc K, Frassoni F, Ball LM, Locatelli F, Roelofs H, Lewis I, Lanino E, Sundberg B, Bernardo 
ME, Remberger M, et al. 2008. Mesenchymal stem cells for treatment of steroid-resistant, 
severe, acute graft-versus-host disease: a phase II study. Lancet 371: 1579–1586. 
Le Blanc K, Mougiakakos D. 2012. Multipotent mesenchymal stromal cells and the innate 
immune system. Nat Rev Immunol 12: 383–396. 
Le Blanc K, Rasmusson I, Sundberg B, Götherström C, Hassan M, Uzunel M, Ringdén O. 2004. 
Treatment of severe acute graft-versus-host disease with third party haploidentical 
mesenchymal stem cells. Lancet 363: 1439–1441. 
Lee JJ, Nam CE, Kook H, Maciejewski JP, Kim YK, Chung IJ, Park KS, Lee IK, Hwang TJ, Kim 
HJ. 2003. Constitution and telomere dynamics of bone marrow stromal cells in patients 
undergoing allogeneic bone marrow transplantation. Bone Marrow Transplant 32: 947–
952. 
Lepperdinger G, Brunauer R, Jamnig A, Laschober G, Kassem M. 2008. Controversial issue: Is 
it safe to employ mesenchymal stem cells in cell-based therapies? Exp Gerontol. 
Liang J, Zhang H, Hua B, Wang H, Lu L, Shi S, Hou Y, Zeng X, Gilkeson GS, Sun L. 2010. 
Allogenic mesenchymal stem cells transplantation in refractory systemic lupus 
erythematosus: A pilot clinical study. Ann Rheum Dis 69: 1423–1429. 
Liu D, O’Connor MS, Qin J, Songyang Z. 2004. Telosome, a mammalian telomere-associated 




Lo Surdo JL, Millis BA, Bauer SR. 2013. Automated microscopy as a quantitative method to 
measure differences in adipogenic differentiation in preparations of human mesenchymal 
stromal cells. Cytotherapy 15: 1527–1540. 
Lohmann M, Walenda G, Hemeda H, Joussen S, Drescher W, Jockenhoevel S, Hutschenreuter 
G, Zenke M, Wagner W. 2012. Donor age of human platelet lysate affects proliferation and 
differentiation of mesenchymal stem cells. PLoS One 7. 
Lovelock JE, Bishop MWH. 1959. Prevention of freezing damage to living cells by dimethyl 
sulphoxide. Nature 183: 1394–5. 
Lucarelli E, Beccheroni A, Donati D, Sangiorgi L, Cenacchi A, Del Vento AM, Meotti C, Bertoja 
AZ, Giardino R, Fornasari PM, et al. 2003. Platelet-derived growth factors enhance 
proliferation of human stromal stem cells. Biomaterials 24: 3095–3100. 
Lucchini G, Introna M, Dander E, Rovelli A, Balduzzi A, Bonanomi S, Salvadè A, Capelli C, 
Belotti D, Gaipa G, et al. 2010. Platelet-lysate-expanded mesenchymal stromal cells as a 
salvage therapy for severe resistant graft-versus-host disease in a pediatric population. Biol 
Blood Marrow Transplant 16: 1293–1301. 
Lundberg AS, Weinberg RA. 1999. Control of the cell cycle and apoptosis. Eur J Cancer 35: 
1886–1894. 
Lunyak V V., Amaro-Ortiz A, Gaur M. 2017. Mesenchymal stem cells secretory responses: 
Senescence messaging secretome and immunomodulation perspective. Front Genet 8. 
MacMillan ML, Blazar BR, DeFor TE, Wagner JE. 2009. Transplantation of ex-vivo culture-
expanded parental haploidentical mesenchymal stem cells to promote engraftment in 
pediatric recipients of unrelated donor umbilical cord blood: Results of a phase I-II clinical 
trial. Bone Marrow Transplant 43: 447–454. 
Maggini J, Mirkin G, Bognanni I, Holmberg J, Piazzón IM, Nepomnaschy I, Costa H, Cañones 
C, Raiden S, Vermeulen M, et al. 2010. Mouse bone marrow-derived mesenchymal stromal 
cells turn activated macrophages into a regulatory-like profile. PLoS One 5. 
Maijenburg MW, Kleijer M, Vermeul K, Mul EPJ, van Alphen FPJ, van der Schoot CE, Voermans 
C. 2012. The composition of the mesenchymal stromal cell compartment in human bone 
marrow changes during development and aging. Haematologica 97: 179–183. 
Marklein RA, Lo Surdo JL, Bellayr IH, Godil SA, Puri RK, Bauer SR. 2016. High Content Imaging 
of Early Morphological Signatures Predicts Long Term Mineralization Capacity of Human 
Mesenchymal Stem Cells upon Osteogenic Induction. Stem Cells 34: 935–947. 
Marquez-Curtis LA, Janowska-Wieczorek A, McGann LE, Elliott JAW. 2015. Mesenchymal 
stromal cells derived from various tissues: Biological, clinical and cryopreservation 
aspects. Cryobiology 71: 181–197. 
Martin-Rendon E, Hale SJM, Ryan D, Baban D, Forde SP, Roubelakis M, Sweeney D, Moukayed 
M, Harris AL, Davies K, et al. 2007.  Transcriptional Profiling of Human Cord Blood CD133 
+ and Cultured Bone Marrow Mesenchymal Stem Cells in Response to Hypoxia . Stem Cells 
25: 1003–1012. 
Martin PJ, Uberti J, Soiffer R, Klingemann H, Waller EK, Daly A, Herrmann RP, Kebriaei P. 
2010. Prochymal Improves Response Rates In Patients With Steroid-Refractory Acute 
Graft Versus Host Disease (SR-GVHD) Involving The Liver And Gut: Results Of A 
Randomized, Placebo-Controlled, Multicenter Phase III Trial In GVHD. Biol Blood 
Marrow Transplant. 
Mattar P, Bieback K. 2015. Comparing the immunomodulatory properties of bone marrow, 
adipose tissue, and birth-associated tissue mesenchymal stromal cells. Front Immunol 6. 
Mauney JR, Kaplan DL, Volloch V. 2004. Matrix-mediated retention of osteogenic 
differentiation potential by human adult bone marrow stromal cells during ex vivo 
expansion. Biomaterials 25: 3233–3243. 
Mazur P. 1970. Cryobiology: The freezing of biological systems. Science (80- ) 168: 939–49. 
McGann LE. 1978. Differing actions of penetrating and nonpenetrating cryoprotective agents. 
Cryobiology 15: 382–390. 
McGann LE, Yang H, Walterson M. 1988. Manifestations of cell damage after freezing and 
thawing. Cryobiology 25: 178–185. 
Meisel R, Zibert A, Laryea M, Göbel U, Däubener W, Dilloo D. 2004. Human bone marrow 




tryptophan degradation. Blood 103: 4619–21. 
Melief SM, Schrama E, Brugman MH, Tiemessen MM, Hoogduijn MJ, Fibbe WE, Roelofs H. 
2013. Multipotent stromal cells induce human regulatory T cells through a novel pathway 
involving skewing of monocytes toward anti-inflammatory macrophages. Stem Cells 31: 
1980–1991. 
Menard C, Pacelli L, Bassi G, Dulong J, Bifari F, Bezier I, Zanoncello J, Ricciardi M, Latour M, 
Bourin P, et al. 2013. Clinical-grade mesenchymal stromal cells produced under various 
good manufacturing practice processes differ in their immunomodulatory properties: 
Standardization of immune quality controls. Stem Cells Dev 22: 1789–1801. 
Mencattini A, Di Giuseppe D, Comes MC, Casti P, Corsi F, Bertani FR, Ghibelli L, Businaro L, Di 
Natale C, Parrini MC, et al. 2020. Discovering the hidden messages within cell trajectories 
using a deep learning approach for in vitro evaluation of cancer drug treatments. Sci Rep 
10: 7653. 
Mendicino M, Bailey AM, Wonnacott K, Puri RK, Bauer SR. 2014. MSC-based product 
characterization for clinical trials: An FDA perspective. Cell Stem Cell 14: 141–145. 
Mesimäki K, Lindroos B, Törnwall J, Mauno J, Lindqvist C, Kontio R, Miettinen S, Suuronen R. 
2009. Novel maxillary reconstruction with ectopic bone formation by GMP adipose stem 
cells. Int J Oral Maxillofac Surg 38: 201–209. 
Mets T, Verdonk G. 1981. In vitro aging of human bone marrow derived stromal cells. Mech 
Ageing Dev. 
Michler RE. 2018. The current status of stem cell therapy in ischemic heart disease. J Card Surg 
33: 520–531. 
Minieri V, Saviozzi S, Gambarotta G, Lo Iacono M, Accomasso L, Cibrario Rocchietti E, Gallina 
C, Turinetto V, Giachino C. 2015. Persistent DNA damage-induced premature senescence 
alters the functional features of human bone marrow mesenchymal stem cells. J Cell Mol 
Med 19: 734–743. 
Mizukami A, Swiech K. 2018. Mesenchymal stromal cells: From discovery to manufacturing and 
commercialization. Stem Cells Int 2018. 
Mo M, Wang S, Zhou Y, Li H, Wu Y. 2016. Mesenchymal stem cell subpopulations: phenotype, 
property and therapeutic potential. Cell Mol Life Sci 73: 3311–3321. 
Moll G, Alm JJ, Davies LC, Von Bahr L, Heldring N, Stenbeck-Funke L, Hamad OA, Hinsch R, 
Ignatowicz L, Locke M, et al. 2014a. Do cryopreserved mesenchymal stromal cells display 
impaired immunomodulatory and therapeutic properties? Stem Cells 32: 2430–2442. 
Moll G, Ankrum JA, Kamhieh-Milz J, Bieback K, Ringdén O, Volk HD, Geissler S, Reinke P. 
2019. Intravascular Mesenchymal Stromal/Stem Cell Therapy Product Diversification: 
Time for New Clinical Guidelines. Trends Mol Med 25: 149–163. 
Moll G, Drzeniek N, Kamhieh-Milz J, Geissler S, Volk HD, Reinke P. 2020a. MSC Therapies for 
COVID-19: Importance of Patient Coagulopathy, Thromboprophylaxis, Cell Product 
Quality and Mode of Delivery for Treatment Safety and Efficacy. Front Immunol 11: 1–10. 
Moll G, Geißler S, Catar R, Ignatowicz L, Hoogduijn MJ, Strunk D, Bieback K, Ringdén O. 2016. 
Cryopreserved or fresh mesenchymal stromal cells: Only a matter of taste or key to unleash 
the full clinical potential of MSC therapy? Adv Exp Med Biol 951: 77–98. 
Moll G, Hoogduijn MJ, Ankrum JA. 2020b. Editorial: Safety, Efficacy and Mechanisms of Action 
of Mesenchymal Stem Cell Therapies. Front Immunol 11: 1–4. 
Moll G, Hult A, Von Bahr L, Alm JJ, Heldring N, Hamad OA, Stenbeck-Funke L, Larsson S, 
Teramura Y, Roelofs H, et al. 2014b. Do ABO blood group antigens hamper the therapeutic 
efficacy of mesenchymal stromal cells? PLoS One 9. 
Moll G, Jitschin R, Bahr Lena V, Rasmusson-Duprez I, Sundberg B, Lönnies L, Elgue G, Nilsson-
Ekdahl K, Mougiakakos D, Lambris JD, et al. 2011. Mesenchymal stromal cells engage 
complement and complement receptor bearing innate effector cells to modulate immune 
responses. PLoS One 6: e21703. 
Moll G, Rasmusson-Duprez I, Von Bahr L, Connolly-Andersen AM, Elgue G, Funke L, Hamad 
OA, Lönnies H, Magnusson PU, Sanchez J, et al. 2012. Are therapeutic human 
mesenchymal stromal cells compatible with human blood? Stem Cells. 
Moretta L, Bottino C, Cantoni C, Mingari MC, Moretta A. 2001. Human natural killer cell 




Morris TJ, Picken A, Sharp DMC, Slater NKH, Hewitt CJ, Coopman K. 2016. The effect of 
Me2SO overexposure during cryopreservation on HOS TE85 and hMSC viability, growth 
and quality. Cryobiology 73: 367–375. 
Moscoso I, Centeno A, López E, Rodriguez-Barbosa JI, Santamarina I, Filgueira P, Sánchez MJ, 
Domínguez-Perles R, Peñuelas-Rivas G, Domenech N. 2005. Differentiation “in vitro” of 
primary and immortalized porcine mesenchymal stem cells into cardiomyocytes for cell 
transplantation. Transplant Proc 37: 481–2. 
Moyzis RK, Buckingham JM, Cram LS, Dani M, Deaven LL, Jones MD, Meyne J, Ratliff RL, Wu 
JR. 1988. A highly conserved repetitive DNA sequence, (TTAGGG)(n), present at the 
telomeres of human chromosomes. Proc Natl Acad Sci U S A 85: 6622–6626. 
Muguruma Y, Yahata T, Miyatake H, Sato T, Uno T, Itoh J, Kato S, Ito M, Hotta T, Ando K. 2006. 
Reconstitution of the functional human hematopoietic microenvironment derived from 
human mesenchymal stem cells in the murine bone marrow compartment. Blood. 
Müller I, Kordowich S, Holzwarth C, Spano C, Isensee G, Staiber A, Viebahn S, Gieseke F, Langer 
H, Gawaz MP, et al. 2006. Animal serum-free culture conditions for isolation and 
expansion of multipotent mesenchymal stromal cells from human BM. Cytotherapy. 
Naji A, Eitoku M, Favier B, Deschaseaux F, Rouas-Freiss N, Suganuma N. 2019. Biological 
functions of mesenchymal stem cells and clinical implications. Cell Mol Life Sci 76: 3323–
3348. 
National Institute of Health (NIH). ImageJ - Image Processing and Analysis in Java. 
https://imagej.nih.gov/ij/. 
Negi N, Griffin MD. 2020. Effects of mesenchymal stromal cells on regulatory T cells: Current 
understanding and clinical relevance. Stem Cells 38: 596–605. 
Németh K, Leelahavanichkul A, Yuen PST, Mayer B, Parmelee A, Doi K, Robey PG, 
Leelahavanichkul K, Koller BH, Brown JM, et al. 2009. Bone marrow stromal cells 
attenuate sepsis via prostaglandin E 2-dependent reprogramming of host macrophages to 
increase their interleukin-10 production. Nat Med 15: 42–9. 
Nishio K, Inoue A. 2005. Senescence-associated alterations of cytoskeleton: Extraordinary 
production of vimentin that anchors cytoplasmic p53 in senescent human fibroblasts. 
Histochem Cell Biol 123: 263–273. 
Noh H Bin, Ahn HJ, Lee WJ, Kwack KB, Kwon Y Do. 2010. The molecular signature of in vitro 
senescence in human mesenchymal stem cells. Genes and Genomics 32: 87–93. 
Nold P, Hackstein H, Riedlinger T, Kasper C, Neumann A, Mernberger M, Fölsch C, Schmitt J, 
Fuchs-Winkelmann S, Barckhausen C, et al. 2015. Immunosuppressive capabilities of 
mesenchymal stromal cells are maintained under hypoxic growth conditions and after 
gamma irradiation. Cytotherapy 17: 152–162. 
Oikawa S, Kawanishi S. 1999. Site-specific DNA damage at GGG sequence by oxidative stress 
may accelerate telomere shortening. FEBS Lett 453: 365. 
Oja S, Kaartinen T, Ahti M, Korhonen M, Laitinen A, Nystedt J. 2019. The utilization of freezing 
steps in mesenchymal stromal cell (MSC) manufacturing: Potential impact on quality and 
cell functionality attributes. Front Immunol 10. 
Oja S, Komulainen P, Penttilä A, Nystedt J, Korhonen M. 2018. Automated image analysis 
detects aging in clinical-grade mesenchymal stromal cell cultures. Stem Cell Res Ther 9. 
Orozco L, Munar A, Soler R, Alberca M, Soler F, Huguet M, Sentís J, Sánchez A, García-Sancho 
J. 2013. Treatment of knee osteoarthritis with autologous mesenchymal stem cells: A pilot 
study. Transplantation 95: 1535–1541. 
Oryan A, Kamali A, Moshirib A, Eslaminejad MB. 2017. Role of Mesenchymal Stem Cells in Bone 
Regenerative Medicine: What Is the Evidence? Cells Tissues Organs 204: 59–83. 
Oswald J, Boxberger S, Jorgensen B, Feldmann S, Ehninger G, Bornhäuser M, Werner C. 2004. 
Mesenchymal Stem Cells Can Be Differentiated Into Endothelial Cells In Vitro. Stem Cells 
22: 377–384. 
Panés J, García-Olmo D, Van Assche G, Colombel JF, Reinisch W, Baumgart DC, Dignass A, 
Nachury M, Ferrante M, Kazemi-Shirazi L, et al. 2016. Expanded allogeneic adipose-
derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn’s disease: 
a phase 3 randomised, double-blind controlled trial. Lancet 388: 1281–1290. 




Nachury M, Ferrante M, Kazemi-Shirazi L, et al. 2018. Long-term Efficacy and Safety of 
Stem Cell Therapy (Cx601) for Complex Perianal Fistulas in Patients With Crohn’s Disease. 
Gastroenterology 154: 1334-1342.e4. 
Papait A, Vertua E, Magatti M, Ceccariglia S, De Munari S, Silini AR, Sheleg M, Ofir R, Parolini 
O. 2020. Mesenchymal Stromal Cells from Fetal and Maternal Placenta Possess Key 
Similarities and Differences: Potential Implications for Their Applications in Regenerative 
Medicine. Cells 9: 127. 
Parolini O, Alviano F, Bagnara GP, Bilic G, Bühring H-J, Evangelista M, Hennerbichler S, Liu B, 
Magatti M, Mao N, et al. 2008. Concise Review: Isolation and Characterization of Cells 
from Human Term Placenta: Outcome of the First International Workshop on Placenta 
Derived Stem Cells. Stem Cells 26: 300–311. 
Passos JF, Saretzki G, von Zglinicki T. 2007. DNA damage in telomeres and mitochondria during 
cellular senescence: Is there a connection? Nucleic Acids Res 35: 7505–7513. 
Patki S, Kadam S, Chandra V, Bhonde R. 2010. Human breast milk is a rich source of 
multipotent mesenchymal stem cells. Hum Cell 23: 35–40. 
Peffers MJ, Collins J, Fang Y, Goljanek-Whysall K, Rushton M, Loughlin J, Proctor C, Clegg PD. 
2016. Age-related changes in mesenchymal stem cells identified using a multi-omics 
approach. Eur Cells Mater 31: 136–159. 
Perico N, Casiraghi F, Introna M, Gotti E, Todeschini M, Cavinato RA, Capelli C, Rambaldi A, 
Cassis P, Rizzo P, et al. 2011. Autologous mesenchymal stromal cells and kidney 
transplantation: A pilot study of safety and clinical feasibility. Clin J Am Soc Nephrol 6: 
412–422. 
Petersen S, Saretzki G, Von Zglinicki T. 1998. Preferential accumulation of single-stranded 
regions in telomeres of human fibroblasts. Exp Cell Res 239: 152–160. 
Petite H, Viateau V, Bensaïd W, Meunier A, De Pollak C, Bourguignon M, Oudina K, Sedel L, 
Guillemin G. 2000. Tissue-engineered bone regeneration. Nat Biotechnol 18: 959–963. 
Phinney DG, Prockop DJ. 2007. Concise review: mesenchymal stem/multipotent stromal cells: 
the state of transdifferentiation …. Stem Cells 25: 2896–2902. 
Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Moorman MA, Simonetti 
DW, Craig S, Marshak DR. 1999a. Multilineage potential of adult human mesenchymal 
stem cells. Science (80- ) 284: 143–147. 
Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Moorman MA, Simonetti 
DW, Craig S, Marshak DR. 1999b. Multilineage potential of adult human mesenchymal 
stem cells. Science (80- ) 284: 143–147. 
Polchert D, Sobinsky J, Douglas GW, Kidd M, Moadsiri A, Reina E, Genrich K, Mehrotra S, Setty 
S, Smith B, et al. 2008. IFN-γ activation of mesenchymal stem cells for treatment and 
prevention of graft versus host disease. Eur J Immunol 38: 1745–55. 
Pollock K, Samsonraj RM, Dudakovic A, Thaler R, Stumbras A, McKenna DH, Dosa PI, Van 
Wijnen AJ, Hubel A. 2017. Improved Post-Thaw Function and Epigenetic Changes in 
Mesenchymal Stromal Cells Cryopreserved Using Multicomponent Osmolyte Solutions. 
Stem Cells Dev 26: 828–842. 
Pollock K, Sumstad D, Kadidlo D, McKenna DH, Hubel A. 2015. Clinical mesenchymal stromal 
cell products undergo functional changes in response to freezing. Cytotherapy 17: 38–45. 
Prasad VK, Lucas KG, Kleiner GI, Talano JAM, Jacobsohn D, Broadwater G, Monroy R, 
Kurtzberg J. 2011. Efficacy and Safety of Ex Vivo Cultured Adult Human Mesenchymal 
Stem Cells (ProchymalTM) in Pediatric Patients with Severe Refractory Acute Graft-Versus-
Host Disease in a Compassionate Use Study. Biol Blood Marrow Transplant 17: 534–541. 
Prasanna SJ, Gopalakrishnan D, Shankar SR, Vasandan AB. 2010. Pro-inflammatory cytokines, 
IFNγ and TNFα, influence immune properties of human bone marrow and Wharton jelly 
mesenchymal stem cells differentially. PLoS One 5. 
Prockop DJ, Sekiya I, Colter DC. 2001. Isolation and characterization of rapidly self-renewing 
stem cells from cultures of human marrow stromal cells. Cytotherapy 3: 393–396. 
Prowse KR, Greider CW. 1995. Developmental and tissue-specific regulation of mouse 
telomerase and telomere length. Proc Natl Acad Sci U S A 92: 4818–4822. 
Puck TT, Cieciura SJ, Robinson A. 1958. Genetics of somatic mammalian cells. III. Long-term 




Purpura KA. 2004. Sustained In Vitro Expansion of Bone Progenitors Is Cell Density 
Dependent. Stem Cells 22: 39-50. 
Quinn C, Flake AW. 2008. In vivo differentiation potential of mesenchymal stem cells: Prenatal 
and postnatal model systems. Transfus Med Hemotherapy 35: 239–247. 
Rasmusson I, Le Blanc K, Sundberg B, Ringdén O. 2007. Mesenchymal stem cells stimulate 
antibody secretion in human B cells. Scand J Immunol 65: 336–343. 
Redondo-Castro E, Cunningham C, Miller J, Martuscelli L, Aoulad-Ali S, Rothwell NJ, Kielty 
CM, Allan SM, Pinteaux E. 2017. Interleukin-1 primes human mesenchymal stem cells 
towards an anti-inflammatory and pro-trophic phenotype in vitro. Stem Cell Res Ther 8: 
1–11. 
Reinders MEJ, Dreyer GJ, Bank JR, Roelofs H, Heidt S, Roelen DL, Zandvliet ML, Huurman 
VAL, Fibbe WE, Kooten C, et al. 2015. Safety of allogeneic bone marrow derived 
mesenchymal stromal cell therapy in renal transplant recipients: The neptune study. J 
Transl Med 13. 
Reinisch A, Etchart N, Thomas D, Hofmann NA, Fruehwirth M, Sinha S, Chan CK, Senarath-
Yapa K, Seo EY, Wearda T, et al. 2015. Epigenetic and in vivo comparison of diverse MSC 
sources reveals an endochondral signature for human hematopoietic niche formation. 
Blood 125: 249–260. 
Ribeiro A, Laranjeira P, Mendes S, Velada I, Leite C, Andrade P, Santos F, Henriques A, Grãos 
M, Cardoso CMP, et al. 2013. Mesenchymal stem cells from umbilical cord matrix, adipose 
tissue and bone marrow exhibit different capability to suppress peripheral blood B, natural 
killer and T cells. Stem Cell Res Ther 4. 
Ringdén O, Uzunel M, Rasmusson I, Remberger M, Sundberg B, Lönnies H, Marschall HU, 
Dlugosz A, Szakos A, Hassan Z, et al. 2006. Mesenchymal stem cells for treatment of 
therapy-resistant graft-versus-host disease. Transplantation 81: 1390–1397. 
Ringe J, Häupl T, Sittinger M. 2003. Mesenchymal Stem Cells for Tissue Engineering of Bone 
and Cartilage. Med Klin. 
Ross SE, Hemati N, Longo KA, Bennett CN, Lucas PC, Erickson RL, MacDougald OA. 2000. 
Inhibition of adipogenesis by Wnt signaling. Science (80- ) 289: 950–953. 
Russell AL, Lefavor RC, Zubair AC. 2018. Characterization and cost–benefit analysis of 
automated bioreactor-expanded mesenchymal stem cells for clinical applications. 
Transfusion 58: 2374–2382. 
Sacchetti B, Funari A, Michienzi S, Di Cesare S, Piersanti S, Saggio I, Tagliafico E, Ferrari S, 
Robey PG, Riminucci M, et al. 2007. Self-Renewing Osteoprogenitors in Bone Marrow 
Sinusoids Can Organize a Hematopoietic Microenvironment. Cell 131: 324–336. 
Sacchetti B, Funari A, Remoli C, Giannicola G, Kogler G, Liedtke S, Cossu G, Serafini M, 
Sampaolesi M, Tagliafico E, et al. 2016. No identical “mesenchymal stem cells” at different 
times and sites: Human committed progenitors of distinct origin and differentiation 
potential are incorporated as adventitial cells in microvessels. Stem Cell Reports 6: 897–
913. 
Salmenniemi U, Itälä-Remes M, Nystedt J, Putkonen M, Niittyvuopio R, Vettenranta K, 
Korhonen M. 2017. Good responses but high TRM in adult patients after MSC therapy for 
GvHD. Bone Marrow Transplant 52: 606–608. 
Samuelsson H, Ringdén O, Lonnies H, Le Blanc K. 2009. Optimizing in vitro conditions for 
immunomodulation and expansion of mesenchymal stromal cells. Cytotherapy 11: 129–
36. 
Santa María L, Rojas C V., Minguell JJ. 2004. Signals from damaged but not undamaged skeletal 
muscle induce myogenic differentiation of rat bone-marrow-derived mesenchymal stem 
cells. Exp Cell Res. 
Saretzki G, von Zglinicki T. 1999. Replicative senescence as a model for aging: The role of 
oxidative stress and telomere shortening. Z Gerontol Geriatr. 
Sarugaser R, Lickorish D, Baksh D, Hosseini MM, Davies JE. 2005. Human Umbilical Cord 
Perivascular (HUCPV) Cells: A Source of Mesenchymal Progenitors. Stem Cells 23: 220–
229. 
Sasaki H, Takeuchi I, Okada M, Sawada R, Kanie K, Kiyota Y, Honda H, Kato R. 2014. Label-




mesenchymal stem cells for early evaluation of intact cells. PLoS One 9. 
Schallmoser K, Bartmann C, Rohde E, Reinisch A, Kashofer K, Stadelmeyer E, Drexler C, Lanzer 
G, Linkesch W, Strunk D. 2007. Human platelet lysate can replace fetal bovine serum for 
clinical-scale expansion of functional mesenchymal stromal cells. Transfusion 47: 1436–
1446. 
Schellenberg A, Hemeda H, Wagner W. 2013. Tracking of replicative senescence in 
mesenchymal stem cells by colony-forming unit frequency. Methods Mol Biol. 
Schellenberg A, Mauen S, Koch CM, Jans R, De Waele P, Wagner W. 2014. Proof of principle: 
Quality control of therapeutic cell preparations using senescence-associated DNA-
methylation changes. BMC Res Notes. 
Schieker M, Gülkan H, Austrup B, Neth P, Mutschler W. 2004. Telomerase activity and telomere 
length of human mesenchymal stem cells. Changes during osteogenic differentiation. 
Orthopade 33: 1373–1377. 
Schneider CK, Celis P, Salmikangas P, Figuerola-Santos MA, D’Apote L, Oliver-Diaz O, Büttel I, 
Mačiulaitis R, Robert JL, Silva Lima B, et al. 2010. Challenges with advanced therapy 
medicinal products and how to meet them. Nat Rev Drug Discov 9: 195–201. 
Scolding NJ, Pasquini M, Reingold SC, Cohen JA. 2017. Cell-based therapeutic strategies for 
multiple sclerosis. Brain 140: 2776–2796. 
Sekiya I, Larson BL, Smith J, Pochampally R, Cui J-G, Prockop DJ. 2002. Expansion of Human 
Adult Stem Cells from Bone Marrow Stroma: Conditions that Maximize the Yields of Early 
Progenitors and Evaluate Their Quality. Stem Cells. 
Selmani Z, Naji A, Zidi I, Favier B, Gaiffe E, Obert L, Borg C, Saas P, Tiberghien P, Rouas-Freiss 
N, et al. 2008. Human Leukocyte Antigen-G5 Secretion by Human Mesenchymal Stem 
Cells Is Required to Suppress T Lymphocyte and Natural Killer Function and to Induce 
CD4 + CD25 high FOXP3 + Regulatory T Cells. Stem Cells 26: 212–222. 
Selvaggi TA, Walker RE, Fleisher TA. 1997. Development of antibodies to fetal calf serum with 
arthus-like reactions in human immunodeficiency virus-infected patients given syngeneic 
lymphocyte infusions. Blood. 
Sensebé L. 2008. Clinical grade production of mesenchymal stem cells. Biomed Mater Eng. 
Sensebé L, Gadelorge M, Fleury-Cappellesso S. 2013. Production of mesenchymal stromal/stem 
cells according to good manufacturing practices: A review. Stem Cell Res Ther 4. 
Sepúlveda CJ, Tomé M, Eugenia Fernández M, Delgado M, Campisi J, Bernad A, González MA. 
2014. Cell senescence abrogates the therapeutic potential of human mesenchymal stem 
cells in the lethal endotoxemia model. Stem Cells 32: 1865–1877. 
Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW. 1997. Oncogenic ras provokes 
premature cell senescence associated with accumulation of p53 and p16(INK4a). Cell 88: 
593–602. 
Sethe S, Scutt A, Stolzing A. 2006. Aging of mesenchymal stem cells. Ageing Res Rev 5: 91–116. 
Severino J, Allen RG, Balin S, Balin A, Cristofalo VJ. 2000. Is β-galactosidase staining a marker 
of senescence in vitro and in vivo? Exp Cell Res 257: 162–171. 
Shahdadfar A, Frønsdal K, Haug T, Reinholt FP, Brinchmann JE. 2005. In Vitro Expansion of 
Human Mesenchymal Stem Cells: Choice of Serum Is a Determinant of Cell Proliferation, 
Differentiation, Gene Expression, and Transcriptome Stability. Stem Cells 23: 1357–1366. 
Sherr CJ, DePinho RA. 2000. Mitotic Clock or Culture Shock? Cell 102: 407–410. 
Sherr CJ, Roberts JM. 1999. CDK inhibitors: Positive and negative regulators of G1-phase 
progression. Genes Dev 13: 1501–12. 
Shih DT, Lee D-C, Chen S-C, Tsai R-Y, Huang C-T, Tsai C-C, Shen E-Y, Chiu W-T. 2005. 
Isolation and Characterization of Neurogenic Mesenchymal Stem Cells in Human Scalp 
Tissue. Stem Cells. 
Shim WSN, Jiang S, Wong P, Tan J, Chua YL, Seng Tan Y, Sin YK, Lim CH, Chua T, Teh M, et 
al. 2004. Ex vivo differentiation of human adult bone marrow stem cells into 
cardiomyocyte-like cells. Biochem Biophys Res Commun 324: 481–488. 
Singer NG, Caplan AI. 2011. Mesenchymal Stem Cells: Mechanisms of Inflammation. Annu Rev 
Pathol Mech Dis. 
Sipp D, Robey PG, Turner L. 2018. Clear up this stem cell mess. Nature 561: 455–457. 




induced mesenchymal stromal cells-mediated mechanism contributing to decreased 
antitumor effect in breast cancer cells. Cell Commun Signal 14. 
Sogo Y, Ito A, Matsuno T, Oyane A, Tamazawa G, Satoh T, Yamazaki A, Uchimura E, Ohno T. 
2007. Fibronectin-calcium phosphate composite layer on hydroxyapatite to enhance 
adhesion, cell spread and osteogenic differentiation of human mesenchymal stem cells in 
vitro. Biomed Mater 2: 116–123. 
Soler R, Orozco L, Munar A, Huguet M, López R, Vives J, Coll R, Codinach M, Garcia-Lopez J. 
2016. Final results of a phase I–II trial using ex vivo expanded autologous Mesenchymal 
Stromal Cells for the treatment of osteoarthritis of the knee confirming safety and 
suggesting cartilage regeneration. Knee 23: 647–654. 
Sotiropoulou PA, Perez SA, Gritzapis AD, Baxevanis CN, Papamichail M. 2006. Interactions 
Between Human Mesenchymal Stem Cells and Natural Killer Cells. Stem Cells 24: 74–85. 
Spaggiari GM, Capobianco A, Becchetti S, Mingari MC, Moretta L. 2006. Mesenchymal stem 
cell-natural killer cell interactions: Evidence that activated NK cells are capable of killing 
MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation. Blood 107: 1484–
1490. 
Spees JL, Gregory CA, Singh H, Tucker HA, Peister A, Lynch PJ, Hsu SC, Smith J, Prockop DJ. 
2004. Internalized antigens must be removed to prepare hypoimmunogenic mesenchymal 
stem cells for cell and gene therapy. Mol Ther 9: 747–56. 
Stagg J, Pommey S, Eliopoulos N, Galipeau J. 2006. Interferon-γ-stimulated marrow stromal 
cells: A new type of nonhematopoietic antigen-presenting cell. Blood 107: 2570–2577. 
Stanovici J, Le Nail LR, Brennan MA, Vidal L, Trichet V, Rosset P, Layrolle P. 2016. Bone 
regeneration strategies with bone marrow stromal cells in orthopaedic surgery. Curr Res 
Transl Med 64: 83–90. 
Stein GH, Drullinger LF, Soulard A, Dulic V. 1999. Differential Roles for Cyclin-Dependent 
Kinase Inhibitors p21 and p16 in the Mechanisms of Senescence and Differentiation in 
Human Fibroblasts. Mol Cell Biol 19: 2109–2117. 
Stenderup K, Justesen J, Clausen C, Kassem M. 2003. Aging is associated with decreased 
maximal life span and accelerated senescence of bone marrow stromal cells. Bone 33: 919–
926. 
Stolzing A, Jones E, McGonagle D, Scutt A. 2008. Age-related changes in human bone marrow-
derived mesenchymal stem cells: Consequences for cell therapies. Mech Ageing Dev 129: 
163–73. 
Strandberg G, Sellberg F, Sommar P, Ronaghi M, Lubenow N, Knutson F, Berglund D. 2017. 
Standardizing the freeze-thaw preparation of growth factors from platelet lysate. 
Transfusion 57: 1058–1065. 
Strioga M, Viswanathan S, Darinskas A, Slaby O, Michalek J. 2012. Same or not the same? 
comparison of adipose tissue-derived versus bone marrow-derived mesenchymal stem and 
stromal cells. Stem Cells Dev 21: 2724–2752. 
Tarte K, Gaillard J, Lataillade J-J, Fouillard L, Becker M, Mossafa H, Tchirkov A, Ne Rouard H, 
Henry C, Splingard M, et al. 2010. Clinical-grade production of human mesenchymal 
stromal cells: occurrence of aneuploidy without transformation. Blood 115: 3541–3552. 
www.bloodjournal.org. 
Timper K, Seboek D, Eberhardt M, Linscheid P, Christ-Crain M, Keller U, Müller B, Zulewski H. 
2006. Human adipose tissue-derived mesenchymal stem cells differentiate into insulin, 
somatostatin, and glucagon expressing cells. Biochem Biophys Res Commun 341: 1135–
1140. 
Tolar J, Le Blanc K, Keating A, Blazar BR. 2010. Concise review: Hitting the right spot with 
mesenchymal stromal cells. Stem Cells 28: 1446–1455. 
Tormin A, Li O, Brune JC, Walsh S, Schütz B, Ehinger M, Ditzel N, Kassem M, Scheding S. 2011. 
CD146 expression on primary nonhematopoietic bone marrow stem cells is correlated with 
in situ localization. Blood 117: 5067–5077. 
Toussaint O, Medrano EE, von Zglinicki T. 2000. Cellular and molecular mechanisms of stress-
induced premature senescence (SIPS) of human diploid fibroblasts and melanocytes. Exp 
Gerontol 35: 927–45. 




Derived Mesenchymal Stem Cells Induce Both Polyclonal Expansion and Differentiation 
of B Cells Isolated from Healthy Donors and Systemic Lupus Erythematosus Patients. 
Stem Cells 26: 562–569. 
Troyer D, Weiss ML. 2008. Wharton’s Jelly-Derived Cells Are a Primitive Stromal Cell 
Population. Stem Cells 26: 591–599. 
Tsai CC, Chen YJ, Yew TL, Chen LL, Wang JY, Chiu CH, Hung SC. 2011. Hypoxia inhibits 
senescence and maintains mesenchymal stem cell properties through down-regulation of 
E2A-p21 by HIF-TWIST. Blood 117: 459–469. 
Turinetto V, Vitale E, Giachino C. 2016. Senescence in human mesenchymal stem cells: 
Functional changes and implications in stem cell-based therapy. Int J Mol Sci 17. 
Tyndall A, Uccelli A. 2009. Multipotent mesenchymal stromal cells for autoimmune diseases: 
Teaching new dogs old tricks. Bone Marrow Transplant 43: 821–828. 
Uccelli A, Moretta L, Pistoia V. 2008. Mesenchymal stem cells in health and disease. Nat Rev 
Immunol 8: 726–736. 
Van der Valk J, Bieback K, Buta C, Cochrane B, Dirks WG, Fu J, Hickman JJ, Hohensee C, Kolar 
R, Liebsch M, et al. 2018. Fetal Bovine Serum (FBS): Past - Present - Future. ALTEX 35: 
99–118. 
van der Valk J, Brunner D, De Smet K, Fex Svenningsen Å, Honegger P, Knudsen LE, Lindl T, 
Noraberg J, Price A, Scarino ML, et al. 2010. Optimization of chemically defined cell 
culture media - Replacing fetal bovine serum in mammalian in vitro methods. Toxicol Vitr. 
Vanikar A V., Trivedi HL, Kumar A, Gopal SC, Patel H V., Gumber MR, Kute VB, Shah PR, Dave 
SD. 2014. Co-infusion of donor adipose tissue-derived mesenchymal and hematopoietic 
stem cells helps safe minimization of immunosuppression in renal transplantation - Single 
center experience. Ren Fail 36: 1376–1384. 
Vaziri H, Benchimol S. 1998. Reconstitution of telomerase activity in normal human cells leads 
to elongation of telomeres and extended replicative life span. Curr Biol 8: 279–282. 
Viswanathan S, Shi Y, Galipeau J, Krampera M, Leblanc K, Martin I, Nolta J, Phinney DG, 
Sensebé L. 2019. Mesenchymal stem versus stromal cells: International Society for Cell & 
Gene Therapy (ISCT®) Mesenchymal Stromal Cell committee position statement on 
nomenclature. Cytotherapy 21: 1019–1024. 
Vogel JP, Szalay K, Geiger F, Kramer M, Richter W, Kasten P. 2006. Platelet-rich plasma 
improves expansion of human mesenchymal stem cells and retains differentiation capacity 
and in vivo bone formation in calcium phosphate ceramics. Platelets 17: 462–469. 
Volkman R, Offen D. 2017. Concise Review: Mesenchymal Stem Cells in Neurodegenerative 
Diseases. Stem Cells 35: 1867–1880. 
Volz AC, Huber B, Kluger PJ. 2016. Adipose-derived stem cell differentiation as a basic tool for 
vascularized adipose tissue engineering. Differentiation 92: 52–64. 
von Bonin M, Stölzel F, Goedecke A, Richter K, Wuschek N, Hölig K, Platzbecker U, Illmer T, 
Schaich M, Schetelig J, et al. 2009. Treatment of refractory acute GVHD with third-party 
MSC expanded in platelet lysate-containing medium. Bone Marrow Transplant 43: 245–
251. 
von Zglinicki T. 2002. Oxidative stress shortens telomeres. Trends Biochem Sci 27: 339–44. 
von Zglinicki T, Pilger R, Sitte N. 2000. Accumulation of single-strand breaks is the major cause 
of telomere shortening in human fibroblasts. Free Radic Biol Med 28: 64–74. 
von Zglinicki T, Saretzki G, Döcke W, Lotze C. 1995. Mild Hyperoxia Shortens Telomeres and 
Inhibits Proliferation of Fibroblasts: A Model for Senescence? Exp Cell Res 220: 186–193. 
Wagner W, Bork S, Lepperdinger G, Joussen S, Ma N, Strunk D, Koch CM. 2010. How to track 
cellular aging of mesenchymal stromal cells? Aging (Albany NY) 2: 224–230. 
Wagner W, Frobel J, Goetzke R. 2016. Epigenetic quality check - How good are your 
mesenchymal stromal cells? Epigenomics 8: 889–94. 
Wagner W, Horn P, Castoldi M, Diehlmann A, Bork S, Saffrich R, Benes V, Blake J, Pfister S, 
Eckstein V, et al. 2008. Replicative senescence of mesenchymal stem cells: A continuous 
and organized process. PLoS One 3: e2213. 
Wagner W, Wein F, Seckinger A, Frankhauser M, Wirkner U, Krause U, Blake J, Schwager C, 
Eckstein V, Ansorge W, et al. 2005. Comparative characteristics of mesenchymal stem cells 





Wang D, Li J, Zhang Y, Zhang M, Chen J, Li X, Hu X, Jiang S, Shi S, Sun L. 2014. Umbilical cord 
mesenchymal stem cell transplantation in active and refractory systemic lupus 
erythematosus: A multicenter clinical study. Arthritis Res Ther 16. 
Warnke PH, Humpe A, Strunk D, Stephens S, Warnke F, Wiltfang J, Schallmoser K, Alamein M, 
Bourke R, Heiner P, et al. 2013. A clinically-feasible protocol for using human platelet 
lysate and mesenchymal stem cells in regenerative therapies. J Cranio-Maxillofacial Surg 
41: 153–161.  
Wei W, Sedivy JM. 1999. Differentiation between senescence (M1) and crisis (M2) in human 
fibroblast cultures. Exp Cell Res. 
Weiss DJ, English K, Krasnodembskaya A, Isaza-Correa JM, Hawthorne IJ, Mahon BP. 2019. 
The necrobiology of mesenchymal stromal cells affects therapeutic efficacy. Front 
Immunol 10: 1–12. 
Wessman SJ, Levings RL. 1999. Benefits and risks due to animal serum used in cell culture 
production. Dev Biol Stand. 
Woodbury D, Schwarz EJ, Prockop DJ, Black IB. 2000. Adult rat and human bone marrow 
stromal cells differentiate into neurons. J Neurosci Res 61: 364–370. 
Wright WE, Piatyszek MA, Rainey WE, Byrd W, Shay JW. 1996. Telomerase activity in human 
germline and embryonic tissues and cells. Dev Genet 18: 173–179. 
Wu LW, Wang YL, Christensen JM, Khalifian S, Schneeberger S, Raimondi G, Cooney DS, Lee 
WPA, Brandacher G. 2014. Donor age negatively affects the immunoregulatory properties 
of both adipose and bone marrow derived mesenchymal stem cells. Transpl Immunol 30: 
122–127. 
Xia W, Li H, Wang Z, Xu R, Fu Y, Zhang X, Ye X, Huang Y, Xiang AP, Yu W. 2011. Human 
platelet lysate supports ex vivo expansion and enhances osteogenic differentiation of 
human bone marrow-derived mesenchymal stem cells. Cell Biol Int 35: 639–643. 
Yamada Y, Ueda M, Naiki T, Takahashi M, Hata KI, Nagasaka T. 2004. Autogenous injectable 
bone for regeneration with mesenchymal stem cells and platelet-rich plasma: Tissue-
engineered bone regeneration. Tissue Eng 10: 955–964. 
Yamout B, Hourani R, Salti H, Barada W, El-Hajj T, Al-Kutoubi A, Herlopian A, Baz EK, 
Mahfouz R, Khalil-Hamdan R, et al. 2010. Bone marrow mesenchymal stem cell 
transplantation in patients with multiple sclerosis: A pilot study. J Neuroimmunol 227: 
185–189. 
Yang H. 2011. South Korea’s stem cell approval. Nat Biotechnol. 
Yang NC, Hu ML. 2005. The limitations and validities of senescence associated-β- galactosidase 
activity as an aging marker for human foreskin fibroblast Hs68 cells. Exp Gerontol 40: 
813–819. 
Yong KW, Safwani WKZW, Xu F, Zhang X, Choi JR, Abas WABW, Omar SZ, Azmi MAN, Chua 
KH, Pingguan-Murphy B. 2017. Assessment of tumourigenic potential in long-term 
cryopreserved human adipose-derived stem cells. J Tissue Eng Regen Med 11: 2217–2226. 
Zajdel A, Kalucka M, Kokoszka-Mikolaj E, Wilczok A. 2017. Osteogenic differentiation of human 
mesenchymal stem cells from adipose tissue and Wharton’s jelly of the umbilical cord. Acta 
Biochim Pol 64: 365–369. 
Zaky SH, Ottonello A, Strada P, Cancedda R, Mastrogiacomo M. 2008. Platelet lysate favours in 
vitro expansion of human bone marrow stromal cells for bone and cartilage engineering. J 
Tissue Eng Regen Med 2: 472–481. 
Zappia E, Casazza S, Pedemonte E, Benvenuto F, Bonanni I, Gerdoni E, Giunti D, Ceravolo A, 
Cazzanti F, Frassoni F, et al. 2005. Mesenchymal stem cells ameliorate experimental 
autoimmune encephalomyelitis inducing T-cell anergy. Blood 106: 1755–1761. 
Zhang B, Liu R, Shi D, Liu X, Chen Y, Dou X, Zhu X, Lu C, Liang W, Liao L, et al. 2009. 
Mesenchymal stem cells induce mature dendritic cells into a novel Jagged-2 dependent 
regulatory dendritic cell population. Blood 113: 46–57. 
Zhang J, Feng F, Wang Q, Zhu X, Fu H, Xu L, Liu K, Huang X, Zhang X. 2016. Platelet-Derived 
Growth Factor-BB Protects Mesenchymal Stem Cells (MSCs) Derived From Immune 
Thrombocytopenia Patients Against Apoptosis and Senescence and Maintains MSC-




Zhang XH, Zhang JM, Wang QM, Feng FE, Zhu XL, Lv M, Fu HX, Xu LP, Liu KY, Huang XJ. 
2015. PDGF-BB protects bone marrow mesenchymal stem cells against apoptosis and 
senescence through the P53/P21 pathway in patients with immune thrombocytopaenia. 
Haematologica. 
Zhu W, Xu W, Jiang R, Qian H, Chen M, Hu J, Cao W, Han C, Chen Y. 2006. Mesenchymal stem 
cells derived from bone marrow favor tumor cell growth in vivo. Exp Mol Pathol 80. 
Zuk PA, Zhu M, Ashjian P, De Ugarte DA, Huang JI, Mizuno H, Alfonso ZC, Fraser JK, Benhaim 
P, Hedrick MH. 2002. Human adipose tissue is a source of multipotent stem cells. Mol Biol 
Cell 13: 4279–95. 
 
